



# RESOURCE AND PATIENT MANAGEMENT SYSTEM

# **Clinical Reporting System**

(BGP)

# CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures

Version 17.0 September 2016

Office of Information Technology (OIT)

Division of Information Resource Management

# **Table of Contents**

1.0	Introdu	ıction	1
2.0	Perfori	nance Measure Logic	2
	2.1	Performance Measure Logic Basics	2
	2.1.1	CRS Denominator Definitions	
	2.1.2	Performance Measure Logic Example	11
	2.1.3	Age Ranges	13
	2.1.4	Standard Health Care Codes	13
	2.2	Diabetes Related Measure Topics	
	2.2.1	Diabetes Prevalence	
	2.2.2	Diabetes Comprehensive Care	
	2.2.3	Diabetes: Glycemic Control	
	2.2.4	Diabetes: Blood Pressure Control	
	2.2.5	Statin Therapy to Reduce Cardiovascular Disease Risk in Patients v	
		Diabetes	
	2.2.6	Diabetes: Nephropathy Assessment	
	2.2.7	Diabetic Retinopathy	
	2.2.8	Diabetes: Access to Dental Services	
	2.3	Dental Measure Topics	
	2.3.1	Access to Dental Services	
	2.3.2	Dental Sealants	
	2.3.3	Topical Fluoride	
	2.4	Immunization Measure Topics	
	2.4.1	Influenza	
	2.4.2	Adult Immunizations	
	2.4.3	Childhood Immunizations	
	2.4.4	Adolescent Immunizations	
	2.5	Childhood Diseases Group	
	2.5.1	Appropriate Treatment for Children with Upper Respiratory Infection	
	2.5.2	Appropriate Testing for Children with Pharyngitis	
	2.6	Cancer Related Measure Topics	
	2.6.1	Cancer Screening: Pap Smear Rates	
	2.6.2	Cancer Screening: Mammogram Rates	
	2.6.3	Colorectal Cancer Screening	
	2.6.4	Comprehensive Cancer Screening	
	2.6.5	Tobacco Use and Exposure Assessment	
	2.6.6	Tobacco Cessation	
	2.7	Behavioral Health Related Performance Measure Topics	
	2.7.1	Alcohol Screening	
	2.7.2	Screening, Brief Intervention, and Referral to Treatment (SBIRT)	
	2.7.3	Intimate Partner (Domestic) Violence Screening	
		·	

2.7.4	Depression Screening	156
2.7.5	Antidepressant Medication Management	
2.8	Cardiovascular Disease Related Measure Topics	
2.8.1	Obesity Assessment	
2.8.2	Childhood Weight Control	
2.8.3	Weight Assessment and Counseling for Nutrition and	
	Physical Activity	174
2.8.4	Nutrition and Exercise Education for At Risk Patients	177
2.8.5	Physical Activity Assessment	182
2.8.6	Comprehensive Health Screening	
2.8.7	Cardiovascular Disease and Blood Pressure Control	192
2.8.8	Controlling High Blood Pressure (Million Hearts)	195
2.8.9	Statin Therapy for the Prevention and Treatment of Cardiovascular	
	Disease	
2.8.10	Appropriate Medication Therapy after a Heart Attack	207
2.8.11	Stroke and Stroke Rehabilitation: Anticoagulant Therapy	
	Prescribed for Atrial Fibrillation	
2.8.12	Heart Failure and Evaluation of LVS Function	
	STD-Related Measure Topics	
2.9.1	HIV Screening	
2.9.2	HIV Quality of Care	
2.9.3	Hepatitis C Screening	
2.9.4	Chlamydia Testing	
2.9.5	Sexually Transmitted Infection Screening	
	Other Clinical Measures Topics	
2.10.1	Asthma	
2.10.2	Asthma Assessments	
2.10.3	Medication Therapy for Persons with Asthma	
2.10.4	Proportion of Days Covered by Medication Therapy	
2.10.5	Primary Medication Non-adherence	
2.10.6	Medications Education	
2.10.7	Medication Therapy Management Services	
	Public Health Nursing	
	Breastfeeding Rates	
	Use of High-Risk Medications in the Elderly	
	Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly	
	Princtional Status Assessment in Elders	
	B Fall Risk Assessment in Elders	
2.10.14	Palliative Care	294
	5 Annual Wellness Visit	
	Optometry	
2.10.17	' Goal Setting	299
ct Inforn	nation	304

# **Preface**

The Government Performance and Results Act (GPRA) requires federal agencies to report annually on how the agency measured up against the performance targets set in its annual Plan. The Indian Health Service (IHS) GPRA report includes measures for clinical prevention and treatment, quality of care, infrastructure, and administrative efficiency functions.

The IHS Clinical Reporting System (CRS) is a Resource and Patient Management System (RPMS) software application designed for national reporting as well as Area Office and local monitoring of clinical GPRA and developmental measures. CRS was first released for Fiscal Year (FY) 2002 performance measures (as GPRA+) and is based on a design by the Aberdeen Area (GPRA2000).

This manual contains the FY 2017 clinical performance measure definitions and logic for the CRS 2017 Version 17.0 software. CRS is the reporting tool used by the IHS Office of Planning and Evaluation to collect and report clinical performance results annually to the Department of Health and Human Services and to Congress.

Each year, an updated version of CRS software is released to reflect changes in the logic descriptions of the different denominators and numerators. Additional performance measures may also be added. Local facilities can run reports as often as they want to and can also use CRS to transmit data to their Area. The Area Office can use CRS to produce an aggregated Area report for either annual GPRA or Area Director Performance reports.

CRS produces reports on demand from local RPMS databases for both GPRA and developmental clinical measures that are based on RPMS data, thus eliminating the need for manual chart audits for evaluating and reporting clinical measures.

To produce reports with comparable data across every facility, the GPRA measures definitions was "translated" into programming code with the assistance of clinical subject matter experts. CRS uses predefined taxonomies to find data items in the RPMS Patient Care Component (PCC) to determine if a patient meets the performance measure criteria. Taxonomies contain groups of codes (e.g., diagnoses or procedures) or site-specific terms. Each performance measure has one or more defined denominators and numerators.

Administrative and clinical users can produce reports for selected measures at any time to:

• Identify potential data issues in their RPMS, i.e., missing or incorrect data.

- Monitor their site's performance against past national performance and upcoming agency goals.
- Identify specific areas where the facility is not meeting the measure in order to initiate business process or other changes.
- Quickly measure impact of process changes on performance measures.
- Identify areas meeting or exceeding measures to provide lessons learned.

#### Users of the RPMS CRS include:

- Area Office and site quality improvement staff
- Compliance Officers
- GPRA coordinators
- Clinical staff, such as physicians, nurses, nurse practitioners, and other providers
- Area Office directors
- Any staff involved with quality assurance initiatives
- Staff who run various CRS reports

# 1.0 Introduction

This manual provides information on the performance measure logic used by the Clinical Reporting System (CRS) Version 17.0 Selected Measures (Local) Report (Fiscal Year [FY] 2017 Clinical Performance Measures). For information on system setup, available reports and steps for running the reports, and performing Area Office functions, refer to the CRS Version 17.0 User Manual.

# 2.0 Performance Measure Logic

This section provides the following information for each performance measure topic:

- For Government Performance and Results Act (GPRA) measures, the measure description is provided as stated in the Indian Health Service (IHS) Annual Performance Report to Congress
- Definitions of all denominators and numerators for each performance measure topic
- Detailed description of the logic for the denominator and numerator, including specific codes, fields, taxonomies, and/or values searched
- Key changes to logic from the previous year, if any
- Description of which patients and information are contained on the patient list
- Performance measure source and past IHS performance, if any, and IHS or Healthy People (HP) 2020 targets for the performance measure
- Report examples
- Patient list examples

**Note:** All report examples and patient list examples used in this section were produced from "scrubbed" demonstration databases and do not represent individual patient data.

# 2.1 Performance Measure Logic Basics

#### 2.1.1 CRS Denominator Definitions

Each performance measure topic has one or more define denominators and numerators. The denominator is the total population that is being reviewed for a specific measure. For the National GPRA/GPRAMA Report, only one denominator for each topic is reported. These denominators are pre-defined, based on the Active Clinical Population definition. For the Selected Measures reports for local use (CRS Version 17.0 User Manual, Section 5.11), multiple denominators may be reported to provide a complete picture of clinical performance. There are also additional options available to further refine denominator definitions.

# 2.1.1.1 Denominator Definitions for National GPRA Reporting

The Active Clinical population is the denominator definition used as the basis for *most* GPRA measures. This denominator was developed in FY 2003 specifically for clinical performance measures because it is more representative of the active clinical population.

Prior to FY 2003, the GPRA User Population denominator definition was used for national reporting, similar to the agency's IHS User Population definition.

The *Active Clinical* population for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the Resource and Patient Management System (RPMS) Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past 3 years prior to the end of the Report Period. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB

Clinic Code	Clinic Description
05	Dermatology
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- Patient must be American Indian/Alaska Native (AI/AN) (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the Purchased and Referred Care (PRC) catchment area specified in the community taxonomy specified by the user.

The *Active Clinical Plus Behavioral Health Population* for National GPRA/GPRAMA Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past 3 years prior to the end of the Report Period. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other

Clinic Code	Clinic Description
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
B9	Oncology – Hematology
C3	Colposcopy
C4	Behavioral Health
C9	Telebehavioral Health

- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the PRC catchment area specified in the community taxonomy that is specified by the user.

The *GPRA User Population* for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have been seen at least once in the 3 years prior to the end of the Report Period, regardless of the clinic type.

- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA
  community taxonomy, defined as all communities of residence in the PRC
  catchment area specified in the community taxonomy specified by the user.

**Note:** The GPRA User Population definition is similar, but not identical, to the definition used by IHS headquarters (HQ) for annual user population statistics. GPRA "visits" are not required to be workload reportable as defined by IHS HQ.

### 2.1.1.2 Denominator Definitions for Selected Measures Reports

In addition to the National GPRA/GPRAMA Report, CRS provides Selected Measures reports intended for local facility use for specific public health and/or performance improvement initiatives (CRS Version 17.0 User Manual, Section 5.11). Multiple denominators and numerators will be reported for each measure (e.g., *both* Active Clinical and GPRA User Population). Users have additional options to define the denominators as explained below.

The Active Clinical Population for Selected Measures (Local) Reports is defined as follows:

- Patients with name "DEMO, PATIENT" or who are included in the RPMS
  Demo/Test Patient Search Template (DPST option located in the PCC
  Management Reports, Other section) will be automatically excluded from the
  denominator.
- Patient must have two visits to medical clinics in the past 3 years prior to the end of the Report Period. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice

Clinic Code	Clinic Description
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the Report period.
- User defines population type: AI/AN patients only, non AI/AN, or both. This data item is entered and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The Active Clinical Plus Behavioral Health Population for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past 3 years prior to the end of the Report Period. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT

Clinic Code	Clinic Description
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
38	Rheumatology
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
B9	Oncology – Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both. This data item is typed and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patients (patient panel); or all patients, regardless of community of residence.

The *User Population* for Selected Measures (Local) reports is defined as follows:

 Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be excluded from the denominator automatically.

- Patient must have been seen at least once in the 3 years prior to the end of the Report Period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

# 2.1.2 Performance Measure Logic Example

Cancer Screening: Mammogram Rates: During GPRA Year 2017, achieve the target rate of 56.7% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

For CRS, the GPRA measure definition is defined as:

- Denominator (total number of patients evaluated): Active Clinical female patients ages 52 through 64, excluding those with documented history of bilateral mastectomy. (The clinical owner of the measure has determined based on current medical guidelines that "eligible" women are defined as ages 52 through 64.)
- Numerator (those from the denominator who meet the criteria for the measure): patients with documented mammogram in past 2 years.

For the programmer, the Mammogram measure is described in terms of the following logic:

- 1. Begin with the Active Clinical population definition.
  - Exclude any patients with the name of "DEMO, PATIENT."
  - Exclude any patient records that are included in the RPMS Demo/Test Patient Search Template.
  - Exclude any patients with a date of death in the Patient Registration file.
  - Exclude any patients who do *not* have value 01 (AI/AN) in the Beneficiary field in Patient Registration file.
  - Exclude any patients whose Community of Residence is not included in the site's defined GPRA Community Taxonomy for this report.
  - For the remaining patients, search Visit files for the 3 years prior to the selected report end date; exclude any patient records whose visits do not meet the "two medical clinics" definition.

- 2. From these patients, identify the subset that are female and at least age 52 on the first day of the current report period and less than age 65 on the last day of the report period.
- 3. Exclude patients with documented bilateral mastectomy by searching the V Procedure file for Procedure Codes ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HBV0ZZ, 0HCV0ZZ, 0HTV0ZZ, V CPT for CPT Codes 19300.50-19307.50 OR 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, 19240, w/modifier of 50 or 09950, or POV or Problem List entry where the status is not Deleted of ICD-10: Z90.13 or SNOMED data set PXRM BGP BILAT MASTECTOMY (Problem List only) any time before the end of the report period; *or* who have two separate occurrences for either (1) one code that indicates a right mastectomy and one code that indicates a left mastectomy, or (2) one code that indicates a mastectomy on unknown side and one code that indicates either a right or left mastectomy, or two codes that indicate a mastectomy on unknown side on two different dates of service.
  - a. Right Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.11; SNOMED data set PXRM BGP RIGHT MASTECTOMY (Problem List only); Procedure ICD-10: 07T50ZZ, 07T80ZZ, 0HBT0ZZ, 0HCT0ZZ, 0HTT0ZZ.
  - b. Left Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.12; SNOMED data set PXRM BGP LEFT MASTECTOMY (Problem List only); Procedure ICD-10: 07T60ZZ, 07T90ZZ, 0HBU0ZZ, 0HCU0ZZ, 0HTU0ZZ.
  - c. Mastectomy on unknown side: 1) CPT 19300-19307, or old codes 19180, 19200, 19220, 19240; 2) Procedure ICD-9: 85.41, 85.43, 85.45, 85.47.
- 4. For these patients (the denominator), check for a mammogram in the past 2 years in the following order:
  - a. Check V Radiology or V CPT for the following CPT Codes: 77052 through 77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206; G0204, G0202
  - b. Check the Purpose of Visit file (V POV) for a diagnosis of ICD-9: V76.11 Screening Mammogram for High Risk Patient; V76.12 Other Screening Mammogram; 793.80 Abnormal Mammogram, Unspecified; 793.81 Mammographic Microcalcification; 793.89 Other Abnormal Findings On Radiological Exam of Breast or ICD-10: R92.0, R92.1, R92.8, Z12.31.
  - c. Check V Procedures for a procedure of ICD-9: 87.36 Xerography of Breast, 87.37 Other Mammography or ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ.

d. Check the Women's Health Tracking package for documentation of a procedure called Mammogram Screening, Mammogram Dx Bilat, or Mammogram Dx Unilat and where the result does *not* have "ERROR/DISREGARD".

If a visit with any of the specified codes is found, the patient is considered to have met the measure, and the program checks the next patient.

# 2.1.3 Age Ranges

Unless otherwise noted, for the purposes of CRS reports, the age of a patient is calculated at the beginning of the report period. For example, for a report period of July 1, 2016 through June 30, 2017, Jane Doe is defined as age 74 if her birth date is June 10, 1942, even though she becomes age 75 during the report period.

#### 2.1.4 Standard Health Care Codes

## 2.1.4.1 Current Procedural Terminology Codes

One of several code sets used by the healthcare industry to standardize data, and allow for comparison and analysis. Current Procedural Terminology (CPT) was developed and is updated annually by the American Medical Association, and is widely used in producing bills for services rendered to patients. CPTs include codes for diagnostic and therapeutic procedures, and specify information that differentiates the codes based on cost. CPT codes are the most widely accepted nomenclature in the United States for reporting physician procedures and services for federal and private insurance third-party reimbursement. CRS searches for CPT and other codes as specified in the logic definition to determine if a patient meets a denominator or numerator definition.

#### 2.1.4.2 International Classification of Disease Codes

One of several code sets used by the healthcare industry to standardize data. The International Classification of Disease (ICD) is an international diagnostic coding scheme. In addition to diseases, ICD also includes several families of terms for medical-specialty diagnoses, health status, disablements, procedure, and reasons for contact with healthcare providers. IHS currently uses ICD, Ninth Revision (ICD-9) for coding, but will be switching to ICD-10 in 2015. CRS searches for ICD and other codes as specified in the logic definition, to determine if a patient meets a denominator or numerator definition.

#### 2.1.4.3 Logical Observation Identifiers Names and Codes

Logical Observation Identifiers Names and Codes (LOINC®). A standard coding system originally initiated for laboratory values, the system is being extended to include non-laboratory observations (electrocardiograms, vital signs, etc.). Standard code sets are used to define individual tests and mitigate variations in local terminologies for laboratory and other healthcare procedures, for example, Glucose or Glucose Test. IHS began integrating LOINC values into RPMS in several pilot sites in 2002.

Refer to the CRS Version 17.0 Technical Guide for a list of specific LOINC codes included in each LOINC taxonomy.

# 2.2 Diabetes Related Measure Topics

#### 2.2.1 Diabetes Prevalence

#### **Denominators**

*User Population patients*. Broken down by gender and age groups (less than (<) 15, 15 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, greater than (>) 64 years).

#### **Numerators**

Patients diagnosed with Diabetes at any time before the end of the Report Period.

Patients diagnosed with Diabetes during the Report Period.

#### **Logic Description**

Age is calculated at the beginning of the Report Period.

*Diabetes definition*: At least one POV diagnosis of ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*.

## **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of diabetic patients with most recent diagnosis.

#### **Measure Source**

HP 2010 5–2, 5–3

#### **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance	14.7%
IHS FY 2015 Performance	14.4%
IHS FY 2014 Performance	14.0%
IHS FY 2013 Performance	13.9%
IHS FY 2012 Performance	13.4%
IHS FY 2011 Performance	12.8%
IHS FY 2010 Performance	12.0%
IHS FY 2009 Performance	12.0%
IHS FY 2008 Performance	12.0%
IHS FY 2007 Performance	11.0%
IHS FY 2006 Performance	11.0%
IHS FY 2005 Performance	11.0%
IHS FY 2004 Performance	10.0%

```
DII
                              November 25, 2017
                                                                       Page 1
       *** IHS 2017 Selected Measures with Community Specified Report ***
                              DEMO INDIAN HOSPITAL
                  Report Period: Jan 01, 2017 to Dec 31, 2017
              Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Diabetes Prevalence
Denominator(s):
- User Population patients. Broken down by gender and by age groups: <15,
15-19, 20-24, 25-34, 35-44, 45-54, 55-64, 65+.
 - Patients diagnosed with Diabetes at any time before the end of the Report
 - Patients diagnosed with Diabetes during the Report Period.
Age is calculated at the beginning of the Report Period. Diabetes
diagnosis is defined as at least one POV diagnosis ICD-9: 250.00-250.93
or ICD-10: E10.*-E13.*.
Performance Measure Description:
Continue tracking (i.e., data collection and analyses) Area age-specific
diabetes prevalence rates to identify trends in the age-specific
prevalence of diabetes (as a surrogate marker for diabetes incidence) for
the AI/AN population.
Past Performance and/or Target:
```

	0.1.6		0015	7.4.40	0014	14.00		0010 10 00
IHS Performance: FY 20 FY 2012 - 13.4%, FY 20					•		•	•
2007 - 11%, FY 2006 -		-		-		126, F1	2006	- 126, Fi
2007 110, F1 2000	110, 11	2003	110, 1	1 200-	100			
Source:								
HP 2010 5-2, 5-3								
Diabetes Prevalence								
T	REPORT	0,	DDEW VD	Q.	CHG from	DACE	Q,	CUC from
	_				PREV YR %			BASE %
•	LLICE		1211102		1100 110 0	ILICIO		D1101 0
User Pop Pts	2,896		2,456			2,346		
# w/ any DM Dx	265	9.2	243	9.9	-0.7	197	8.4	+0.8
# w/ DM Dx	177	<i>c</i> 0	1.4.0	г о	+0.0	100	4 2	+1.7
during Report Period	1/3	6.0	140	5.9	+0.0	100	4.3	+1./
Male User Pop Pts	1.368		1,152			1,109		
	_, -,		_,			_,_,		
# w/ any DM Dx	114	8.3	104	9.0	-0.7	72	6.5	+1.8
# w/DM Dx								
during Report Period	82	6.0	78	6.8	-0.8	48	4.3	+1.7
Fomale Haar Don Dta	1 520		1,304			1,237		
Female User Pop Pts	1,520		1,304			1,43/		
# w/ any DM Dx	151	9.9	139	10.7	-0.8	125	10.1	-0.2
# w/ DM Dx								
during Report Period	91	6.0	68	5.2	+0.7	52	4.2	+1.8

Figure 2-1: Sample Summary Report, Diabetes Prevalence Topic

DU November 25, 2017 Page 2  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016									
	Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Diabetes Prevalence (co	n't)								
	TOTAL USER POPULATION								
			Age	Distri	bution				
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs	
CURRENT REPORT PERIOD									
Total # User Pop	730	239	261	403	389	390	262	222	
# w/ any DM Dx	1	3	7	37	57	67	50	43	
% w/ any DM Dx	0.1	1.3	2.7	9.2	14.7	17.2	19.1	19.4	
# w/ DM Dx									
during Report Period	0	2	3	14	42	49	34	29	
% w/ DM Dx during Report Period	0.0	0.8	1.1	3.5	10.8	12.6	13.0	13.1	
PREVIOUS YEAR PERIOD									
Total # User Pop	711	227	2/12	350	216	277	181	149	
# w/ any DM Dx		4	9	31	54	57	45	40	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

% w/ any DM Dx	0.4	1.8	3.7	8.8	17.1	20.6	24.9	26.8	
J 1	1	3	3	9	33	37	31	29	
% w/ DM Dx during Report Period	0.1	1.3	1.2	2.6	10.4	13.4	17.1	19.5	

CHANGE FROM PREV YR %									
w/ any DM Dx	-0.3	-0.5	-1.0	+0.4	-2.4	-3.4	-5.8	-7.5	
w/ DM Dx									
during Report Period	-0.1	-0.5	-0.1	+0.9	+0.4	-0.8	-4.1	-6.4	
BASELINE REPORT PERIOD									
Total # User Pop	787	208	217	329	293	228	141	143	
# w/ any DM Dx	2	4	12	20	38	46	31	44	
% w/ any DM Dx	0.3	1.9	5.5	6.1	13.0	20.2	22.0	30.8	
# w/ DM Dx									
during Report Period	2	1	3	7	18	21	20	28	
% w/ DM Dx									
during Report Period	0.3	0.5	1.4	2.1	6.1	9.2	14.2	19.6	
CHANGE FROM BASE YR %									
w/ any DM Dx	-0.1	-0.7	-2.8	+3.1	+1.7	-3.0	-2.9	-11.4	
w/ DM Dx									
during Report Period	-0.3	+0.4	-0.2	+1.3	+4.7	+3.4	-1.2	-6.5	

Figure 2-2: Sample Age Breakdown Page, Diabetes Prevalence Topic

DU	November 25, 2017	Page 1						
*** IHS 2017 Clinical Performance Measure Patient List ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Entire Patient List								
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient  Diabetes Prevalence: List of diabetic patients with most recent diagnosis								
PATIENT NAME DENOMINATOR	HRN COMMUNITY SEX AGE DOB NUMERATOR							
PATIENT1, DEBORAH UP	000001 COMMUNITY #1 F 20 01/06/9 02/01/17 POV 250.00	7						
PATIENT2, TARA	000002 COMMUNITY #1 F 21 03/15/9 05/24/16 POV E11.21	16						
PATIENT3, BOBBIE	000003 COMMUNITY #1 F 28 10/01/8	39						
PATIENT4, WINONA	000004 COMMUNITY #1 F 37 05/03/8 04/30/17 POV 250.00	30						
PATIENT5, NADINE	000005 COMMUNITY #1 F 44 07/07/7 03/19/16 POV 250.00	'3						
PATIENT6, RUTH UP	000006 COMMUNITY #1 F 44 11/03/7 03/19/17 POV E10.10	'3						

Figure 2-3: Sample Patient List, Diabetes Prevalence, Patients with Diabetes Diagnosis

# 2.2.2 Diabetes Comprehensive Care

#### **Denominators**

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral blindness.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

#### **Numerators**

Patients with hemoglobin A1c documented during the Report Period, regardless of result

Patients with blood pressure (BP) documented during the Report Period

Patients with controlled BP, defined as less than (<) 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period *or* with the evidence of diagnosis and/or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period

Patients receiving a qualified retinal evaluation during the Report Period

**Note**: This numerator does *not* include refusals.

Patients with diabetic foot exam during the Report Period

**Note**: This numerator does *not* include refusals.

Patients with comprehensive diabetes care (documented A1c and blood pressure and nephropathy assessment and retinal exam and diabetic foot exam).

#### **Logic Description**

*Diabetes definition*: First Purpose of Visit (POV) ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the POV file prior to the Report Period.

*A1c definition*: Searches for most recent A1c test with a result during the Report Period. If none found, CRS searches for the most recent A1c test without a result. A1c defined as: CPT 83036, 83037, 3044F through 3046F, 3047F (old code); LOINC taxonomy; or site-populated taxonomy DM AUDIT HGB A1C TAX.

*BP documented definition*: Having a minimum of 1 BP documented during the Report Period.

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs, or one BP if there is only one documented. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) BPs and dividing by 3 (or 2).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

Controlled BP definition: CRS uses a mean, as described above. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from BP measurements, it will search for the most recent of any of the following CPT codes documented during the Report Period: BP Documented: 0001F, 2000F, G9273, G9274 or POV ICD-9: V81.1; or Systolic 3074F, 3075F, or 3077F with Diastolic: 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<) 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F; or G9273. All other combinations will not be included in the Controlled BP numerator.

Nephropathy assessment definition: (1) Estimated GFR with result during the report period, defined as any of the following: (A) Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or (B) LOINC taxonomy, and (2) Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, defined as any of the following: (A) CPT 82043 WITH 82570; (B) LOINC taxonomy; or (C) site-populated taxonomy BGP QUANT UACR TESTS.

**Note**: Be sure to check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values.

(3) ESRD diagnosis/treatment defined as any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) Diagnosis (POV or Problem List entry where the status is not Deleted) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only); (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

Qualified retinal evaluation definition: (1) diabetic retinal exam or (2) other eye exam. The following methods are qualifying for this measure: (1) dilated retinal evaluation by an optometrist or ophthalmologist, or (2) seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist, or (3) any photographic method formally validated to seven standard fields (ETDRS).

• Diabetic Retinal Exam: Any of the following during the Report Period: (1) Exam Code 03 Diabetic Eye Exam (dilated retinal examination or formally validated\* ETDRS photographic equivalent), (2) CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging formally validated\* to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.

• Other Eye Exam: Non-DNKA (did not keep appointment) visits to ophthalmology or optometry clinics with an optometrist or ophthalmologist, or visits to formally validated\* tele-ophthalmology retinal evaluation clinics. Searches for the following codes in the following order: CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014; Clinic Code A2 (Diabetic Retinopathy)\*\*; Clinic Codes 17 or 18 with Provider Code 08, 24, or 79 where the Service Category is not C (Chart Review) or T (Telecommunications).

Bilateral blindness defined as Diagnosis (POV or Problem List entry where the status is not Deleted) of any of the following: 1) ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0; 2) SNOMED data set PXRM BGP BILAT BLINDNESS (Problem List only); 3) SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral (Problem List only); 4) One code from (SNOMED data set PXRM BGP LEFT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left (Problem List only)) AND one code from (SNOMED data set PXRM BGP RIGHT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right (Problem List only)).

*Diabetic foot exam definition:* (1) Exam Code 28 Diabetic Foot Exam, Complete; (2) non-DNKA visit with a podiatrist (Provider Codes 33, 84 or 25), (3) non-DNKA visit to Podiatry Clinic or Diabetic Foot Clinic (Clinic Codes 65 and B7), or (4) CPT 2028F, G9226.

Bilateral foot amputation definition: CPT 27290.50 through 27295.50, 27590.50 through 27592.50, 27598.50, 27880.50 through 27882.50 (50 modifier indicates bilateral), G9224; 2) Procedure ICD-10: 0Y640ZZ.

Unilateral foot amputation definition: Must have two separate occurrences on two different dates of service: (1) CPT 27290 through 27295, 27590 through 27592, 27598, 27880 through 27882; (2) Procedure ICD-9: 84.10, 84.13 through 84.19; ICD-10: 0Y620ZZ, 0Y630ZZ, 0Y670ZZ, 0Y680ZZ, 0Y6C0Z\*, 0Y6D0Z\*, 0Y6F0ZZ, 0Y6G0ZZ, 0Y6H0Z\*, 0Y6J0Z\*, 0Y6M0Z0, 0Y6N0Z0, or (3) POV ICD-9: V49.7\*.

#### **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to ESRD definition to look at the Problem List.
- 2. Added SNOMED data set PXRM END STAGE RENAL DISEASE to ESRD definition (for Problem List only).

<sup>\*</sup>Validation study properly powered and controlled against the ETDRS gold standard.

<sup>\*\*</sup>Validated photographic (teleophthalmology) retinal surveillance.

- 3. Removed ICD-10 codes H54.10-H54.12 from bilateral blindness definition.
- 4. Changed logic for bilateral blindness to include inactive problems on the Problem List.
- 5. Added SNOMED data set PXRM BGP BILAT BLINDNESS and PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral to bilateral blindness definition (for Problem List only).
- 6. Added SNOMED data sets PXRM BGP LEFT EYE BLIND, PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left, PXRM BGP RIGHT EYE BLIND, and PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right to bilateral blindness definition (for Problem List only).
- 7. Removed LOINC codes 24362-6, 45066-8, and 50261-7 from BGP ESTIMATED GFR LOINC taxonomy.

### **Patient List Description**

List of diabetic patients with documented tests, if any.

#### **Measure Source**

Foot Exam: HP 2020 D-9

# **Measure Past Performance and Long-Term Targets**

Target	Percent
HP 2020 goal for foot exam	74.8%

DU November 25, 2017 Page 9  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Diabetes Comprehens:	ive Care REPORT PERIOD	% PREV YR PERIOD	% CHG from B PREV YR % P		HG from		
Active Diabetic Pts	417	467		445			
<pre># w/ Comp Diabetes   Care # w /Alc w/ or w/o   result</pre>			6.0 -5.0 76.4 -26.8				

# w/ BPs								
documented	374	89.7	453	97.0	-7.3	433	97.3	-7.6
# w/ Controlled BP								
<140/90	251	60.2	319	68.3	-8.1	310	69.7	-9.5
# w/ Est GFR & UACR or w/ ESRD	131	31.4	258	55 2	-23.8	297	66.7	-35.3
official of w/ Edits	131	51.1	250	33.2	23.0	2,,	00.7	33.3
Active Diabetic								
Pts w/o Hx of								
Bilateral Blindness	417		467			445		
Billianess	11,		10,			113		
# w/ Retinal								
Evaluation-No Refusals	27	8.9	100	27 0	-18.1	1 - 0	24.0	25.3
Refusais	3 /	8.9	120	27.0	-18.1	152	34.2	-25.3
Active Diabetic								
Pts w/o Hx of								
Bilateral	204		4.4.6			400		
Amputation	394		446			428		
# w/ Diabetic Foot								
Exam-No Refusals	47	11.9	90	20.2	-8.3	111	25.9	-14.0

Figure 2-4: Sample Summary Report, Diabetes Comprehensive Care Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes Comprehensive Care: List of diabetic patients with documented tests, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 05/23/72 ΑD Alc: 02/28/17 6.6; BPs: 143/92 UNC; EYE: 01/07/17 Cl PATIENT2, TARA 000002 COMMUNITY #1 F 51 09/10/66 BP: <140/90: BPs: 118/61; ESRD: 03/03/17 90951; FOOT AMPUTATION PATIENT3, BARBIE 000003 COMMUNITY #1 F 52 02/12/65 Alc: 04/09/17 6.5; BPs: 148/86 UNC; GFR: 04/09/17 & UACR: 03/31/17 QUANT UACR; EYE: 03/30/17 Cl 18; FOOT EXAM: 01/07/17 Cl 65 PATIENT4, DONALD 000004 COMMUNITY #1 M 25 08/01/92 BILATERAL BLINDNESS

Figure 2-5: Sample Patient List, Diabetes Comprehensive Care

## 2.2.3 Diabetes: Glycemic Control

### **GPRAMA Measure Description, Good Glycemic Control**

During GPRA Year 2017, achieve the target rate of 48.4% for the proportion of patients with diagnosed diabetes who have good glycemic control (defined as A1c less than (<) 8).

#### **Denominators**

User Population patients diagnosed with diabetes prior to the report period.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRAMA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 and older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever; (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerators**

Patients with a hemoglobin A1c documented during the Report Period, regardless of result.

*Poor Control*: Total of Poor and Very Poor Control: Patients with A1c greater than (>) 9.5.

*Very Poor Control*: Patients with A1c greater than or equal to (>=) 12.

*Poor Control*: Patients with A1c greater than (>) 9.5 and less than (<) 12.

Fair Control: Patients with A1c greater than or equal to (>=) 8 and less than or equal to (<=) 9.5.

Patients with A1c greater than or equal to (>=) 7 and less than (<) 8.

Good Control: Patients with A1c less than (<) 8. (GPRAMA Numerator)

Patients with A1c less than (<) 7.

Without Result: Patients with A1c documented but no value.

## **Logic Description**

*Diabetes definition*: First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Hemoglobin A1c definition: Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If both tests have a result, the last test done on the visit will be used. If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result. Without result is defined as A1c documented but with no value.

CRS uses the following definitions:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Hemoglobin A1c	83036, 83037, 3044F-3046F, 3047F (old code) <b>Note</b> : CPT 3044F represents A1c less than (<) 7 and will be included in the A1c less than (<) 7 and A1c less than (<) 8 numerators.	Yes	DM AUDIT HGB A1C TAX

In the CPT Codes column, specific LOINC codes used CRS are located in the *CRS Technical Manual*.

#### **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of diabetic patients with most recent A1c value, if any.

#### **Measure Source**

HEDIS; HP 2020 D-11, D-5

# **Measure Past Performance and Long-Term Targets Hemoglobin A1c Documented**

Performance	Percent
IHS FY 2016 Performance	85.5%
IHS FY 2015 Performance	84.7%
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	85.2%
IHS FY 2012 Performance	84.9%
IHS FY 2011 Performance	83.0%
IHS FY 2010 Performance	82.0%
IHS FY 2009 Performance	80.0%
IHS FY 2008 Performance	79.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	79.0%
IHS FY 2005 Performance	78.0%
IHS FY 2004 Performance	77.0%
IHS FY 2003 Performance	75.0%
IHS FY 2002 Performance	73.0%
HP 2020 Goal	71.1%

# Good Glycemic Control (A1c less than (<) 8)

Performance	Percent
IHS FY 2016 Performance	46.9%
IHS FY 2015 Performance	47.4%
IHS FY 2014 Performance	48.6%
IHS FY 2013 Performance	48.3%

# Poor Glycemic Control (A1c greater than (>) 9.5)

Performance	Percent
IHS FY 2016 Performance	21.7%
IHS FY 2015 Performance	20.9%
IHS FY 2014 Performance	20.7%
IHS FY 2013 Performance	20.7%
IHS FY 2012 Performance	19.8%
IHS FY 2011 Performance	19.1%
IHS FY 2010 Performance	18.0%

Performance	Percent
IHS FY 2009 Performance	18.0%
IHS FY 2008 Performance	17.0%
IHS FY 2007 Performance	16.0%
IHS FY 2006 Performance	16.0%
IHS FY 2005 Performance	15.0%
IHS FY 2004 Performance	17.0%
IHS FY 2003 Performance	17.0%
IHS FY 2002 Performance	18.0%

# Ideal Glycemic Control (A1c less than (<) 7)

Performance	Percent
IHS FY 2012 Performance	33.2%
IHS FY 2011 Performance	31.9%
IHS FY 2010 Performance	32.0%
IHS FY 2009 Performance	31.0%
IHS FY 2008 Performance	32.0%
IHS FY 2007 Performance	31.0%
IHS FY 2006 Performance	31.0%
IHS FY 2005 Performance	30.0%
IHS FY 2004 Performance	27.0%
IHS FY 2003 Performance	28.0%
IHS FY 2002 Performance	25.0%
HP 2020 Goal	58.9%

Previ	Selected Meport Perious Year Pesseline Peri	DEMO IND od: Jan O eriod: J	with C DIAN HO D1, 201 Jan 01,	ommun SPITA 7 to 2016	L Dec 31, 20 to Dec 31	17	age 11 *	
Diabetes: Glycemic			EV YR		CHG from		CHG from	
User Pop Pts w/ DM	621	PEF	606		FREV IR 6	571	DASE 6	
<pre># w/ Alc w/ or w/o   result # w/ Alc &gt;=12 # w/ Alc &gt;9.5 and</pre>					-24.8 -3.3		-32.8 +1.5	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

<12	57	9.2	88	14.5	-5.3	81	14.2	-5.0	
# w/ A1c >=8 and									
<=9.5	41	6.6	52	8.6	-2.0	72	12.6	-6.0	
# w/ Alc >=7 and									
<8	26	4.2	44	7.3	-3.1	61	10.7	-6.5	
# w/ Alc <8	76	12.2		27.7	-15.5		36.4		
# w/ Alc <7	50	8.1		20.5	-13.3	147	25.7		
	50	0.1	124	20.5	-12.4	14/	25.7	-1/./	
# w/ A1c w/o	0	1 2	0	0 0	. 1 2	0	0 4	. 0 0	
Result	8	1.3	0	0.0	+1.3	2	0.4	+0.9	
Active Diabetic									
Pts (GPRAMA)	417		467			445			
# w/ Alc w/ or w/o									
result	207	49.6	357	76.4	-26.8	372	83.6	-34.0	
# w/ A1c > 9.5	96	23.0	150	32.1	-9.1	112	25.2	-2.1	
# w/ A1c >=12	42	10.1	62	13.3	-3.2	31	7.0	+3.1	
# w/ Alc >9.5 and									
<12	54	12.9	88	18.8	-5.9	81	18.2	-5.3	
# w/ A1c >=8 and	0.		0.0	20.0	3.,	0.2		3.3	
<=9.5	38	9.1	5.1	10.9	-1.8	72	16.2	-7.1	
# w/ A1c >=7 and	30	9.⊥	31	10.9	-1.0	/ 2	10.2	- / . 1	
# W/ AIC >= / and   <8	26	6.2	12	9.2	-3.0	60	13.5	-7.2	
*	∠6	0.2	43	9.2	-3.0	60	13.5	- / . 2	
# w/ Alc <8	6.5		156	22.4	1	106	41 0	05.5	
(GPRAMA)	67	16.1		33.4			41.8		
# w/ Alc <7	41	9.8	113	24.2	-14.4	126	28.3	-18.5	
# w/ Alc w/o									
Result	6	1.4	0	0.0	+1.4	2	0.4	+1.0	
Active Adult									
Diabetic Pts	309		388			374			
# w/ A1c w/ or w/o									
result	193	62.5	325	83.8	-21.3	336	89.8	-27.4	
# w/ Alc >=12	39	12.6		15.2	-2.6	28	7.5	+5.1	
# w/ A1c >9.5 and					•	_0			
<12	5.4	17.5	22	22.7	-5.2	79	21.1	-3.6	
# w/ A1c >=8 and	24	17.5	00	22.7	5.2	, ,	21.1	5.0	
<=9.5	38	12.3	E O	12.9	-0.6	68	18.2	-5.9	
	38	12.3	30	12.9	-0.6	08	10.2	-5.9	
# w/ A1c >=7 and	0.0	- A	4.0	10 2	0 0		14 🖪	7 2	
<8	23	7.4		10.3	-2.9		14.7		
# w/ Alc <8	57	18.4		33.0	-14.5		42.5		
# w/ A1c <7	34	11.0	88	22.7	-11.7	104	27.8	-16.8	
# w/ Alc w/o									
Result	5	1.6	0	0.0	+1.6	2	0.5	+1.1	

Figure 2-6: Sample Report, Diabetes: Glycemic Control Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetes: Glycemic Control: List of diabetic patients with most recent Alc value, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR

PATIENT1, DEBORAH	000001 COMMUNITY #1 F 45 11/11/72
UP,AD,AAD	03/28/17 Alc: 6.6
PATIENT2, TARA	000002 COMMUNITY #1 F 51 02/10/66
UP,AD,AAD	02/20/17 Alc: 12.4
PATIENT3, BOBBIE	000003 COMMUNITY #1 F 52 05/06/65
UP,AD,AAD	04/09/17 Alc: 6.5
PATIENT4, WINONA	000004 COMMUNITY #1 F 53 07/21/64
UP	
PATIENT5, NADINE	000005 COMMUNITY #1 F 61 08/12/56
UP,AD,AAD	02/01/17 Alc: 6.5
PATIENT6, RUTH	000006 COMMUNITY #1 F 64 06/30/53
UP	

Figure 2-7: Sample Patient List, Diabetes: Glycemic Control

#### 2.2.4 Diabetes: Blood Pressure Control

#### **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 63.8% for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as less than (<) 140/90).

#### **Denominators**

User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 and older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM-related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerators**

Patients with blood pressure documented during the report period.

Patients with controlled blood pressure, defined as less than (<) 140/90, i.e., the mean systolic value is less than 140 and the mean diastolic value is less than 90 (GPRA Numerator).

Patients with blood pressure that is not controlled.

#### **Logic Description**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

BP documented definition: CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of the last 2 BPs, or one BP if there is only one documented. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F-3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

Controlled BP definition: CRS uses a mean, as described above where BP is less than (<)140/90. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented during the Report Period: BP Documented: CPT 0001F, 2000F, G9273, G9274 or ICD-9: POV V81.1; or Systolic: CPT 3074F, 3075F or 3077F with Diastolic: CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<)140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F; or G9273. All other combinations will not be included in the Controlled BP numerator.

CRS uses the following definition:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX

In the LOINC Codes column, specific LOINC codes by CRS are location in the *CRS Technical Manual*.

# **Key Logic Changes from CRS Version 16.1**

None.

# **Patient List Description**

List of diabetic patients with BP value, if any.

#### **Measure Source**

HP 2020 D-7

# **Measure Past Performance and Long-Term Targets Controlled BP**

Performance	Percent
IHS FY 2016 Performance	68.3%
IHS FY 2015 Performance	62.5%
IHS FY 2014 Performance	63.8%
IHS FY 2013 Performance	64.6%
Former definition of BP less than (<) 130/80:	
IHS FY 2012 Performance	38.9%
IHS FY 2011 Performance	37.8%
IHS FY 2010 Performance	38.0%
IHS FY 2009 Performance	37.0%
IHS FY 2008 Performance	38.0%
IHS FY 2007 Performance	39.0%
IHS FY 2006 Performance	37.0%
IHS FY 2005 Performance	37.0%
IHS FY 2004 Performance	35.0%

Performance	Percent
IHS FY 2003 Performance	37.0%
IHS FY 2002 Performance	36.1%
HP 2020 Goal	57.0%

## **BP Assessed**

Performance	Percent
IHS FY 2016 Performance	95.7%
IHS FY 2015 Performance	86.7%
IHS FY 2014 Performance	87.5%
IHS FY 2013 Performance	87.5%
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	87.9%
IHS FY 2010 Performance	89.0%
IHS FY 2009 Performance	88.0%
IHS FY 2008 Performance	89.0%
IHS FY 2005 Performance	89.0%

November 25, 2017 Page 13  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Diabetes: Blood Pre	ssure Con	trol							
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %	
User Pop Pts w/ DM Dx	621		606			571			
# w/ BPs Documented # w/ Controlled BP	445	71.7	525	86.6	-15.0	495	86.7	-15.0	
<140/90	303	48.8	374	61.7	-12.9	361	63.2	-14.4	
# w/ Not Controlled BP	142	22.9	151	24.9	-2.1	134	23.5	-0.6	
Active Diabetic Pts (GPRA)	417		467			445			
<pre># w/ BPs   Documented # w/ Controlled BP</pre>	374	89.7	453	97.0	-7.3	433	97.3	-7.6	
<140/90 (GPRA)	251	60.2	319	68.3	-8.1	310	69.7	-9.5	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Not Controlled BP	123	29.5	134	28.7	+0.8	123	27.6	+1.9
Active Adult Diabetic Pts	309		388			374		
<pre># w/ BPs Documented # w/ Controlled BP</pre>	306	99.0	387	99.7	-0.7	370	98.9	+0.1
<140/90	206	66.7	277	71.4	-4.7	269	71.9	-5.3
# w/ Not Controlled BP	100	32.4	110	28.4	+4.0	101	27.0	+5.4

Figure 2-8: Sample Report, Diabetes: Blood Pressure Control Topic

UP-User Pop; AC-Active Clinical; AD-Active Diabetic; AAD-Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes: Blood Pressure Control: List of diabetic patients with blood pressure value, if any. PATIENT NAME DENOMINATOR HRN COMMUNITY SEX AGE DOB NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 11/11/72 UP,AD,AAD
PATIENT2,TARA
000002 COMMUNITY #1 F 51 02/10/66
UP,AD,AAD
3074F/3080F UNC
PATIENT3,BOBBIE
000003 COMMUNITY #1 F 52 05/06/65 UP,AD,AAD 138/66 CON
PATIENT4,WINONA 000004 COMMUNITY #1 F 53 07/21/64 PATIENT5, NADINE 000005 COMMUNITY #1 F 61 08/12/56 UP,AD,AAD PATIENT6,RUTH 159/86 UNC 000006 COMMUNITY #1 F 64 06/30/53 139/74 CON

Figure 2-9: Sample Patient List, Diabetes: Blood Pressure Control

# 2.2.5 Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 61.9% for the proportion of patients with diagnosed diabetes and cardiovascular disease who are on statin therapy.

#### **Denominators**

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, ages 40 through 75; and Active Diabetic patients age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190. Broken down by age groups 21 through 39, 40 through 75, 76 and older. (GPRA Denominator)

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least 2 visits during the Report Period, and 2 DM-related visits ever, ages 40 through 75.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, ages 40 through 75; and Active Diabetic patients age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190, including denominator exclusions.

*User Population patients* diagnosed with diabetes prior to the Report Period, ages 40 through 75; and *Active Diabetic patients* age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190.

#### **Numerators**

Patients who are statin therapy users during the Report Period or who receive an order (prescription) to receive statin therapy at any point during the Report Period. (GPRA Numerator)

Patients with any of the listed denominator exclusions.

a. Patients with documented allergy, intolerance, or other adverse effect to statin medication.

#### **Logic Description**

Age is calculated at the beginning of the Report Period.

#### **Denominator Logic**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Cardiovascular Disease (CVD) diagnosis defined as any of the following:

Subject Defined	ICD and Other Codes
Coronary Heart Disease (CHD)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 410.0-413.*, 414.0-414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9, Z95.5; SNOMED data set PXRM ISCHEMIC HEART DISEASE (Problem List only)
Acute Myocardial Infarction (AMI)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 410.0*-410.9*, 412; ICD-10: I21.*, I22.*, I23.*, I25.2; SNOMED data set PXRM BGP AMI (Problem List only)
Ischemic Vascular Disease (IVD)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 411.*, 413.*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, 445.*; ICD-10: I20.*, I24.*, I25.1*, I25.5-I25.812, I65.*, I66.*, I70.1, I70.201-I70.299, I70.92, I74.*, I75.*; SNOMED data set PXRM BGP IVD (Problem List only)
Ischemic Stroke or Transient Ischemic Attack (TIA)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.*; SNOMED data set PXRM BGP ISCHEMIC STROKE TIA (Problem List only)
CABG	POV: ICD-9: V45.81; ICD-10: Z95.1  CPT: 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209  Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61  CPT: 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607  Procedure: ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05 (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**
Other Revascularization	CPT: 37220, 37221, 37224-37231

# CRS uses the following to define the tests:

Subject Defined	LOINC Codes	Taxonomy
LDL Done	Yes	DM AUDIT LDL CHOLESTEROL TAX

Subject Defined	LOINC Codes	Taxonomy
LDL greater than or equal to (=>) 190		Tests in above taxonomy with LDL greater than or equal to (=>) 190
LDL less than (<) 70		Tests in above taxonomy with LDL less than (<) 70

In the LOINC Codes column, specific LOINC codes used by CRS are located in the CRS Technical Manual.

#### **Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- 1. Patients with documented allergy, intolerance, or other adverse effect to statin medication.
- 2. Patients who have an active diagnosis of pregnancy or who are breastfeeding.
- 3. Patients with a diagnosis of cirrhosis of the liver during the Report Period or the year prior to the Report Period.
- 4. Patients who are receiving palliative care.
- 5. Patients with end-stage renal disease (ESRD).
- 6. Patients with diabetes whose most recent LDL result is less than (<) 70 and who have never had an LDL result greater than or equal to (>=) 190 and who are not taking statin therapy.

CRS uses the following codes to define contraindications to statins.

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		See below for definition

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Acute Alcoholic Hepatitis		POV or Problem List entry where the status is not Inactive or Deleted during the Report Period: ICD-9: 571.1; ICD-10: K70.10, K70.11; SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
NMI Refusal		Refusal: NMI refusal for any statin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

# Adverse Drug Reaction/Allergy to Statins

#### ICD and Other Codes

Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period

Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period

Myopathy/Myalgia, defined as any of the following during the Report Period: **POV or Problem List entry where the status is not Inactive or Deleted:** ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1; SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)

Any of the following occurring anytime ever:

POV: ICD-9: 995.0-995.3 AND E942.9

Entry in ART (Patient Allergies File): "statin" or "statins"

Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

**Problem List entry where the status is not Deleted**: SNOMED data set PXRM BGP ADR STATIN

Subject Defined	ICD and CPT Codes
Pregnancy	Any of the following: 1) The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period, or 2) At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with:  POV or Problem List: ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 658.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: 009.00-010.02, 010.111-010.12, 010.211-010.22, 010.311-010.32, 010.411-024.12, 024.311-024.32, 024.41*, 024.811-024.82, 024.911-024.92, 025.10-025.2, 026.00-026.62, 026.711-026.72, 026.811-026.93, 029.011-030.33, 031.*-048.*, 060.0*, 061.*-066.*, 068, 069.*, 071.00-071.1, 071.89, 071.9, 074.0-075.81, 075.89, 075.9, 076-077.*, 088.011-088.02, 088.111-088.12, 088.211-088.22, 088.311-088.32, 088.811-088.82, 090.3, 091.011-091.019, 091.111-091.119, 091.211-091.219, 092.011-092.019, 092.20, 092.29, 098.011-098.02, 098.111-098.12, 098.211-098.22, 098.311-098.32, 098.411-098.42, 098.511-098.52, 099.611-098.62, 098.711-099.12, 099.210-099.214, 099.280-099.284, 099.310-099.314, 099.320-099.324, 099.314, 099.334, 099.344, 099.340-099.344, 099.350-099.324, 099.311-098.02, 099.111-099.12, 099.210-099.214, 099.280-099.284, 099.310-099.314, 099.320-099.324, 099.311-098.22, 098.311-098.42, 098.511-098.42, 098.511-098.52, 099.611-099.62, 099.711-099.72, 099.810, 099.814, 099.89, 09A.111-09A.12, 09A.211-09A.22, 09A.311-09A.32, 09A.411-09A.42, 09A.511-09A.52, Zou.7*, Zou.7*
	The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes".
Abortion	CPT: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267  POV: ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z,
	0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z

Miscarriage	<b>CPT:</b> 59812, 59820, 59821, 59830
	<b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9
Breastfeeding	POV: ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
	<b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period

*Cirrhosis of the liver definition*: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-9: 571.2, 571.5, 571.6; ICD-10: K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81; SNOMED data set PXRM BGP CIRRHOSIS (Problem List only).

Palliative care visit definition: POV ICD-9: V66.7; ICD-10: Z51.5.

ESRD diagnosis/treatment definition: Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only); (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

#### **Numerator Logic**

Statin therapy user definition: CPT 4013F

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

#### **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to CVD definitions to look at the Problem List.
- 2. Added SNOMED data set PXRM ISCHEMIC HEART DISEASE to CHD definition (for Problem List only).

- 3. Added SNOMED data set PXRM BGP AMI to AMI definition (for Problem List only).
- 4. Added SNOMED data set PXRM BGP IVD to IVD definition (for Problem List only).
- 5. Added SNOMED data set PXRM BGP ISCHEMIC STROKE TIA to ischemic stroke/TIA definition (for Problem List only).
- 6. Added logic to Acute Alcoholic Hepatitis definition to look at the Problem List.
- 7. Added SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS to acute alcoholic hepatitis definition (for Problem List only).
- 8. Added logic to Myopathy/Myalgia definition to look at the Problem List.
- 9. Added SNOMED data set PXRM BGP MYOPATHY MYALGIA to myopathy/myalgia definition (for Problem List only).
- 10. Updated adverse drug reaction/documented statin allergy logic to clarify that Problem List entry status is not Deleted.
- 11. Added SNOMED data set PXRM BGP ADR STATIN to statin adverse reaction definition (for Problem List only).
- 12. Added logic to cirrhosis of the liver definition to look at the Problem List.
- 13. Added SNOMED data set PXRM BGP CIRRHOSIS to cirrhosis of the liver definition (for Problem List only).
- 14. Added logic to ESRD definition to look at the Problem List.
- 15. Added SNOMED data set PXRM END STAGE RENAL DISEASE to ESRD definition (for Problem List only).

## **Patient List Description**

List of diabetic patients with statin therapy or exclusion, if any.

#### **Measure Source**

HHS Statin Therapy eMeasure

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	61.9%

DU *** IHS 2017	Selected		mber 25,			fied Rem		age 15 **	
		DEMO	INDIAN H	OSPITA			JOI C		
Previo	us Year	Period	: Jan 01	, 201	6 to Dec 31,	1, 2016			
Statin Therapy to Re									
	REPORT PERIOD		PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %	
Active Diabetic Pts 40-75 or 21+ w/ CVD or LDL>=190 (GPRA)	261		276			282			
# w/ Statin Rx (GPRA)	86	33.0	95	34.4	-1.5	116	41.1	-8.2	
Active Diabetic Pts 21-39 w/ CVD or LDL>=190	6		5			3			
# w/ Statin Rx	2	33.3	2	40.0	-6.7	3	100.0	-66.7	
Active Diabetic Pts 40-75 w/ CVD or LDL>=190	72		77			70			
# w/ Statin Rx	33	45.8	36	46.8	-0.9	36	51.4	-5.6	
Active Diabetic Pts 76+ w/ CVD or LDL>=190	15		11			12			
# w/ Statin Rx	5	33.3	3	27.3	+6.1	3	25.0	+8.3	
Active Diabetic Pts 40-75	240		260			267			
# w/ Statin Rx	79	32.9	90	34.6	-1.7	110	41.2	-8.3	
Active Diabetic Pts 40-75 or 21+ w/ CVD or LDL>=190, incl									
Exclusions	336		343			327			
<pre># w/ Exclusions A. # w/ Allergy/ADR w/ % of Total</pre>	75	22.3	67	19.5	+2.8	45	13.8	+8.6	
Exclusions	16	21.3	31	46.3	-24.9	19	42.2	-20.9	
User Pop Pts w/ DM Dx 40-75 or 21+ w/ CVD or LDL>=190	368		352			341			

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Statin Rx	89	24.2	97	27.6	-3.4	120	35.2	-11.0	

Figure 2-10: Sample Report, Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes: List of diabetic patients with statin therapy or exclusion, if any. PATIENT NAME HRN COMMUNITY
DENOMINATOR NUMERATOR HRN COMMUNITY SEX AGE DOB PATIENT1, DEBORAH 000001 COMMUNITY #1 F 35 11/11/81
UP, AD (CHD) Statin: 02/27/17 SIMVASTATIN 40MG TABLET
PATIENT2, TARA 000002 COMMUNITY #1 F 51 02/10/65
UP PATIENT3, BOBBIE 000003 COMMUNITY #1 F 52 05/06/64
UP,AD (CHD) Exclusion: 02/02/13 ESRD
PATIENT4, WINONA 000004 COMMUNITY #1 F 53 07/21/63
UP,AD Statin: 01/08/17 SIMVASTATIN 4
PATIENT5, NADINE 000005 COMMUNITY #1 F 61 08/12/55 Statin: 01/08/17 SIMVASTATIN 40MG TABLET UP,AD 000006 COMMUNITY #1 F 64 06/30/52 PATIENT6, RUTH Exclusion: 02/15/17 ADR/Allergy POV 995.2 UP (CHD)

Figure 2-11: Sample Patient List, Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

# 2.2.6 Diabetes: Nephropathy Assessment

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 63.3% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

#### **Denominators**

User Population patients diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever (GPRA Denominator).

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are aged 19 and older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### Numerator

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the Report Period (GPRA Numerator).

## **Logic Description**

*Diabetes definition*: First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Nephropathy assessment definition:* 

- Estimated GFR with result during the Report Period and Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, *or*
- ESRD diagnosis/treatment defined as any diagnosis ever.

CRS uses the following to define the tests/diagnoses:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic Denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Estimated GFR		Yes	BGP GPRA ESTIMATED GFR TAX

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Urine Albumin-to- Creatinine Ratio (UACR)	<b>CPT</b> : 82043 WITH 82570	Yes	BGP QUANT UACR TESTS Note: Be sure to check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values
End Stage Renal Disease	CPT: 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918 through 90925, 90935, 90937, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old code), G0392 (old code), G0393 (old code),		

In the LOINC Codes column, specific LOINC codes used by CRS are located in the CRS Technical Manual.

# **Key Logic Changes from CRS Version 16.1**

1. Added logic to ESRD definition to look at the Problem List.

- 2. Added SNOMED data set PXRM END STAGE RENAL DISEASE to ESRD definition (for Problem List only).
- 3. Removed LOINC codes 24362-6, 45066-8, and 50261-7 from BGP ESTIMATED GFR LOINC taxonomy.

# **Patient List Description**

List of diabetic patients with nephropathy assessment, if any.

#### **Measure Source**

HP 2010 5-11

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	63.3%
IHS FY 2015 Performance	62.0%
IHS FY 2014 Performance	60.0%
IHS FY 2013 Performance	68.2%
IHS FY 2012 Performance	66.7%
IHS FY 2011 Performance	56.5%
IHS FY 2010 Performance	55.0%
IHS FY 2009 Performance	50.0%
IHS FY 2008 Performance	50.0%
IHS FY 2007 Performance (new baseline established; revised standards of care resulted in revised measure definition)	40.0%
IHS FY 2006 Performance (measure definition was different from current definition)	55.0%
IHS FY 2005 Performance (measure definition was different from current definition)	47.0%
IHS FY 2004 Performance (measure definition was different from current definition)	42.0%
IHS FY 2003 Performance (measure definition was different from current definition)	37.5%
IHS FY 2002 Performance (measure definition was different from current definition)	35.0%

DU November 25, 2017 Page 17

\*\*\* IHS 2017 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016 Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Diabetes: Nephropath	ny Assess	ment							
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %	
User Pop Pts w/ DM Dx	621		606			571			
# w/ Est GFR & UACR or w/ ESRD	138	22.2	261	43.1	-20.8	304	53.2	-31.0	
Active Diabetic Pts (GPRA)	417		467			445			
# w/ Est GFR & UACR or w/ ESRD (GPRA)	131	31.4	258	55.2	-23.8	297	66.7	-35.3	
Active Adult Diabetic Pts	309		388			374			
# w/ Est GFR & UACR or w/ ESRD	109	35.3	234	60.3	-25.0	272	72.7	-37.5	

Figure 2-12: Sample Report, Diabetes: Nephropathy Assessment

UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes: Nephropathy Assessment: List of diabetic patients with nephropathy assessment, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT NAME PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 11/11/72 PATIENT2, TARA 000002 COMMUNITY #1 F 51 02/10/66

UP,AD,AAD GFR: 08/06/17 & UACR: 08/06/17 CPT 82043/82570

PATIENT3,BOBBIE 000003 COMMUNITY #1 F 52 05/06/65

UP,AD,AAD GFR: 09/09/17 & QUANT UP: 03/31/17 QUANT URINE UP,AD,AAD PROTEIN PATIENT4, WINONA 000004 COMMUNITY #1 F 53 07/21/64 PATIENT5, NADINE 000005 COMMUNITY #1 F 61 08/12/56 UP, AD, AAD ESRD: 03/03/17 CPT 90967 PATIENT6, RUTH 000006 COMMUNITY #1 F 64 06/30/53 000007 COMMUNITY #1 F 79 03/22/38 PATIENT7, DANIELLE ESRD: 11/01/16 POV V56.8

Figure 2-13: Sample Patient List, Diabetes: Nephropathy Assessment

# 2.2.7 Diabetic Retinopathy

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 63.1% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

#### **Denominators**

*User Population patients* diagnosed with diabetes prior to the Report Period, without a documented history of bilateral blindness.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral blindness. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are 19 and older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5, without a documented history of bilateral blindness.

#### **Numerators**

Patients receiving a qualified retinal evaluation during the Report Period.

**Note**: This numerator does not include refusals. (GPRA Numerator)

- a. Patients receiving diabetic retinal exam during the Report Period
- b. Patients receiving other eye exams during the Report Period
- c. Patients with a JVN visit during the Report Period.
- d. Patients with an Ophthalmology visit during the Report Period.
- e. Patients with an Optometry visit during the Report Period.

## **Logic Description**

*Diabetes definition*: First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Serum creatinine definition (used with Active Adult Diabetic denominator): Site-populated taxonomy DM AUDIT CREATININE TAX; or LOINC taxonomy (NOTE: CPT codes are not included since they do not store the result, which is used in this topic.).

Qualified retinal evaluation definition: (1) Diabetic retinal exam or (2) other eye exam, as shown below. The following methods are qualifying for this measure:

- Dilated retinal evaluation by an optometrist or ophthalmologist
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist
- Any photographic method validated to seven standard fields (ETDRS).

CRS searches in the following order for:

# Diabetic Retinal Exam (any of the following during the report period)

Exam	CPT Codes	Other Codes
Diabetic Retinal Exam	2022F, 2024F, 2026F, S0620, S0621, S3000	Exam: 03 (dilated retinal examination or formally validated* photographic equivalent)

# Other Eye Exam (any of the following during the report period)

67020 (57020 (ald aada)	
67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014	
	Clinic codes: A2 (Diabetic Retinopathy)**
	Clinic codes: 17 or 18 with Provider Codes: 08, 24, or 79
	* * * * * * * * * * * * * * * * * * * *

<sup>\*</sup>Validation study properly powered and controlled against the ETDRS gold standard.

<sup>\*\*</sup>Validated photographic (teleophthalmology) retinal surveillance.

# JVN visit (any of the following during the report period)

Subject Defined	Other Codes
JVN	Clinic code: A2

# Ophthalmology visit (any of the following during the report period)

Subject Defined	Other Codes
Ophthalmology	Clinic code: 17 with
	Provider Code: 79
	where the Service Category is not C (Chart Review) or T (Telecommunications)

# Optometry visit (any of the following during the report period)

Subject Defined	Other Codes
Optometry	Clinic code: 18 with Provider Code: 08 or 24 where the Service Category is not C (Chart Review) or T (Telecommunications)

## Bilateral Blindness Exclusion

Subject Defined	Other Codes
Bilateral blindness	POV or Problem List entry where the status is not Deleted: 1) ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0; 2) SNOMED data set PXRM BGP BILAT BLINDNESS (Problem List only); 3) SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral (Problem List only); 4) One code from (SNOMED data set PXRM BGP LEFT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left (Problem List only)) AND one code from (SNOMED data set PXRM BGP RIGHT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right (Problem List only)).

# **Key Logic Changes from CRS Version 16.1**

- 1. Removed ICD-10 codes H54.10-H54.12 from bilateral blindness definition.
- 2. Changed logic for bilateral blindness to include inactive problems on the Problem List.
- 3. Added SNOMED data set PXRM BGP BILAT BLINDNESS and PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral to bilateral blindness definition (for Problem List only).
- 4. Added SNOMED data sets PXRM BGP LEFT EYE BLIND, PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left, PXRM BGP RIGHT EYE BLIND, and PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right to bilateral blindness definition (for Problem List only).

# **Patient List Description**

List of diabetic patients with qualified retinal evaluation, if any.

#### **Measure Source**

HP 2020 D-10

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	59.1% (National rate)
IHS FY 2015 Performance	61.3% (National rate)
IHS FY 2014 Performance	59.9% (National rate)
IHS FY 2013 Performance	57.6% (National rate)
IHS FY 2012 Performance	55.7% (National rate)
IHS FY 2011 Performance	54.8% (National rate)
IHS FY 2010 Performance	53.0% (National rate)
IHS FY 2009 Performance	51.0% (National rate)
IHS FY 2008 Performance	50.0% (National rate)
IHS FY 2007 Performance	49.0% (National rate)
IHS FY 2006 Performance	49.0% (National Rate) 52.0% (Designated Sites Rate)
IHS FY 2005 Performance	50.0% (National Rate) 50.0% (Designated Sites Rate)
IHS FY 2004 Performance	47.0% (National Rate) 55.0% (Designated Sites Rate)
IHS FY 2003 Performance	49.0%

Performance	Percent
IHS FY 2002 Performance	49.0%
HP 2020 Goal	58.7%

DU *** IHS 2017	Selected	Measu	mber 25, res with	Commu		fied Rep		age 19 **	
Previo	us Year	Period	: Jan 01	, 201	Dec 31, 206 to Dec 31,	1, 2016			
Diabetic Retinopathy									
					CHG from PREV YR %			CHG from BASE %	
User Pop Pts w/ DM D w/o Hx of Bilateral	x								
Blindness	621		606			571			
# w/ Retinal Evaluation-No Refusals	27	6.0	141	22.2	-17.3	166	20 1	-23.1	
A. # w/ DM Retinal exam w/ % of Total	31	0.0	141	43.3	-17.3	100	29.1	-23.1	
Eval B. # w/ Other Eye	16	43.2	99	70.2	-27.0	43	25.9	+17.3	
exams w/ % of Total Eval	21	56.8	42	29.8	+27.0	123	74.1	-17.3	
Active Diabetic Pts of Bilateral Blindne									
(GPRA)	417		467			445			
# w/ Retinal Evaluation-No									
Refusals (GPRA) A. # w/ DM Retinal exam w/ % of Total	37	8.9	126	27.0	-18.1	152	34.2	-25.3	
Eval B. # w/ Other Eye	16	43.2	89	70.6	-27.4	42	27.6	+15.6	
exams w/ % of Total Eval	21	56.8	37	29.4	+27.4	110	72.4	-15.6	
# w/ Validated Teleretinal visit	2	0.5	0	0.0	+0.5	16	3.6	-3.1	
# w/ Ophthalmology visit # w/ Optomotry	8	1.9	40	8.6	-6.6	39	8.8	-6.8	
# w/ Optometry visit	24	5.8	106	22.7	-16.9	133	29.9	-24.1	
Active Adult Diabeti w/o Hx of Bilateral	c Pts								
Blindness	309		388			374			
# w/ Retinal Evaluation-No									
Refusals	32	10.4	110	28.4	-18.0	129	34.5	-24.1	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

A. # w/ DM Retinal exam w/ % of Total Eval B. # w/ Other Eye	14	43.8	79	71.8	-28.1	38	29.5	+14.3	
exams w/ % of Total Eval	18	56.3	31	28.2	+28.1	91	70.5	-14.3	

Figure 2-14: Sample Report, Diabetic Retinopathy

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Diabetic Retinopathy: List of diabetic patients with qualified retinal
evaluation, if any.
PATIENT NAME
                        HRN COMMUNITY SEX AGE DOB
PATIENT NAME
DENOMINATOR
                         NUMERATOR
PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 11/11/72
UP, AD, AAD Eval: 01/07/17 Cl 18; Optom: 01
PATIENT2, TARA 000002 COMMUNITY #1 F 51 02/10/66
                           Eval: 01/07/17 Cl 18; Optom: 01/07/17 Cl 18
UP,AD,AAD
UP,AD,AAD
PATIENT3,BOBBIE 000003 COMMUNITY #1 F 52 05/06/65
                                Eval: 05/29/17 Cl 17; Ophth: 05/29/17 Cl 17
UP,AD,AAD
UP,AD,AAD Eval: 05/29/17 Cl 17; Ophth: 05
PATIENT4,WINONA 000004 COMMUNITY #1 F 53 07/21/64
PATIENT5, NADINE 000005 COMMUNITY #1 F 61 08/12/56
UP,AD,AAD
                                Eval: 02/06/17 Cl A2; JVN: 02/06/17 Cl A2
UP,AD,AAD Eval: 02/06/17 Cl A2; JVN: 02/0
PATIENT6,RUTH 000006 COMMUNITY #1 F 64 06/30/53
PATIENT7, JONELLE 000007 COMMUNITY #1 F 69 10/27/48
UP,AD,AAD
                                 03/29/17 Diab Eye Ex
```

Figure 2-15: Sample Patient List, Diabetic Retinopathy

#### 2.2.8 Diabetes: Access to Dental Services

#### **Denominator**

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

#### **Numerators**

Patients with documented dental visit during the Report Period.

**Note**: This numerator does *not* include refusals.

### **Logic Description**

*Diabetes definition:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Dental visit definition: For non-PRC dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For PRC dental visits, searches for any visit with an ADA code. PRC visit defined as Type code of C in Visit file.

### **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of diabetic patients with documented dental visit, if any.

#### **Measure Source**

HP 2020 D-8

### **Measure Past Performance and Long-Term Targets:**

Past Performance	Percent
IHS FY 2005 Performance	39.0%
IHS FY 2004 Performance	37.0%
IHS FY 2003 Performance	36.0%
IHS FY 2002 Performance	36.0%
HP 2020 Goal	61.2%

#### **Performance Improvement Tip**

If your facility's dental services are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```
DU November 25, 2017 Page 26

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Diabetes: Access to Dental Services

REPORT % PREV YR % CHG from BASE % CHG from
```

	PERIOD	PERIOD	PREV YR % PERIOD	BASE %
Active Diabetic Pts	417	467	445	
# w/ Dental Visit-No Refusals	71	17.0 165	35.3 -18.3 155	34.8 -17.8

Figure 2-16: Sample Report, Diabetes and Dental Access

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes: Access to Dental Services: List of diabetic patients and documented dental visit, if any. HRN PATIENT NAME COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 11/11/72 AD 03/03/17 ADA 0000 PATIENT2, TARA 000002 COMMUNITY #1 F 51 02/10/66 AD PATIENT3, BOBBIE 000003 COMMUNITY #1 F 52 05/06/65 01/06/17 ADA 0190 PATIENT4, NADINE 000004 COMMUNITY #1 F 61 08/12/56 PATIENT5, SHERRY 000005 COMMUNITY #1 F 68 03/18/49 PATIENT6, JONELLE 000006 COMMUNITY #1 F 69 09/22/48 03/29/17 ADA 0000

Figure 2-17: Sample Patient List, Diabetes and Dental Access

# 2.3 Dental Measure Topics

#### 2.3.1 Access to Dental Services

#### **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 29.7% for the proportion of patients who receive dental services.

#### **Denominators**

*User Population* patients. Broken down by age groups (0 through 5, 6 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older). (GPRA Denominator)

#### **Numerators**

Patients with documented dental visit during the Report Period.

Note:	This numerator does <i>not</i> include refusals. (GPRA
	Numerator)

# **Logic Description**

Dental visit definition: For non-PRC dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For PRC dental visits, searches for any visit with an ADA code. PRC visit defined as Type code of C in Visit file.

### **Key Logic Changes from CRS Version 16.1**

None.

### **Patient List Description**

List of patients with documented dental visit and date.

#### **Measure Source**

HP 2020 OH-7

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	28.7%

Performance	Percent
IHS FY 2015 Performance	29.2%
IHS FY 2014 Performance	28.8%
IHS FY 2013 Performance	28.3%
IHS FY 2012 Performance	28.8%
IHS FY 2011 Performance	26.9%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	25.0%
IHS FY 2007 Performance	25.0%
IHS FY 2006 Performance	23.0%
IHS FY 2005 Performance	24.0%
IHS FY 2004 Performance	24.0%
IHS FY 2003 Performance	25.0%
IHS FY 2002 Performance	24.9%
HP 2020 Goal	49.0%

## **Performance Improvement Tip**

If your facility's dental services are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```
DU
                            November 25, 2017
      *** IHS 2017 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Access to Dental Services
                   REPORT % PREV YR
PERIOD PERIOD
                                           % CHG from BASE
                                                                  % CHG from
                                            PREV YR % PERIOD
                                                                    BASE %
User Pop Pts
 (GPRA)
                    2,466
                                  2,561
                                                         2,516
# w/ Dental
 Visit-No Refusals
 (GPRA)
                      377 15.3
                                     821 32.1 -16.8
                                                           860 34.2
                                                                       -18.9
```

Figure 2-18: Sample Report, Access to Dental Services

```
DU November 25, 2017 Page 29

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017
```

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

Previous Year Period: Jan 01, 2016 to Dec 31, 2016 Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Access to Dental Services (con't)							
		TOTAL II	SER POP	III.ATTON	r		
		1011111 0	-	Distri			
	0-5	6-21	_			55-74	75+ yrs
CURRENT REPORT PERIOD							
Total # User Pop	343	755	507	244	259	314	44
# w/ Dental Visit-No							
Refusals (GPRA)	110	104	54	34	33	37	5
% w/ Dental Visit-No							
Refusals (GPRA)	32.1	13.8	10.7	13.9	12.7	11.8	11.4
PREVIOUS YEAR PERIOD							
Total # User Pop	405	779	500	250	285	305	37
# w/ Dental Visit-No							
Refusals (GPRA)	185	234	154	75	81	86	6
% w/ Dental Visit-No							
Refusals (GPRA)	45.7	30.0	30.8	30.0	28.4	28.2	16.2
CHANGE FROM PREV YR %							
w/ Dental Visit-No							
Refusals (GPRA)	-13.6	-16.3	-20.1	-16.1	-15.7	-16.4	-4.9
BASELINE REPORT PERIOD							
Total # User Pop		795	482	264	280	279	44
# w/ Dental Visit-No							
	174	264	162	80	92	83	5
w/ Dental Visit-No							
Refusals (GPRA)	46.8	33.2	33.6	30.3	32.9	29.7	11.4
CHANGE FROM BASE YR %							
v/ Dental Visit-No							
Refusals (GPRA)	-14.7	-19.4	-23.0	-16.4	-20.1	-18.0	+0.0

Figure 2-19: Sample Age Breakdown Report, Access to Dental Services

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

HR=High Risk Patient							
Access to Dental Service (con't)	vice: List of patients with documented dental visit and date.						
PATIENT NAME DENOMINATOR	HRN COMMUNITY SEX AGE DOB NUMERATOR						
PATIENT10, JOHN	000010 COMMUNITY #1 M 17 01/10/00 01/03/17 ADA 0190						
PATIENT11, HOWARD UP	000011 COMMUNITY #1 M 25 03/16/92 01/24/17 ADA 0000						
PATIENT12,JAMES UP	000012 COMMUNITY #1 M 31 05/10/86 02/19/17 ADA 0000						
PATIENT13,STEVEN UP	000013 COMMUNITY #1 M 32 02/18/85 01/24/17 ADA 0000						
PATIENT14,EDWARD UP	000014 COMMUNITY #1 M 32 09/29/85 06/10/17 ADA 0000						
PATIENT15, DAVID UP	000015 COMMUNITY #1 M 33 07/19/84 04/10/17 ADA 0190						

Figure 2-20: Sample Patient List, Access to Dental Services

#### 2.3.2 Dental Sealants

# **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 16.6% for the proportion of patients with at least one or more intact dental sealants.

#### **Denominator**

User Population patients ages 2 through 15. Broken down by age groups (2 through 5, 3 through 5, 6 through 9, 10 through 12, 13 through 15, and 5 through 19 (GPRA Denominator))

#### **Numerators**

Patients with at least one or more intact dental sealants (GPRA Numerator)

Count only: For patients meeting the *User Population* definition, the total number of dental sealants during the report period.

**Note**: This numerator does not include refusals.

- a. Dental sealants in patients 2 through 15 years.
- b. Dental sealants in patients greater than (>) 15 yrs.

Age breakouts are based on Healthy People 2020 age groups for dental sealants.

# **Logic Description**

Age of the patient is calculated at the beginning of the report period.

Sealants definition: Dental ADA Code 1351, 1352, 1353 or CPT Code D1351, D1352, D1353 documented during the Report Period or Dental ADA code 0007 documented during the past 3 years from the end of the Report Period, as long as the 007 code is not documented on the same visits as 1351, 1352, 1353, D1351, D1352, or D1353. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

For the count measure, only two sealants per tooth and only one repair (ADA code 1353 or CPT D1353) per tooth will be counted during the Report Period. Each tooth is identified by the data element Operative Site in RPMS.

# **Key Logic Changes from CRS Version 16.1**

None.

# **Patient List Description**

List of patients with intact dental sealants.

#### **Measure Source**

HP 2020 OH-2

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	18.1%
IHS FY 2015 Performance	16.3%
IHS FY 2014 Performance	14.6%
IHS FY 2013 Performance	13.9%

Performance	# of Sealants
IHS FY 2012 Performance	295,734
IHS FY 2011 Performance	276,893
IHS FY 2010 Performance	275,459
IHS FY 2009 Performance	257,067
IHS FY 2008 Performance	241,207
IHS FY 2007 Performance	245,449
IHS FY 2006 Performance	246,645
IHS FY 2005 Performance	249,882

Performance	# of Sealants
IHS FY 2004 Performance	230,295 287,158
IHS FY 2003 Performance	232,182
IHS FY 2002 Performance	227,945
IHS FY 2001 Performance	212,612

For the IHS FY 2004 Performance, # of Sealants, please note this was reported by the National Patient Information Reporting System (NPIRS).

# **Performance Improvement Tip**

If your facility's dental visits are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

DU November 25, 2017 Page 30  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Dental Sealants									
	REPORT PERIOD				CHG from PREV YR %			HG from ASE %	
User Pop Pts 2-15 (GPRA)	702		709			695			
# w/ Intact Dental Sealants (GPRA)	37	5.3	44	6.2	-0.9	46	6.6	-1.3	
Total User Population, Ages 2-5 yrs	231		237			230			
# w/ Intact Dental Sealants (GPRA)	11	4.8	10	4.2	+0.5	10	4.3	+0.4	
Total User Population, Ages 3-5 yrs	169		182			161			
# w/ Intact Dental Sealants (GPRA)	11	6.5	9	4.9	+1.6	9	5.6	+0.9	
Total User Population, Ages 6-9 yrs	206		213			217			

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Intact Dental Sealants (GPRA)	16	7.8	15	7.0	+0.7	19	8.8	-1.0	
Total User Population, Ages 10-12 yrs	151		135			116			
# w/ Intact Dental Sealants (GPRA)	5	3.3	13	9.6	-6.3	7	6.0	-2.7	
Total User Population, Ages 13-15 yrs	114		124			132			
# w/ Intact Dental Sealants (GPRA)	5	4.4	6	4.8	-0.5	10	7.6	-3.2	
Total User Population, Ages 5-19 yrs	719		726			752			
# w/ Intact Dental Sealants (GPRA) Total # of	36	5.0	41	5.6	-0.6	43	5.7	-0.7	
Sealants Documented A. # Dental	195		281		-86	296		-101	
Sealants, pts 2-15 yrs B. # Dental	166		223		-57	218		-52	
Sealants, pts 16+ yrs	29		58		-29	76		-47	

Figure 2-21: Sample Report, Dental Sealants

```
UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Dental Sealants: List of patients with intact dental sealants.
                   HRN COMMUNITY SEX AGE DOB
PATIENT NAME
DENOMINATOR
                          NUMERATOR
PATIENT20, GEORGE 000020 COMMUNITY #1 M 5 03/02/12
                           4 sealants: 03/28/17 ADA 1351 (1); 03/28/17 ADA 1351
(1); 03/28/17 ADA 1351 (1); 03/28/17 ADA 1351 (1)
PATIENT21, CODY 000021 COMMUNITY #1 M 7
                                                   10/02/10
                           1 sealants: 03/03/17 ADA 1351
UP 1 sealants: 03/03/17 ADA 1351
PATIENT50,DAWN 000050 COMMUNITY #2 F 4 08/06/13
                           3 sealants: 04/15/17 ADA 1351 (1); 05/19/17 ADA 1351
(1); 05/19/17 ADA 1351 (1)
PATIENT51, JOY 000051 COMMUNITY #2 F 6 06/08/11
                           2 sealants: 03/17/17 ADA 1351 (2)
PATIENT52, DONALD 000052 COMMUNITY #2 M 8 05/25/09
                            1 sealants: 02/02/17 CPT D1351 (1)
```

Figure 2-22: Sample Patient List, Dental Sealants

# 2.3.3 Topical Fluoride

### **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 29.9% for the proportion of patients who received one or more topical fluoride applications.

#### Denominator

User Population patients ages 1 through 15 (GPRA Denominator).

#### **Numerators**

Patients who received one or more topical fluoride applications during the report period (GPRA Numerator).

Count only: For patients meeting the *User Population* definition, the total number of patients with at least one topical fluoride treatment during the Report Period.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

a. Topical fluoride treatment in patients 1 through 15 yrs.

Count only: For patients meeting the *User Population* definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Topical fluoride application definition: (1) Dental ADA Codes 1201 (old code), 1203 (old code), 1204 (old code), 1205 (old code), 1206, 1208 or 5986; (2) CPT Codes D1201 (old code), D1203 (old code), D1204 (old code), D1205 (old code), D1206, D1208, D5986, or 99188; 3) POV ICD-9: V07.31.

For the count measure, a maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

# **Key Logic Changes from CRS Version 16.1**

None.

# **Patient List Description**

List of patients who received at least one topical fluoride application during Report Period.

#### **Measure Source**

Not Available

## **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	31.1%
IHS FY 2015 Performance	29.4%
IHS FY 2014 Performance	27.9%
IHS FY 2013 Performance	26.7%

Performance	Number of Patients
IHS FY 2012 Performance	169,083
IHS FY 2011 Performance	161,461
IHS FY 2010 Performance	145,181
IHS FY 2009 Performance	136,794
IHS FY 2008 Performance	120,754
IHS FY 2007 Performance	107,934
IHS FY 2006 Performance	95,439
IHS FY 2005 Performance	85,318
IHS FY 2005 Performance	113,324

For the IHS FY 2005 Performance, Number of Patients (113,324) is the number of applications.

### **Performance Improvement Tip**

If your facility's dental visits are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

DU November 25, 2017 Page 33

*** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Topical Fluoride							
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		% CHG from BASE %
User Pop Pts 1-15 (GPRA)	767		774			747	
<pre># w/ Topical Fluoride Application (GPRA) Total # of</pre>	161	21.0	292	37.7	-16.7	226	30.3 -9.3
Patients w/ 1+ Topical Fluoride App-No Refusals A. # Topical	194		392		-198	289	-95
Fluoride App, pts 1-15 yrs Total # of Topical	199		565		-366	364	-165
Fluoride Applications	234		705		-471	433	-199

Figure 2-23: Sample Report, Topical Fluoride

UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Topical Fluoride: List of patients who received or refused at least one topical fluoride application during Report Period. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT20, GEORGE 000020 COMMUNITY #1 M 5 03/02/12 1 topical fluoride: 06/18/17 CPT D5986 PATIENT21,RYAN 000021 COMMUNITY #1 M 8 05/25/09 1 topical fluoride: 03/03/17 ADA 1201 PATIENT22, MICHAEL 000022 COMMUNITY #1 M 9 06/22/08 1 topical fluoride: 03/03/17 CPT D1203 PATIENT23, MARTY 000023 COMMUNITY #1 M 15 11/23/02 UP 2 topical fluoride: 01/07/17 ADA 1204; 08/27/17 ADA 1204

Figure 2-24: Sample Patient List, Topical Fluoride

# 2.4 Immunization Measure Topics

## 2.4.1 Influenza

# **GPRA Measure Description**

Children: During GPRA Year 2017, achieve the target rate of 37.1% for the proportion of patients age 6 months to 17 years who receive an influenza immunization.

Adults: During GPRA Year 2017, achieve the target rate of 38.7% for the proportion of patients age 18 years and older who receive an influenza immunization.

#### **Denominators**

Active Clinical patients. Broken down by age groups.

- a. *Active Clinical patients* ages 6 months through 17 years. (GPRA Denominator)
- b. Active Clinical patients ages 18 and older. (GPRA Denominator)
- c. Active Clinical patients ages 18 through 49.
- d. *Active Clinical patients* ages 18 through 49 and considered high risk for influenza.
- e. Active Clinical patients ages 50 through 64.
- f. Active Clinical patients ages 65 and older.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

*User Population patients*. Broken down by age groups.

- a. User Population patients ages 6 months through 17 years.
- b. *User Population patients* ages 18 and older.
- c. *User Population patients* ages 18 through 49.
- d. *User Population patients* ages 18 through 49 and considered high risk for influenza.
- e. *User Population patients* ages 50 through 64.
- f. User Population patients ages 65 and older.

#### **Numerators**

Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

**Note**: The only refusals included in this numerator are not medically indicated (NMI) refusals. (GPRA Numerator)

a. Patients with a contraindication or a documented NMI refusal.

## **Logic Description**

Age of the patient is calculated at the beginning of the report period.

*Diabetes:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90630, 90654-90662, 90672, 90673, 90685- 90688, 90724 (old code), G0008, G8108 (old code)	Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166  POV: ICD-9: V04.8 (old code), V04.81  NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666, 90666, 90668, 90470, G9141 or G9142

- 2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.
- 3. **High Risk for Influenza:** Persons considered high risk for influenza are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21

High Risk Category	ICD-9 Codes	ICD-10 Codes
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Rheumatic Heart Disease	393. through 398.99	I05.* through I09.*
Hypertensive Heart Disease	402.00 through 402.91	l11.*
Hypertensive Heart/Renal Disease	404.00 through 404.93	l13.*
Ischemic Heart Disease	410.00 through 414.9	I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9
Pulmonary Heart Disease	415.0 through 416.9	I26.* through I27.*
Other Endocardial Heart Disease	424.0 through 424.9	I34.* through I39
Cardiomyopathy	425.0 through 425.9	I42.*, I43
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Chronic Bronchitis	491.0 through 491.9	J41.*, J42
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.*, J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.*, N04.*, N08
Renal Failure	585.6, 585.9	N18.6 through N19
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

# **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients with Influenza code, if any.

## **Measure Source**

HP 2020 IID-12.7

## **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance (age 6 mos – 17 yrs)	37.1%

Performance	Percent
IHS FY 2016 Performance (age 18+)	38.7%

Performance	Percent
IHS FY 2015 Performance (age 65+)	65.4%
IHS FY 2014 Performance (age 65+)	68.1%
IHS FY 2013 Performance (age 65+)	68.0%
IHS FY 2012 Performance (age 65+)	65.0%
IHS FY 2011 Performance (age 65+)	62.0%
IHS FY 2010 Performance (age 65+)	62.0%
IHS FY 2009 Performance (age 65+)	59.0%
IHS FY 2008 Performance (age 65+)	62.0%
IHS FY 2007 Performance (age 65+)	59.0%
IHS FY 2006 Performance (age 65+)	58.0%
IHS FY 2005 Performance (age 65+)	59.0%
IHS FY 2004 Performance (age 65+)	54.0%
IHS FY 2003 Performance (age 65+)	51.0%
IHS FY 2002 Performance (age 65+)	51.4%
HP 2020 Goal (age 65+)	90.0%

## **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in Influenza Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU			ember 25,			5		age 35	
*** IHS 2017 S		DEMO	INDIAN H	OSPIT	AL	_	ort *	* *	
Previou	ıs Year	Period	l: Jan 01	, 201	Dec 31, 2 6 to Dec 3	1, 2016			
Base	eline Pe	riod:	Jan 01,	2010	to Dec 31,	2010 			
Influenza									
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts	2,100		2,223			2,207			
# w/ Influenza/Contra NMI Refusal A. # w/ Contra/NMI Ref w/ % of Total		9.4	959	43.1	-33.7	898	40.7	-31.3	
IZ	14	7.1	2	0.2	+6.9	2	0.2	+6.8	
Active Clinical Pts 6 months-17 years (GPRA)	760		798			793			
# w/ Influenza/Contra	ı/								
NMI Refusal (GPRA) A. # w/ Contra/NMI	83	10.9	374	46.9	-35.9	331	41.7	-30.8	
Ref w/ % of Total IZ	4	4.8	0	0.0	+4.8	1	0.3	+4.5	
Active Clinical Pts 18+ (GPRA)	1,333		1,378			1,367			
# w/ Influenza/Contra NMI Refusal	ı/								
(GPRA) A. # w/ Contra/NMI Ref w/ % of Total	115	8.6	575	41.7	-33.1	545	39.9	-31.2	
IZ	10	8.7	2	0.3	+8.3	1	0.2	+8.5	
Active Clinical Pts 18-49	893		948			954			
# w/ Influenza/Contra NMI Refusal A. # w/ Contra/NMI	82	9.2	341	36.0	-26.8	341	35.7	-26.6	
Ref w/ % of Total	3	3.7	1	0.3	+3.4	0	0.0	+3.7	
Active Clinical Pts 18-49 High Risk	305		317			323			
			317			343			
<pre># w/ Influenza/Contra     NMI Refusal     A. # w/ Contra/NMI     Ref w/ % of Total</pre>		10.5	143	45.1	-34.6	140	43.3	-32.9	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

IZ	2	6.3	1	0.7	+5.6	0	0.0	+6.3	
Active Clinical Pts 50-64	313		312			304			
# w/ Influenza/Contra/ NMI Refusal A. # w/ Contra/NMI	23	7.3	167	53.5	-46.2	140	46.1	-38.7	
Ref w/ % of Total IZ	5	21.7	1	0.6	+21.1	1	0.7	+21.0	
Active Clinical Pts 65+	127		118			109			
# w/ Influenza/Contra/ NMI Refusal A. # w/ Contra/NMI	10	7.9	67	56.8	-48.9	64	58.7	-50.8	
Ref w/ % of Total	2	20.0	0	0.0	+20.0	0	0.0	+20.0	
Active Diabetic Pts	417		467			445			
<pre># w/ Influenza/Contra/   NMI Refusal A. # w/ Contra/NMI   Ref w/ % of Total</pre>	44	10.6	268	57.4	-46.8	239	53.7	-43.2	
IZ	5	11.4	0	0.0	+11.4	0	0.0	+11.4	

Figure 2-25: Sample Report, Adult Immunizations: Influenza

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Influenza: List of patients with Influenza code, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1, DEBORAH 000001 COMMUNITY #1 F 15 06/22/02
AD 01/28/17 Imm 88
PATIENT2, CRYSTAL 000002 COMMUNITY #1 F 24 08/11/93
UP, AC
PATIENT3, DEMETRIA 000003 COMMUNITY #1 F 35 03/20/82
UP, AC, HR 02/25/17 Imm 140
PATIENT4, JADE 000004 COMMUNITY #1 F 50 06/09/67
UP
PATIENT5, MARIE 000005 COMMUNITY #1 F 65 12/12/52
UP, AC, AD, HR 01/21/17 NMI Refusal

Figure 2-26: Sample Patient List, Adult Immunization: Influenza

#### 2.4.2 Adult Immunizations

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 86.7% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

#### **Denominators**

Active Clinical patients ages 19 through 59.

Active Clinical patients ages 60 through 64.

Active Clinical patients ages 65 and older. (GPRA Denominator)

Active Clinical patients ages 18 through 64 and considered high risk for pneumococcal.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

Active Clinical patients ages 18 and older. Broken down by age group: 18 through 64.

User Population patients 19 through 59.

User Population patients 60 through 64.

User Population patients ages 65 and older.

*User Population patients* ages 18 through 64 and considered high risk for pneumococcal.

User Population patients ages 18 and older. Broken down by age group: 18 through 64.

#### **Numerators**

Patients who have received 1 dose of Tdap/Td in the past 10 years, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Tdap ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Zoster ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumococcal vaccine after the age of 65 or a dose of pneumococcal vaccine in the past 5 years. (GPRA Numerator)

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever, 1 up-to-date pneumococcal vaccine), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever, 1 up-to-date pneumococcal vaccine), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the Report Period.

**Note**: The only refusals included in this numerator are NMI refusals.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report period.

*Diabetes definition:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Pneumococcal Immunization definition:* Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Pneumoccocal immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Pneumoccocal	90669, 90670, 90732,	Immunization (CVX) Codes:
Vaccine	G0009, G8115 (old	33, 100, 109, 133, 152
	code), G9279	<b>POV:</b> ICD-9: V06.6; V03.82

- 2. **Pneumoccocal Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.
- 3. **High Risk for Pneumococcal:** Persons considered high risk for pneumococcal are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
HIV Infection	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Chronic alcoholism	303.90, 303.91	F10.20, F10.220 through F10.29
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.*, J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.*, N04.*, N08
Renal Failure	585.6, 585.9	N18.6 through N19
Injury to spleen	865.00 through 865.19	

High Risk Category	ICD-9 Codes	ICD-10 Codes
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

*Tdap/Td Immunization definition:* Any of the following documented during the applicable time frame.

1. **Tdap/Td immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Tdap Vaccine	90715	Immunization (CVX) Codes: 115
Td Vaccine	90714, 90718	Immunization (CVX) Codes:
		9, 113, 138, 139
		<b>POV:</b> ICD-9: V06.5

2. **Tdap/Td Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90630, 90654-90662, 90672, 90673, 90685- 90688, 90724 (old code), G0008, G8108 (old code)	Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166  POV: ICD-9: V04.8 (old code), V04.81  NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666, 90666, 90668, 90470, G9141 or G9142

2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.

Zoster definition: Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Zoster immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Zoster Vaccine	90736	Immunization (CVX) Codes: 121

2. **Zoster Contraindication:** (A) Contraindication in the Immunization Package of "Immune Deficiency" or "Anaphylaxis" or (B) PCC NMI Refusal.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients greater than or equal to (=>)18 yrs or DM DX with IZ or contraindication, if any.

#### **Measure Source**

HP 2020 IID-13.1

#### **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance	86.4%
IHS FY 2015 Performance	84.9%
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	89.2%
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	85.5%
IHS FY 2010 Performance	84.0%
IHS FY 2009 Performance	82.0%
IHS FY 2008 Performance	82.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	74.0%
IHS FY 2005 Performance	69.0%
IHS FY 2004 Performance	69.0%
IHS FY 2003 Performance	65.0%

Performance	Percent
IHS FY 2002 Performance	64.0%
HP 2020 Goal for % of patients greater than or equal to (=>) 65	90.0%

## **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in Pneumo Vax Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU *** IHS 2017	Selected		mber 25, ires with		nity Speci:	fied Rep		age 41 **	
Po	nort Der		INDIAN H		AL Dec 31, 2	017			
					6 to Dec 31				
					to Dec 31,				
Adult Immunizations									
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts 19-59	1,087		1,136			1,130			
<pre># w/ Tdap/Td or w/   Contra/NMI Refusal   in past 10 yrs A. # w/ Contra/NMI</pre>	1,007	92.6	1,050	92.4	+0.2	1,009	89.3	+3.3	
Ref w/ % of Total Tdap/Td # w/ Tdap or w/	2	0.2	0	0.0	+0.2	0	0.0	+0.2	
Contra/NMI Refusal A. # w/ Contra/NMI Ref w/ % of Total	909	83.6	881	77.6	+6.1	453	40.1	+43.5	
Tdap # w/ Influenza/Contr	2	0.2	0	0.0	+0.2	0	0.0	+0.2	
NMI Refusal A. # w/ Contra/NMI Ref w/ % of Total	93	8.6	450	39.6	-31.1	423	37.4	-28.9	
Influenza # w/ 1:1:1 Combo	6	0.6	2	0.2	+0.4	1	0.1	+0.5	
or w/ Contra/NMI Refusal A. # w/ Contra/NMI	87	8.0	415	36.5	-28.5	187	16.5	-8.5	
Ref w/ % of Total 1:1:1 # w/ 1:1 Combo or	4	4.6	1	0.2	+4.4	0	0.0	+4.6	
w/ Contra/NMI Refusal - No Influenza A. # w/ Contra/NMI	908	83.5	880	77.5	+6.1	453	40.1	+43.4	
Ref w/ % of Total 1:1	2	0.2	0	0.0	+0.2	0	0.0	+0.2	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Active Clinical									
Pts 60-64	80		78			79			
# w/ Tdap/Td or w/									
Contra/NMI Refusal									
in past 10 yrs	72	90.0	72	92.3	-2.3	69	87.3	+2.7	
A. # w/ Contra/NMI									
Ref w/ % of Total									
Tdap/Td	1	1.3	0	0.0	+1.3	0	0.0	+1.3	
# w/ Tdap or w/									
Contra/NMI Refusal	65	81.3	62	79.5	+1.8	26	32.9	+48.3	
A. # w/ Contra/NMI									
Ref w/ % of Total									
Tdap	1	1.3	0	0.0	+1.3	0	0.0	+1.3	
# w/ Influenza/Contra/									
NMI Refusal	4	5.0	47	60.3	-55.3	39	49.4	-44.4	
A. # w/ Contra/NMI	-	5.0	- '	00.5	33.3	0,0			
Ref w/ % of Total									
Influenza	1	1.3	0	0.0	+1.3	0	0.0	+1.3	
# w/ Zoster or w/	_	1.5	Ü	0.0		Ü	0.0	. 1.3	
Contra/NMI Refusal	39	48.8	36	46.2	+2.6	1	1.3	+47.5	
A. # w/ Contra/NMI	33	10.0	30	10.2	+2.0	_	1.3	+1/.5	
Ref w/ % of Total									
·	1	1.3	0	0.0	+1.3	0	0.0	+1.3	
Zoster	1	1.3	U	0.0	+1.3	U	0.0	+1.3	
# w/ 1:1:1:1 Combo									
or w/ Contra/NMI	_	2 0	2.0	20 5	24 5	•	0 0	2 2	
Refusal	3	3.8	30	38.5	-34.7	0	0.0	+3.8	
A. # w/ Contra/NMI									
Ref w/ % of Total							•		
1:1:1:1	1	33.3	0	0.0	+33.3	0	0.0	+33.3	
# w/ 1:1:1 Combo									
or w/ Contra/NMI									
Refusal - No									
Influenza	39	48.8	36	46.2	+2.6	1	1.3	+47.5	
A. # w/ Contra/NMI									
Ref w/ % of Total									
1:1:1	1	2.6	0	0.0	+2.6	0	0.0	+2.6	

Figure 2-27: Sample Report, Adult Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Adult Immunizations: List of patients 18+ yrs or DM Dx with IZ or contraindication, if any. HRN COMMUNITY SEX AGE DOB PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 18 02/25/99
UP, AC, HR TDAP/TD: 12/22/15 Imm 9 (past 10 PATIENT2, TARA 000002 COMMUNITY #1 F 27 11/23/90 TDAP/TD: 12/22/15 Imm 9 (past 10 yrs) UP,AC TDAP: 03/03/16 Imm 115 (ever); TDAP/TD: 03/03/17 UP,AC TDAP: 03/03/16 Imm 115 (ever); PATIENT3,BOBBIE 000003 COMMUNITY #1 F 41 06/11/76 UP,AC PATIENT4, NADINE 000004 COMMUNITY #1 F 55 08/12/62

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
UP,AC,HR,AD Pneumo: 03/27/14 Imm 33 (ever) (up-to-date);
TDAP/TD: 03/27/14 Imm 9 (past 10 yrs)
PATIENT5,SHERRY 000005 COMMUNITY #1 F 68 09/02/49
UP,AC,HR Pneumo: 02/03/17 CPT 90669
```

Figure 2-28: Sample Patient List, Adult Immunizations

#### 2.4.3 Childhood Immunizations

## **GPRAMA Measure Description**

During GPRA Year 2017, achieve the target rate of 74.8% for the proportion of American Indian/Alaska Native children ages 19 through 35 months who have received the recommended immunizations.

#### **Denominators**

Active Clinical patients ages 19 through 35 months at end of Report Period.

User Population patients ages 19 through 35 months at end of Report Period.

*User Population patients active in the Immunization Package* who are 19 through 35 months at end of Report Period. (GPRAMA Denominator)

**Note:** Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

#### **Numerators**

Patients who have received the 4:3:1:3\*:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals. (GPRAMA Numerator)

Patients who have received 4 doses of DTaP ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Polio ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of MMR ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 or 4 doses of HiB ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Hepatitis B vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Varicella ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 4 doses of Pneumococcal conjugate vaccine ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Hepatitis A vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 2 or 3 doses of Rotavirus vaccine ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 2 doses of Influenza vaccine ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

For each of the above numerators, the following sub-numerators are included:

a. Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal

## **Logic Description**

Age definition: Age of the patient is calculated at the beginning of the Report Period. Therefore the age range will be adjusted to 7 through 23 months, which makes the patient between the ages of 19 through 35 months at the end of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

Active Immunization Package Patients denominator definition: Same as User Pop definition except includes only patients flagged as active in the Immunization Package.

**Note**: Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Dosage and types of immunization definitions:

- 4 doses of DTaP: (1) 4 DTaP/DTP/Tdap; (2) 1 DTaP/DTP/Tdap and 3 DT/td; (3) 1 DTaP/DTP/Tdap and 3 each of Diphtheria and Tetanus; (4) 4 DT and 4 Acellular Pertussis; (5) 4 Td and 4 Acellular Pertussis; or (6) 4 each of Diphtheria, Tetanus, and Acellular Pertussis.
- 3 doses of Polio: (1) v OPV; (2) 3 IPV; or (3) combination of OPV and IPV totaling 3 doses.
- One dose of MMR: (1) MMR; (2) 1 M/R and 1 Mumps; (3) 1 R/M and 1 Measles; or (4) 1 each of Measles, Mumps, and Rubella.
- 3 doses of Hep B
- 3 or 4 doses of HIB, depending on the vaccine administered
- 1 dose of Varicella
- 4 doses of Pneumococcal

- 1 dose of Hepatitis A
- 2 or 3 doses of Rotavirus, depending on the vaccine administered
- 2 doses of Influenza

NMI refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note**: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g. 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all 2 doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator. An exception to this is for the HIB vaccine: if the first 2 doses are part of the 3-dose series, then the patient only needs 3 doses (even if the third dose is included in the 4-dose series).
- Each immunization must be refused and documented separately. For example, if a
  patient has an NMI refusal for Rubella only, then there must be an immunization,
  contraindication, or separate NMI refusal for the Measles and Mumps
  immunizations.
- For immunizations where required number of doses is greater than (>) 1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period.)
- To be counted in sub-numerator A, a patient must meet the numerator definition and have a REF refusal in PCC or a Parent or Patient Refusal in the IZ program for any of the immunizations in the numerator. For example, if a patient refused Rubella only but had immunizations for Measles and Mumps, the patient would be included in sub-numerator A.

NMI refusals are defined as PCC Refusal type NMI for any of the following IZ codes:

Immunization	Immunization Codes for Refusals	CPT Codes for Refusals
DTaP	20, 50, 102, 106, 107, 110, 120, 130, 132, 146	90696, 90698, 90700, 90721, 90723
DTP	1, 22, 102	90701, 90711 (old code), 90720
Tdap	115	90715
DT (Diphtheria & Tetanus)	28	90702
Td (Tetanus & Diphtheria)	9, 113, 138, 139	90714, 90718
Tetanus	35, 112	90703
Acellular Pertussis	11	
OPV	2, 89	90712
IPV	10, 89, 110, 120, 130, 132, 146	90696, 90698, 90711 (old code), 90713, 90723
MMR	3, 94	90707, 90710; M/R: 90708
M/R (Measles/ Rubella)	4	
R/M (Rubella/ Mumps)	38	90709 (old code)
Measles	5	90705
Mumps	7	90704
Rubella	6	90706
HiB	17, 22, 46-49, 50, 51, 102, 120, 132, 146	90645-90648, 90698, 90720- 90721, 90737 (old code), 90748
Hepatitis B	8, 42-45, 51, 102, 104, 110, 132, 146	90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)
Varicella	21, 94	90710, 90716
Pneumococcal	33, 100, 109, 133, 152	90669, 90670, 90732, G0009, G8115 (old code), G9279
Hepatitis A	1, 52, 83, 84, 85, 104	90632-90634, 90636, 90730 (old code)
Rotavirus	74, 116, 119, 122	90680
Influenza	15, 16, 88, 111, 135, 140, 141, 149, 150, 151, 153, 155, 158, 166	90630, 90654-90658, 90659 (old code), 90660-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)

Childhood immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
DTaP	90696, 90698, 90700, 90721, 90723	Immunization (CVX) Codes: 20, 50, 102, 106, 107, 110, 120, 130, 132, 146  POV: ICD-9: V06.1  Contraindications: Immunization Package contraindication of "Anaphylaxis."
DTP	90701, 90711 (old code), 90720	Immunization (CVX) Codes: 1, 22, 102 POV: ICD-9: V06.1, V06.2, V06.3 Contraindications: Immunization Package contraindication of "Anaphylaxis."
Tdap	90715	Immunization (CVX) Codes: 115 Contraindications: Immunization Package contraindication of  "Anaphylaxis."
DT (Diphtheria & Tetanus)	90702	Immunization (CVX) Codes: 28 POV: ICD-9: V06.5 Contraindications: Immunization Package contraindication of "Anaphylaxis."
Td (Tetanus & Diphtheria)	90714, 90718	Immunization (CVX) Codes: 9, 113, 138, 139 POV: ICD-9: V06.5 Contraindications: Immunization Package contraindication of "Anaphylaxis."
Diphtheria	90719	POV: ICD-9: V03.5 Contraindications: Immunization Package contraindication of "Anaphylaxis."
Tetanus	90703	Immunization (CVX) Codes: 35, 112 POV: ICD-9: V03.7 Contraindications: Immunization Package contraindication of "Anaphylaxis."
Acellular Pertussis		Immunization (CVX) Codes: 11 POV: ICD-9: V03.6 Contraindications: Immunization Package contraindication of "Anaphylaxis."
OPV	90712	Immunization (CVX) Codes: 2, 89 Contraindications: Immunization Package contraindication of "Immune Deficiency."
IPV	90696, 90698, 90711 (old code), 90713, 90723	Immunization (CVX) Codes: 10, 89, 110, 120, 130, 132, 146 POV: ICD-9: V04.0, V06.3 Evidence of Disease: POV or PCC Problem List (active or inactive) ICD-9: 730.70-730.79; ICD-10: M89.6*; SNOMED data set PXRM BGP POLIO (Problem List only) Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Neomycin Allergy."

Immunization	CPT Codes	ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
MMR	90707, 90710	Immunization (CVX) Codes: 3, 94
		<b>POV:</b> ICD-9: V06.4
		Contraindications: Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."
M/R (Measles/	90708	Immunization (CVX) Codes: 4
Rubella)		Contraindications: Immunization Package contraindication of "Anaphylaxis"
R/M (Rubella/	90709 (old code)	Immunization (CVX) Codes: 38
Mumps)		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis"
Measles	90705	Immunization (CVX) Codes: 5 POV: ICD-9: V04.2
		<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 055*; ICD-10: B05.*; SNOMED data set PXRM BGP MEASLES (Problem List only)
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
Mumps	90704	Immunization (CVX) Codes: 7
		<b>POV:</b> ICD-9: V04.6
		<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 072*; ICD-10: B26.*
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis"
Rubella	90706	Immunization (CVX) Codes: 6
		<b>POV:</b> ICD-9: V04.3
		<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 056*, 771.0; ICD-10: B06.*; SNOMED data set PXRM BGP RUBELLA (Problem List only)
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
HiB – 3-dose	90647, 90748	Immunization (CVX) Codes: 49, 51
series		<b>POV:</b> ICD-9: V03.81
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis"
HiB – 4-dose	90645, 90646,	Immunization (CVX) Codes: 17, 22, 46-48, 50, 102, 120, 132, 146
series	90648, 90698,	<b>POV:</b> ICD-9: V03.81
	90720-90721, 90737 (old code)	Contraindications: Immunization Package contraindication of "Anaphylaxis"

Immunization	CPT Codes	ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
Hepatitis B	90636, 90723, 90731 (old code),	Immunization (CVX) Codes: 8, 42-45, 51, 102, 104, 110, 132, 146  Evidence of Disease: POV or PCC Problem List (active or inactive)
	90740, 90743- 90748, G0010,	ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B19.1*, Z22.51; SNOMED data set PXRM BGP HEPATITIS B (Problem List only)
	Q3021, (old code) Q3023 (old code)	Contraindications: Immunization Package contraindication of "Anaphylaxis"
Varicella	90710, 90716	Immunization (CVX) Codes: 21, 94 POV: ICD-9: V05.4
		Evidence of Disease: 1) POV or PCC Problem List (active or inactive) ICD-9: 052*, 053*; ICD-10: B01.* through B02.*; SNOMED data set PXRM BGP VARICELLA (Problem List only) or 2) Immunization Package contraindication of "Hx of Chicken Pox" or "Immune."
		Contraindications: Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."
Pneumococcal	90669, 90670, 90732, G0009,	Immunization (CVX) Codes: 33, 100, 109, 133, 152 POV: ICD-9: V06.6; V03.82
	G8115 (old code), G9279	Contraindications: Immunization Package contraindication of "Anaphylaxis"
Hepatitis A	90632-90634,	Immunization (CVX) Codes: 31, 52, 83, 84, 85, 104
	90636, 90730 (old code)	Evidence of Disease: POV or PCC Problem List (active or inactive) ICD-9: 070.0, 070.1; ICD-10: B15.*; SNOMED data set PXRM BGP HEPATITIS A (Problem List only)
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
Rotavirus – 2-	90681	Immunization (CVX) Codes: 119
dose series		Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
Rotavirus – 3- dose series	90680	Immunization (CVX) Codes: 74, 116, 122 POV: ICD-9: V05.8
		Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
Influenza	90630, 90654- 90658, 90659 (old	<b>Immunization (CVX) Codes:</b> 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166
	code), 90660-	<b>POV</b> : ICD-9: V04.8 (old code), V04.81, V06.6
	90662, 90672, 90673, 90685- 90688, 90724 (old code), G0008, G8108 (old code)	Contraindications: Immunization Package contraindication of "Egg Allergy" or "Anaphylaxis"

# **Key Logic Changes from CRS Version 16.1**

1. Added SNOMED data set PXRM BGP POLIO to IPV evidence of disease definition (for Problem List only).

- 2. Added SNOMED data set PXRM BGP MEASLES to measles evidence of disease definition (for Problem List only).
- 3. Added SNOMED data set PXRM BGP RUBELLA to rubella evidence of disease definition (for Problem List only).
- 4. Added SNOMED data set PXRM BGP HEPATITIS A to Hepatitis A evidence of disease definition (for Problem List only).
- 5. Added SNOMED data set PXRM BGP HEPATITIS B to Hepatitis B evidence of disease definition (for Problem List only).
- 6. Added SNOMED data set PXRM BGP VARICELLA to varicella evidence of disease definition (for Problem List only).

## **Patient List Description**

List of patients 19 through 35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

**Notes:** Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7 through 23 months.

The order of the display for the immunizations is: 4 Dtap/Dtp;3 IPV/OPV;MMR;3 or 4 HIB;3 HEP;Vari;4 PNEUMO. A blank value in the Numerator column means the patient didn't meet the requirements for any of the immunizations. Another example is "MMR; vari;4 PNEUMO," which means the patient did not have 4 Dtap/Dtp, 3 IPV/OPV, 3 or 4 HIB and 3 Hep B immunizations.

#### **Measure Source**

CDC; HP 2020 IID-7, IID-8; HEDIS

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 GPRAMA Performance Active Immunization Package 4:3:1:3*:3:1:4	72.3%
(rate for children age 19 through 35 months)	

Performance	Percent
IHS FY 2015 GPRAMA Performance Active Immunization Package 4:3:1:3*:3:1:4 (rate for children age 19 through 35 months)	73.3%
IHS FY 2014 GPRAMA Performance Active Immunization Package	75.4%
4:3:1:3*:3:1:4	75.476
(rate for children age 19 through 35 months)	
IHS FY 2013 GPRA Performance Active Immunization Package 4:3:1:3*:3:1:4	74.8%
(rate for children age 19 through 35 months)	
IHS FY 2012 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months)	76.8%
IHS FY 2011 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4	75.9%
(rate for children age 19 through 35 months)	70.00/
IHS FY 2010 GPRA Performance Active Immunization Package 4:3:1:3:3:1	79.0%
(rate for children age 19 through 35 months)	79.0%
IHS FY 2009 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months)	79.0%
IHS FY 2008 GPRA Performance Active Immunization Package	78.0%
4:3:1:3:3 (rate for children age 19 through 35 months)	
IHS FY 2008 Non-GPRA Performance Active Clinical 4:3:1:3:3 (rate for children age 19 through 35 months)	68.0%
IHS FY 2007 GPRA Performance Active Immunization Package 4:3:1:3:3(rate for children age 19 through 35 months)	78.0%
IHS FY 2006 Performance (rate for children age 19 through 35 months)	80.0%
IHS FY 2005 Performance (rate for children age 19 through 35 months)	75.0%
IHS FY 2004 Performance(baseline rate for children age 19 through 35 months)	72.0%
IHS FY 2004 Performance(rate for children age 3 through 27 months)	81.0%
IHS FY 2003 Performance(rate for children age 3 through 27 months)	80.0%
IHS FY 2002 Performance(rate for children age 3 through 27 months)	80.0%
HP 2020 goal for % of children age 19 through 35 months with 4:3:1:3:3:4 vaccines	80.0%
HP 2020 goal for % of children age 19 through 35 months with each individual vaccine	90.0%

For the IHS FY 2006 Performance (rate for children 19 through 35 months), the Percent (80.0) please consider: All 2002 through 2006 rates reported on this table were reported by the Immunization Program from the quarterly immunization reports. Effective in 2007, CRS reports the rate and not the Immunization Program. The CRS rate is reported using the CRS Active Immunization Package denominator.

## **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in appropriate vaccine order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU November 25, 2017 Page 51  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Childhood Immunizati	ons							
	REPORT PERIOD	જ	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts 19-35 months	79		81			72		
<pre># w/ 4313*314 Combo or w/ Dx/ Contra/NMI Refusal A. # w/ Dx/Contra/NMI Ref</pre>	29	36.7	51	63.0	-26.3	50	69.4	-32.7
w/ % of Total 4313*314	0	0.0	0	0.0	+0.0	0	0.0	+0.0
<pre># w/ 4 doses DTaP   or w/ Contra/NMI   Refusal A. # w/ Contra/NMI   Ref w/ % of Total</pre>					-27.4			
DTaP	2	6.1	0	0.0	+6.1	0	0.0	+6.1
<pre># w/ 3 doses Polio   or w/ Dx/Contra/   NMI Refusal A. # w/   Dx/Contra/NMI Ref   w/ % of Total</pre>					-20.5			
Polio # w/ 1 dose MMR or	1	1.8	0	0.0	+1.8	0	0.0	+1.8

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

w/ Dx/Contra/NMI Refusal A. # w/	39	49.4	69	85.2	-35.8	64	88.9	-39.5	
Dx/Contra/NMI Ref w/ % of Total MMR	1	2.6	1	1.4	+1.1	0	0.0	+2.6	
# w/ 3-4 doses HiB or w/ Contra/NMI Refusal A. # w/ Contra/NMI	43	54.4	64	79.0	-24.6	61	84.7	-30.3	
Ref w/ % of Total HiB	1	2.3	0	0.0	+2.3	0	0.0	+2.3	
<pre># w/ 3 doses Hep B   or w/ Dx/   Contra/NMI Refusal A. # w/   Dx/Contra/NMI Ref</pre>	70	88.6	78	96.3	-7.7	69	95.8	-7.2	
w/ % of Total Hep B	2	2.9	0	0.0	+2.9	0	0.0	+2.9	

Figure 2-29: Sample Report, Childhood Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Childhood Immunizations: List of patients 19-35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP. NOTE: Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7-23 months. PATTENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMBERATOR PATIENT NAME \_\_\_\_\_ PATIENTI, ANDREA 000001 COMMUNITY #1 F 0 01/01/17
IIP AC IMM 4 DTAP/DTP: 3 Polic: MMR: 3 3-Dd UP,AC,IMM

4 DTaP/DTP; 3 Polio; MMR; 3 3-Dose Hib; 3 Hep B;
Vari; 2 Influenza
PATIENT2,HEATHER

UP,AC,IMM

NMI DTaP/DTP; NMI Polio; 2 Hep A; 2 Influenza
PATIENT3,TONYA

000003 COMMUNITY #1 F 1 10/03/16

UP PATIENT4, JAMES 000004 COMMUNITY #1 M 0 05/05/17 UP, AC, IMM 3 Polio; MMR; 3 Hep B; Vari; NM 3 Polio; MMR; 3 Hep B; Vari; NMI Rota PATIENT5, SCOTT 000005 COMMUNITY #1 M 0 12/13/17 UP,AC,IMM 4 4-Dose Hib; 2 Hep A; 3 Rota; 2 Influenza

Figure 2-30: Sample Patient List, Childhood Immunizations

#### 2.4.4 Adolescent Immunizations

#### **Denominators**

Active Clinical patients age 13. Broken down by gender where noted.

Active Clinical patients ages 13 through 17. Broken down by gender where noted.

#### **Numerators**

Patients who have received the 1:1:3 combination (i.e., 1 Td/Tdap, 1 meningococcal, 3 HPV), including contraindications.

**Notes**: The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

Patient who have received the 1:1 combination (i.e., 1 Td/Tdap, 1 meningococcal), including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Tdap/Td ever, including contraindications.

- a. Patients with a contraindication or a documented NMI refusal.
- b. Patients who have received 1 dose of Tdap ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of meningococcal ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of HPV ever, including contraindications.

**Notes**: The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

For each of the above numerators, the following sub-numerators are included:

a. Patients with a contraindication or a documented NMI refusal.

## **Logic Description**

Age definition: Age of the patient is calculated at the beginning of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within ten days of each other will be considered as the same immunization.

Dosage and types of immunization definitions:

- 1 dose of Td or Tdap
- 1 dose of Meningococcal
- 3 doses of HPV

Not Medically Indicated (NMI) refusals and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note**: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations where required number of doses is greater than (>) 1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for HPV, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>) 1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HPV, the patient will be included in the numerator.

Adolescent immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes					
Tdap	90715	Immunization code: 115					
		NMI Refusals: Immunization code 115					
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."					
Td	90714, 90718	Immunization codes: 9, 113, 138, 139					
		<b>POV:</b> ICD-9: V06.5					
		NMI Refusals: Immunization codes 9, 113, 138, 139					
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."					
Meningococcal	90733, 90734	Immunization codes: 32, 108, 114, 136, 147					
		<b>NMI Refusals:</b> Immunization codes 32, 108, 114, 136, 147					
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."					

Immunization	CPT Codes	ICD and Other Codes
HPV	90649, 90650,	<b>Immunization codes:</b> 62, 118, 137, 165
	90651	NMI Refusals: Immunization codes 62, 118, 137, 165
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 13 through 17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 HPV, no IZ will be listed for HPV.

**Note:** An absent value in the Numerator column means the patient did not meet the requirements for any of the immunizations. An example for a female patient age 13 with a value of ";3 HPV" which means the patient did not have 1 Td/Tdap and 1 Meningococcal immunizations.

#### **Measure Source**

**HEDIS, HP 2020 IID-11** 

## **Measure Past Performance and Long-Term Targets:**

Target	Percent
HP 2020 goal for each individual IZ: Tdap, Meningococcal, HPV	80.0%
HP 2020 goal for each individual IZ: varicella	90.0%

#### **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in appropriate vaccine Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

```
DU November 25, 2017 Page 66

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Adolescent Immunizat	cions								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		%	CHG from BASE %	
Active Clinical Pts Age 13	30		35			40			
# w/ 1:1:3 Combo or w/ Contra/NMI Refusal A. # w/ Contra/NMI	6	20.0	13	37.1	-17.1	13	32.5	-12.5	
Ref w/ % of Total 1:1:3	1	16.7	0	0.0	+16.7	0	0.0	+16.7	
Male Active Clinical Pts Age 13	13		14			20			
<pre># w/ 1:1:3 Combo   or w/ Contra/NMI   Refusal A. # w/ Contra/NMI   Ref w/ % of Total   1:1:3</pre>	1	7.7	0	0.0		0			
Female Active Clinical Pts Age 13	17		21			20			
<pre># w/ 1:1:3 Combo or w/ Contra/NMI Refusal A. # w/ Contra/NMI Ref w/ % of Total</pre>	5	29.4	13	61.9	-32.5	13	65.0	-35.6	
1:1:3	1	20.0	0	0.0	+20.0	0	0.0	+20.0	

Figure 2-31: Sample Report, Adolescent Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Adolescent Immunizations: List of patients 13-17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 Hep B, no IZ will be listed for Hep B. HRN PATIENT NAME COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, LINDA 000001 COMMUNITY #3 F 13 01/31/04 PATIENT2, SHERRY 000002 COMMUNITY #3 F 13 04/11/04 NMI Tdap PATIENT22, JESSICA 000022 COMMUNITY #4 F 13 06/24/04

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

AC	Tdap; 3 HPV	
PATIENT23, SAMANTHA	000023 COMMUNITY #4 F 13	07/12/04
AC	Td; NMI Meningococcal	
PATIENT24,NINA	000024 COMMUNITY #4 F 13	07/19/04
AC	Contra HPV	
PATIENT25, RHONDA	000025 COMMUNITY #4 F 13	12/12/04
AC	Td; 3 HPV	
	10, 5 111 1	

Figure 2-32: Sample Patient List, Adolescent Immunizations

# 2.5 Childhood Diseases Group

# 2.5.1 Appropriate Treatment for Children with Upper Respiratory Infection

#### **Denominators**

Active Clinical patients ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

User Population patients ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

#### Numerator

Patients who were *not* prescribed an antibiotic on or within 3 days after diagnosis. In this measure, appropriate treatment is *not* to receive an antibiotic.

## **Logic Description**

Age is calculated as follows: Children 3 months as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

- 1. Patient's diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit. Upper Respiratory Infection defined as POV ICD-9: 460 or 465.\*; ICD-10: J00. Outpatient visit defined as Service Category A, S, or O.
- 2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.

- 3. Patient's visit must only have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
- 4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
- 5. The patient did not have an active prescription for antibiotics as of the URI visit date. "Active" prescription defined as:

Rx Days Supply greater than or equal to (>=) (URI Visit Date–Prescription Date)

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. Medications are: Aminopenicillins (Amoxicillin, Ampicillin), Beta-lactamase inhibitors (Amoxicillin-clavulanate), First generation cephalosporins (Cefadroxil, Cefazolin, Cephalexin), Folate antagonist (Trimethoprim), Lincomycin derivatives (Clindamycin), Macrolides (Azithromycin, Clarithromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate), Miscellaneous antibiotics (Erythromycinsulfisoxazole), Natural penicillins (Penicillin G potassium, Penicillin G sodium, Penicillin V potassium), Penicillinase-resistant penicillins (Dicloxacillin), Quinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin), Second generation cephalosporins (Cefaclor, Cefprozil, Cefuroxime), Sulfonamides (Sulfamethoxazoletrimethoprim), Tetracyclines (Doxycycline, Minocycline, Tetracycline), Third generation cephalosporins (Cefdinir, Cefixime, Cefpodoxime, Ceftibuten, Cefditoren, Ceftriaxone). Medications must not have a comment of RETURNED TO STOCK.

#### **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of patients 3 months to 18 years of age with upper respiratory infection, with antibiotic prescription, if any.

#### **Measure Source**

**HEDIS** 

## **Measure Past Performance and Long-Term Targets**

None

November 25, 2017 Page 72  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Appropriate Treatmen	t for Ch	ildren	with Upp	er Re	spiratory	Infectio	n (co	n't)
	REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %							
Active Clinical Pts 3 months-18 yrs w/ Upper Respiratory Infection	158		110			134		
# w/o Antibiotic Rx	119	75.3	97	88.2	-12.9	129	96.3	-21.0
User Pop Pts 3 months-18 yrs w/ Upper Respiratory Infection	159		110			136		
# w/o Antibiotic Rx	120	75.5	97	88.2	-12.7	131	96.3	-20.9

Figure 2-33: Sample Report, Appropriate Treatment for Children with Upper Respiratory Infection

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Appropriate Treatment for Children with Upper Respiratory Infection: List of patients 3 months to 18 years with upper respiratory infection, with antibiotic prescription, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR

PATIENT1, PAMELA 000001 COMMUNITY #3 F 3 02/15/14
UP,AC MEETS MEASURE
PATIENT2, ALICIA 000002 COMMUNITY #3 F 7 06/18/10
UP,AC MEETS MEASURE
PATIENT3, JAMES 000003 COMMUNITY #3 M 0 03/14/17

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

UP,AC	MEETS MEASURE	]		
PATIENT4, HENRY	000004 COMMUNITY #3	8 M 12	11/21/05	
UP,AC	MEETS MEASURE	3		
PATIENT25, HEATHER	000025 COMMUNITY #4	F 7	12/06/10	
UP,AC	MEETS MEASURE	]		
PATIENT26, DYLAN	000026 COMMUNITY #4	4 M 3	03/02/14	
UP,AC	MEETS MEASURE	3		
PATIENT27, CODY	000027 COMMUNITY #4	M 4	04/12/13	
UP,AC	MEETS MEASURE	3		
PATIENT28, KAREN	000028 COMMUNITY #5	5 F 0	09/22/17	
UP,AC	antibiotic in	jection:	01/06/17 DOES NOT	MEET MEASURE
PATIENT26, DYLAN UP, AC PATIENT27, CODY UP, AC PATIENT28, KAREN	000026 COMMUNITY #4  MEETS MEASURE 000027 COMMUNITY #4  MEETS MEASURE 000028 COMMUNITY #5	M 3 M 4 F 0	04/12/13	MEET MEASURE

Figure 2-34: Sample Patient List, Appropriate Treatment for Children with Upper Respiratory Infection

# 2.5.2 Appropriate Testing for Children with Pharyngitis

#### **Denominators**

Active Clinical patients ages 3 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

*User Population patients* ages 3 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

#### **Numerator**

Patients who received a Group A strep test.

#### **Logic Description**

Age is calculated as follows: Children three years as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

- 1. Patient's diagnosis of pharyngitis must have occurred at an outpatient visit. Pharyngitis defined as POV ICD-9: 462, 463, 034.0; ICD-10: J02.0, J03.\*. Outpatient visit defined as Service Category A, S, or O.
- 2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with pharyngitis diagnosis.
- 3. Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.

- 4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
- 5. The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. "Active" prescription defined as:
- 6. Rx Days Supply greater than or equal to (>= )(URI Visit Date Prescription Date)
- 7. The patient filled a prescription for antibiotics on or within 3 days after the pharyngitis visit.

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. Medications are: Aminopenicillins (Amoxicillin, Ampicillin), Beta-lactamase inhibitors (Amoxicillin-clavulanate), First generation cephalosporins (Cefadroxil, Cefazolin, Cephalexin), Folate antagonist (Trimethoprim), Lincomycin derivatives (Clindamycin), Macrolides (Azithromycin, Clarithromycin, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate), Miscellaneous antibiotics (Erythromycinsulfisoxazole), Natural penicillins (Penicillin G potassium, Penicillin G sodium, Penicillin V potassium), Penicillinase-resistant penicillins (Dicloxacillin), Quinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin), Second generation cephalosporins (Cefaclor, Cefprozil, Cefuroxime), Sulfonamides (Sulfamethoxazoletrimethoprim), Tetracyclines (Doxycycline, Minocycline, Tetracycline), Third generation cephalosporins (Cefdinir, Cefixime, Cefpodoxime, Ceftibuten, Cefditoren, Ceftriaxone). Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, a patient must have received a Group A Streptococcus test within the 7-day period beginning 3 days prior through 3 days after the Pharyngitis visit date.

*Group A Streptococcus* test defined as: CPT 87430 (by enzyme immunoassay), 87650-87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test); site-populated taxonomy BGP GROUP A STREP TESTS; and LOINC taxonomy.

## **Key Logic Changes from CRS Version 16.1**

1. Added LOINC code 78012-2 to BGP GROUP A STREP LOINC taxonomy.

## **Patient List Description**

List of patients 3 through 18 years of age with pharyngitis and a Group A Strep test, if any.

#### **Measure Source**

**HEDIS** 

## Measure Past Performance and Long-Term Targets

None

DU November 25, 2017 Page 75  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Appropriate Testing	for Child	lren wit	th Phary	ngiti	s (con't)			
					CHG from PREV YR %			
Active Clinical Pts 3-18 yrs w/ Pharyngitis & Antibiotic Rx	8		8			12		
# w/ Group A Strep Test	1	12.5	4	50.0	-37.5	4	33.3	-20.8
User Pop Pts 3-18 yrs w/ Pharyngitis & Antibiotic Rx	8		8			12		
# w/ Group A Strep Test	1	12.5	4	50.0	-37.5	4	33.3	-20.8

Figure 2-35: Sample Report, Appropriate Testing for Children with Pharyngitis

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Appropriate Testing for Children with Pharyngitis: List of patients 3-18 years with pharyngitis and a Group A Strep test, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB	
PATIENT1, MICHAEL	000001	COMMUNITY #1	М	9	05/23/08	
UP,AC		03/19/17 RAPID	ANT:	IGEN	(STREP A)	
PATIENT2, JOSEPH	000002	COMMUNITY #1	M	12	02/16/05	
UP,AC		05/01/17 RAPID	ANT:	IGEN	(STREP A)	
PATIENT3, LESTER	000003	COMMUNITY #1	M	13	02/19/04	
UP						
PATIENT24,MONICA	000024	COMMUNITY #2	F	5	07/04/12	
UP,AC		01/23/17 RAPID	ANT:	IGEN	(STREP A)	
PATIENT25, MICHAEL JAMES	000025	COMMUNITY #2	M	7	09/09/10	
UP,AC		03/12/17 RAPID	ANT	IGEN	(STREP A)	

Figure 2-36: Sample Patient List, Appropriate Testing for Children with Pharyngitis

# 2.6 Cancer Related Measure Topics

# 2.6.1 Cancer Screening: Pap Smear Rates

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 56.1% for the proportion of female patients ages 24 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous 3 years, or if the patient is over 30, had a Pap screen in the past 3 years or a Pap screen and HPV DNA within the previous 5 years.

#### **Denominators**

*Female Active Clinical patients* ages 24 through 64 without documented history of hysterectomy. (GPRA Denominator)

Female Active Clinical patients ages 24 through 29 without documented history of hysterectomy.

Female Active Clinical patients ages 30 through 64 without documented history of hysterectomy.

Female User Population patients ages 24 through 64 without documented history of hysterectomy.

Female User Population patients ages 24 through 29 without documented history of hysterectomy.

Female User Population patients ages 30 through 64 without documented history of hysterectomy.

#### **Numerators**

Patients with a Pap smear documented in the past 3 years, or if a patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years. (GPRA Numerator)

**Note**: This numerator does *not* include refusals.

Patients with a Pap Smear documented in the past 3 years.

Patients with a Pap Smear documented 3-5 years ago and an HPV DNA documented in the past 5 years

## **Logic Description**

Age of the patient is calculated at the beginning of the report period. Patients must be at least 24 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Subject Defined	CPT Codes	IICI) and Other Codes	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200- 58294, 58548, 58550-58554, 58570-58573, 58951, 58953- 58954, 58956, 59135	Procedure: ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ  Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-9: 618.5, 752.43, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710, Z90.712, Q51.5; SNOMED data set PXRM BGP HYSTERECTOMY DX (Problem List only)  Women's Health: Procedure called Hysterectomy.		

Subject Defined	CPT Codes	IICD and Other Codes	LOINC Codes	Taxonomy
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	Lab: PAP SMEAR POV: ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 Women's Health: Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD"	Yes	BGP PAP SMEAR TAX
HPV DNA Note: CRS will only search for a documented HPV DNA if the patient had a Pap Smear 3 to 5 years ago.	87620-87622 (old codes), 87623-87625	Lab: HPV POV: ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.821, Z11.51 Women's Health: Procedure called HPV Screen and where the result does NOT have "ERROR/DISREGARD"; Procedure called Pap Smear and where the HPV field equals Yes	Yes	BGP HPV TAX

### **Key Logic Changes from CRS Version 16.1**

- 1. Removed ICD-10 code Z90.711 from hysterectomy definition.
- 2. Updated hysterectomy definition to include inactive Problem List items.
- 3. Added SNOMED data set PXRM BGP HYSTERECTOMY DX to hysterectomy definition (for Problem List only).

# **Patient List Description**

List of women 24 through 64 with documented Pap Smear and HPV, if any.

### **Measure Source**

HP 2020 C-15

### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	54.8%
IHS FY 2015 Performance	54.9%
IHS FY 2014 Performance	54.6%
IHS FY 2013 Performance	61.7%
IHS FY 2012 Performance	57.1%
IHS FY 2011 Performance	58.1%
IHS FY 2010 Performance	59.0%
IHS FY 2009 Performance	59.0%
IHS FY 2008 Performance	59.0%
IHS FY 2007 Performance	59.0%
IHS FY 2006 Performance	59.0%
IHS FY 2005 Performance	60.0%
IHS FY 2004 Performance	58.0%
IHS FY 2003 Performance	61.0%
IHS FY 2002 Performance	62.0%
HP 2020 Goal	93.0%

### **Performance Improvement Tips**

- Providers should ask about and record off-site tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should document refusals; write "Refused" in Pap Order box on PCC form. Data entry mnemonic: REF (Lab Test Value, Date Refused).

```
DU
                               November 25, 2017
                                                                         Page 77
       *** IHS 2017 Selected Measures with Community Specified Report ***
                              DEMO INDIAN HOSPITAL
                  Report Period: Jan 01, 2017 to Dec 31, 2017
              Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                 Baseline Period: Jan 01, 2010 to Dec 31, 2010
Cancer Screening: Pap Smear Rates (con't)
                    REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %
Female Active
 Clinical Pts 24-64
                         498
                                         508
                                                                 499
 (GPRA)
# w/ Pap Smear 3
```

yrs / Pap+HPV 5yrs-No Refusals									
(GPRA) Female Active	168	33.7	223	43.9	-10.2	203	40.7	-6.9	
Clinical Pts 24-29	105		113			113			
<pre># w/ Pap Smear w/in 3 years-No Refusals</pre>	43	41.0	57	50.4	-9.5	44	38.9	+2.0	
Female Active Clinical Pts 30-64	393		395			386			
# w/ Pap Smear w/in 3 years-No									
Refusals # w/ Pap Smear and HPV w/in 5	118	30.0	165	41.8	-11.7	156	40.4	-10.4	
years-No Refusals	7	1.8	1	0.3	+1.5	3	0.8	+1.0	
Female User Pop Pts 24-64	554		566			559			
<pre># w/ Pap Smear 3 yrs / Pap+HPV 5yrs-No Refusals</pre>	172	31.0	226	39.9	-8.9	204	36.5	-5.4	
Female User Pop	115		129			124			
	113		129			124			
<pre># w/ Pap Smear w/in 3 years-No Refusals</pre>	44	38.3	58	45.0	-6.7	45	36.3	+2.0	
Female User Pop	439		437			435			
	433		<b>1</b> 37			100			
<pre># w/ Pap Smear w/in 3 years-No Refusals # w/ Pap Smear and</pre>	121	27.6	167	38.2	-10.7	156	35.9	-8.3	
HPV w/in 5 years-No Refusals	7	1.6	1	0.2	+1.4	3	0.7	+0.9	

Figure 2-37: Sample Report, Cancer Screening: Pap Smear Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Cancer Screening: Pap Smear Rates: List of women 25-64 with documented
Pap smear, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1, EVELYN 000001 COMMUNITY #1 F 21 11/19/96
UP 05/05/15 POV 795.06

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

000002 COMMUNITY #1 F 22 01/10/95
05/31/17 Lab
000003 COMMUNITY #1 F 22 03/01/95
05/08/15 CPT 88150
000004 COMMUNITY #1 F 22 09/22/95
01/10/17 POV V72.32
000005 COMMUNITY #1 F 31 05/07/86
PAP: 07/01/13 PROC 91.46; HPV: 01/10/14 POV 079.4

Figure 2-38: Sample Patient List, Cancer Screening: Pap Smear rates

# 2.6.2 Cancer Screening: Mammogram Rates

### **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 56.7% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

#### **Denominators**

Female Active Clinical patients ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRA Denominator)

Female User Population patients ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

#### **Numerators**

All patients who had a Mammogram documented in the past 2 years.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented mammogram refusal in the past year

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period. For all denominators, patients must be at least the minimum age as of the beginning of the Report Period. For the 52 through 64 denominators, the patients must be less than 65 years of age as of the end of the Report Period.

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 <b>OR</b> 19300-19307 with modifier 09950 (50 and 09950 modifiers indicate bilateral) <b>OR</b> 19240, with modifier of 50 or 09950	Procedure: ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HBV0ZZ, 0HCV0ZZ, 0HTV0ZZ Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-10: Z90.13; SNOMED data set PXRM BGP BILAT MASTECTOMY (Problem List only)
Unilateral Mastectomy	Two separate unilateral mastectomies defined as either of the following: 1) Must have one code that indicates a right mastectomy and one code that indicates a left mastectomy; or 2) Must have 2 separate occurrences on 2 different dates of service for one code that indicates a mastectomy on unknown side and one code that indicates either a right or left mastectomy, or two codes that indicate a mastectomy on unknown side.  Right Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.11; SNOMED data set PXRM BGP RIGHT MASTECTOMY (Problem List only); Procedure ICD-10: 07T50ZZ, 07T80ZZ, 0HBT0ZZ, 0HCT0ZZ, 0HTT0ZZ.	
	Left Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.12; SNOMED data set PXRM BGP LEFT MASTECTOMY (Problem List only); Procedure ICD-10: 07T60ZZ, 07T90ZZ, 0HBU0ZZ, 0HCU0ZZ, 0HTU0ZZ.  Mastectomy on unknown side: 1) CPT 19300-19307, or old codes 19180, 19200, 19220, 19240; 2) Procedure ICD-9: 85.41, 85.43, 85.45, 85.47.	

Subject Defined	CPT Codes	ICD and Other Codes
Mammogram	Radiology or CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	POV: ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 Procedure: ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ Women's Health: Mammogram
		Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD"
Refusal (during the Report Period)	Radiology Mammogram or CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	

### **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to look at the Problem List for bilateral and unilateral mastectomies.
- 2. Added SNOMED data set PXRM BGP BILAT MASTECTOMY to bilateral mastectomy definition (for Problem List only).
- 3. Added SNOMED data set PXRM BGP RIGHT MASTECTOMY to right mastectomy definition (for Problem List only).
- 4. Added SNOMED data set PXRM BGP LEFT MASTECTOMY to left mastectomy definition (for Problem List only).

### **Patient List Description**

List of women 52 through 64 with mammogram/refusal, if any.

#### **Measure Source**

HP 2020 C-17

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	54.8%
IHS FY 2015 Performance	54.5%
IHS FY 2014 Performance	54.2%
IHS FY 2013 Performance	53.8%

Performance	Percent
IHS FY 2012 Performance	51.9%
IHS FY 2011 Performance	49.8%
IHS FY 2010 Performance	48.0%
IHS FY 2009 Performance	45.0%
IHS FY 2008 Performance	45.0%
IHS FY 2007 Performance	43.0%
IHS FY 2006 Performance	41.0%
IHS FY 2005 Performance	41.0%
IHS FY 2004 Performance	40.0%
IHS FY 2003 Performance	40.0%
IHS FY 2002 Performance	42.0%
HP 2020 Goal	81.1%

### **Performance Improvement Tips**

- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should document refusals; write "Refused" in Mammogram Order box on PCC form. Data entry mnemonic: REF (Mammogram, Procedure (CPT) Code, Date Refused).

DU November 25, 2017 Page 79  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Cancer Screening: Ma	Cancer Screening: Mammogram Rates (con't)								
			PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %	
Female Active Clinical Pts 52-64 (GPRA)	134		138			132			
<pre># w/ Mammogram w/in 2 years-No Refusals (GPRA)</pre>	55	41.0	82	59.4	-18.4	35	26.5	+14.5	
# w/ Mammogram Refusal	1	0.7	0	0.0	+0.7	1	0.8	+0.0	
Female User Pop Pts 52-64	145		147			142			
# w/ Mammogram w/in 2 years-No Refusals	55	37.9	82	55.8	-17.9	35	24.6	+13.3	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Mammogram								
Refusal	1	0.7	0	0.0	+0.7	1	0.7	+0.0

Figure 2-39: Sample Report, Cancer Screening: Mammogram rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Cancer Screening: Mammogram Rates: List of women 42+ with mammogram/refusal, if any. PATIENT NAME HRN COMMUNITY
DENOMINATOR NUMERATOR HRN COMMUNITY SEX AGE DOB PATIENT1, CARLA 000001 COMMUNITY #1 F 42 02/20/75
UP, AC 10/01/16 CPT 77052
PATIENT2, CRYSTAL 000002 COMMUNITY #1 F 43 06/30/74
UP
PATIENT3, ALEXA 000003 COMMUNITY #1 F 45 03/09/72 UP,AC 04/24/16 CPT 76090 PATIENT4,HANNAH 000004 COMMUNITY #1 F 45 05/10/72 PATIENT5, MARTHA 000005 COMMUNITY #1 F 47 12/01/70 000006 COMMUNITY #1 F 48 10/22/69 PATIENT6, TARA 01/15/17 Refused CPT G0206 UP,AC UP,AC 01/15/17 Refused CPT G0206 PATIENT7,CAROL LYNN 000007 COMMUNITY #2 F 44 08/08/73 03/05/17 RAD 76092 UP,AC UP,AC 03/05/17 RAD 76092 PATIENT8,MARY ANN 000008 COMMUNITY #2 F 52 06/22/65 UP,AC PATIENT9, BARBARA 000009 COMMUNITY #2 F 52 09/14/65 04/22/17 CPT 77057 UP.AC

Figure 2-40: Sample Patient List, Cancer Screening: Mammogram rates

# 2.6.3 Colorectal Cancer Screening

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 40.2% for the proportion of clinically appropriate patients ages 50-75 who have received colorectal screening.

#### **Denominators**

Active Clinical patients ages 50 through 75 without a documented diagnosis of colorectal cancer or total colectomy. Broken down by gender. (GPRA Denominator)

*User Population patients* ages 50 through 75 without any documented diagnosis of colorectal cancer or total colectomy.

#### **Numerators**

Patients who have had any CRC screening, defined as any of the following: (1) Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report Period; (2) flexible sigmoidoscopy in the past 5 years; or (3) colonoscopy in the past 10 years.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented CRC screening refusal during the Report Period.

Patients with FOBT or FIT during the Report Period.

Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.

#### **Logic Description**

Age is calculated at the beginning of the Report Period.

Denominator Exclusions

Any diagnosis ever of one of the following:

- 1. Colorectal Cancer: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-9: 153.\*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.\*, C19, C20, C78.5, Z85.030, Z85.038; SNOMED data set PXRM COLORECTAL CANCER (Problem List only); CPT G0213–G0215 (old codes), G0231 (old code).
- 2. **Total Colectomy:** CPT 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210 through 44212; Procedure ICD-9: 45.8\*; ICD-10: 0DTE\*ZZ.

Colorectal cancer screening definition: The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

# Colorectal Cancer Screening (CRS looks for the most recent of any of the following during timeframes specified in numerator section above)

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Fecal Occult Blood lab test (FOBT) or Fecal Immuno- chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330-45345, G0104	<b>Procedure:</b> ICD-9: 45.24; ICD-10: 0DJD8ZZ		
Colonoscopy	44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253	Procedure: ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E3ZX, 0D9E4ZX, 0D9F7ZX, 0D9F3ZX, 0D9F3ZX, 0D9F3ZX, 0D9F3ZX, 0D9F3ZX, 0D9G4ZX, 0D9F3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G4ZX, 0D9G7ZX, 0D9G4ZX, 0D9H4ZX, 0D9H7ZX, 0D9H4ZX, 0D9H7ZX, 0D9H4ZX, 0D9H3ZX, 0D9L4ZX, 0D9L4ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M3ZX, 0D9M4ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0DBE7ZX, 0DBE7ZX, 0DBE7ZX, 0DBE7ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBG3ZX, 0DBG4ZX, 0DBG8ZZ, 0DBG3ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH7ZX, 0DBH7ZX, 0DBH7ZX, 0DBH7ZX, 0DBH8ZZ, 0DBK3ZX, 0DBL8ZZ, 0DBL8ZZ, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM5ZZ, 0DBM5ZX, 0DBM5ZZ, 0DBM5ZX, 0DBM5ZZ, 0DBM5ZX, 0DBM5ZX, 0DBM7ZX, 0DBM5ZX, 0DBM5ZX, 0DBM7ZX, 0DBM5ZZ, 0DBM5ZX, 0DBM5ZZ, 0DBM3ZX, 0DBM7ZX, 0DBM5ZZ, 0DBN3ZX, 0DBM5ZZ, 0DBN3ZX, 0DBM5ZZ, 0DBN3ZX, 0DBN5ZZ, 0DSN5ZZ		

# Refusal definition: Any of the following in the past year:

Subject Defined	CPT Codes	ICD and Other Codes	Taxonomy
Refusals	FOBT or FIT: 82270, 82274, 89205 (old code), G0107 (old code), G0328, or G0394 (old code) Flexible Sigmoidoscopy: 45330-45345, G0104 Colonoscopy: 44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253	Flexible Sigmoidoscopy Procedure: ICD-9: 45.24, 45.42; ICD-10: 0DJD8ZZ  Colonoscopy Procedure: ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5M4ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E3ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F3ZX, 0D9G3ZX, 0D9H3ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K3ZX, 0D9L3ZX, 0D9L4ZX, 0D9K3ZX, 0D9L3ZX, 0D9M3ZX, 0D9K8ZX, 0D9L3ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9M4ZX, 0D9M7ZX, 0D9N3ZX, 0D9M4ZX, 0D9M7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBF3ZX, 0DBE3ZX, 0DBE4ZX, 0DBF3ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBK8ZZ, 0DBL3ZX, 0DBK3ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBM7ZX, 0DBM8ZZ, 0DBM7ZX, 0DBM8ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ,	V Lab Fecal Occult Blood Test

# **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to colorectal cancer screening definition to look at the Problem List.
- 2. Added SNOMED data set PXRM COLORECTAL CANCER to colorectal cancer definition (for Problem List only).
- 3. Added LOINC code 80372-6 to BGP FOBT LOINC CODES taxonomy.

#### **Patient List Description**

List of patients 50 through 75 with CRC screening or refusal, if any.

#### **Measure Source**

HEDIS, HP 2020 C-16

### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2016 Performance	39.6%
IHS FY 2015 Performance	38.6%
IHS FY 2014 Performance	37.5%
IHS FY 2013 Performance	35.0%
Former definition of CRC:	
IHS FY 2012 Performance	46.1%
IHS FY 2011 Performance	41.7%
IHS FY 2010 Performance	37.0%
IHS FY 2009 Performance	33.0%
IHS FY 2008 Performance	29.0%
IHS FY 2007 Performance	26.0%
IHS FY 2006 Performance	22.0%
HP 2020 Goal	70.5%

### **Performance Improvement Tip**

Providers should ask about and record off-site historical tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy). Providers should also enter as a refusal if the patient refuses the colorectal cancer screening. Refusals may be entered with the data entry mnemonic of REF (refusal).

```
DU
                             November 25, 2017
                                                                     Page 82
       *** IHS 2017 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Colorectal Cancer Screening (con't)
                                  PREV YR
                                             % CHG from BASE
                                                                    % CHG from
                    REPORT
                    PERIOD
                                  PERIOD
                                                PREV YR % PERIOD
                                                                       BASE %
Active Clinical
```

Pts 50-75 w/o CRC or Total Colectomy (GPRA)	403		399			379			
# w/ CRC Screening-No									
Refusals (GPRA) # w/ CRC Screening	38	9.4	60	15.0	-5.6	55	14.5	-5.1	
Refusal # w/ FOBT/FIT during Report	2	0.5	0	0.0	+0.5	0	0.0	+0.5	
Period # w/ Flex Sig or	3	0.7	27	6.8	-6.0	32	8.4	-7.7	
Colonoscopy	35	8.7	34	8.5	+0.2	24	6.3	+2.4	
Male Active									
Clinical Pts 50-75	178		174			160			
# w/ CRC									
Screening-No Refusals	14	7.9	19	10.9	-3.1	18	11.3	-3.4	
# w/ CRC Screening									
Refusal	1	0.6	0	0.0	+0.6	0	0.0	+0.6	
# w/ FOBT/FIT during Report									
Period	2	1.1	8	4.6	-3.5	10	6.3	-5.1	
# w/ Flex Sig or	_								
Colonoscopy	12	6.7	12	6.9	-0.2	9	5.6	+1.1	

Figure 2-41: Sample Report, Colorectal Cancer Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Colorectal Cancer Screening: List of patients 51-80 with CRC screening or refusal, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR PATIENT NAME PATIENT1, DANIELLE 000001 COMMUNITY #1 F 51 03/03/66

UP FOB: 08/19/17 CPT G0107

PATIENT2, MARIE 000002 COMMUNITY #1 F 51 05/10/66

UP, AC COLO: 02/12/15 Refused CPT

PATIENT3, MARY ANN 000003 COMMUNITY #1 F 52 05/22/65

UP, AC PATIENT4, BOBBIE 000004 COMMUNITY #1 F 52 07/18/65 UP,AC 000005 COMMUNITY #1 F 53 08/05/64 PATIENT5, WINONA UP,AC PATIENT6, DARLENE 000006 COMMUNITY #1 F 54 08/04/63 SIG: 04/07/13 UP,AC 45.24 PATIENT7, JOYCE 000007 COMMUNITY #1 F 57 06/27/60 UP,AC COLO: 07/07/15 POV V76.51

Figure 2-42: Sample Patient List, Colorectal Cancer Screening

### 2.6.4 Comprehensive Cancer Screening

## **GPRA Measure Description**

Increase the proportion of patients ages 24 through 75 who received a comprehensive cancer screening.

#### **Denominators**

Active Clinical patients ages 24 through 75 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening. (GPRA Developmental Denominator)

- a. Active Clinical female patients ages 24 through 75.
- b. Active Clinical male patients ages 50 through 75.

#### **Numerators**

Patients who have had all screenings for which they are eligible.

**Note**: This numerator does *not* include refusals. (GPRA Developmental Numerator)

- a. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
- b. Male patients with colorectal cancer screening.

### **Logic Description**

Age is calculated at the beginning of the Report Period.

Cervical Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 24 through 64 and not have a documented history of hysterectomy. Patients must be at least 24 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Pap Smear documented in the past 3 years, or if the patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	IICD and Other Codes	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135	Procedure: ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ  Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-9: 618.5, 752.43, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710, Z90.712, Q51.5; SNOMED data set PXRM BGP HYSTERECTOMY DX (Problem List only)  Women's Health: Procedure called Hysterectomy.		
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	Lab: PAP SMEAR POV: ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 Women's Health: Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD"	Yes	BGP PAP SMEAR TAX
HPV DNA Note: CRS will only search for a documented HPV DNA if the patient had a Pap Smear 3 to 5 years ago.	87620-87622	Lab: HPV POV: ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51 Women's Health: Procedure called HPV Screen and where the result does NOT have "ERROR/DISREGARD"; Procedure called Pap Smear and where the HPV field equals Yes	Yes	BGP HPV TAX

Breast Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies. Patients must be at least age 52 as of the beginning of the Report Period and must be less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Mammogram documented in the past 2 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 OR 19300-19307 with modifier 09950 (50 and 09950 modifiers indicate bilateral) OR 19240, with modifier of 50 or 09950	Procedure: ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HBV0ZZ, 0HCV0ZZ, 0HTV0ZZ  Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-10: Z90.13; SNOMED data set PXRM BGP BILAT MASTECTOMY (Problem List only)

Subject Defined	CPT Codes	ICD and Other Codes
Unilateral Mastectomy	Two separate unilateral mastectomies defined as either of the following: 1) Must have one code that indicates a right mastectomy and one code that indicates a left mastectomy; or 2) Must have 2 separate occurrences on 2 different dates of service for one code that indicates a mastectomy on unknown side and one code that indicates either a right or left mastectomy, or two codes that indicate a mastectomy on unknown side.	
	Right Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.11; SNOMED data set PXRM BGP RIGHT MASTECTOMY (Problem List only); Procedure ICD-10: 07T50ZZ, 07T80ZZ, 0HBT0ZZ, 0HCT0ZZ, 0HTT0ZZ.	
	Left Mastectomy: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-10: Z90.12; SNOMED data set PXRM BGP LEFT MASTECTOMY (Problem List only); Procedure ICD-10: 07T60ZZ, 07T90ZZ, 0HBU0ZZ, 0HCU0ZZ, 0HTU0ZZ.	
	Mastectomy on unknown side: 1) CPT 19300-19307, or old codes 19180, 19200, 19220, 19240; 2) Procedure ICD-9: 85.41, 85.43, 85.45, 85.47.	
Mammogram	Rad or CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	POV: ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 Procedure: ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ Women's Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD".

Colorectal cancer screening definition: To be eligible for this screening, patients must be Active Clinical ages 50 through 75 and not have a documented history ever of colorectal cancer or total colectomy. To be counted as having the screening, patients must have had any of the following: (1) FOBT or FIT during the Report Period; (2) flexible sigmoidoscopy or double contrast barium enema in the past 5 years; or (3) colonoscopy in the past 10 years.

The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colorectal Cancer	G0213 through G0215, G0231	Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-9: 153.*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.*, C19, C20, C78.5, Z85.030, Z85.038; SNOMED data set PXRM COLORECTAL CANCER (Problem List only)		
Total Colectomy	44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210-44212	Procedure: ICD-9: 45.8*; ICD-10: 0DTE*ZZ		
Fecal Occult Blood lab test (FOBT) or Fecal Immuno- chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330 through 45345, G0104	Procedure: ICD-9: 45.24; ICD-10: 0DJD8ZZ		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colonoscopy	44397, 45355, 45378-	Procedure: ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5F8ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E7ZX, 0D9F7ZX, 0D9F3ZX, 0D9F4ZX, 0D9G3ZX, 0D9G4ZX, 0D9G3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H3ZX, 0D9M3ZX, 0D9M4ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0DBE3ZX, 0DBE3ZX, 0DBE3ZX, 0DBE3ZX, 0DBF3ZX, 0DBH3ZX, 0DBM3ZX, 0DBM3ZX, 0DBM3ZX, 0DBM3ZX, 0DBM3ZX, 0DBM5ZX, 0DBM3ZX, 0DBM5ZX, 0DBM5ZZ, 0DBM5ZZ		

### **Key Logic Changes from CRS Version 16.1**

- 1. Removed ICD-10 code Z90.711 from hysterectomy definition.
- 2. Updated hysterectomy definition to include inactive Problem List items.
- 3. Added SNOMED data set PXRM BGP HYSTERECTOMY DX to hysterectomy definition (for Problem List only).
- 4. Added logic to look at the Problem List for bilateral and unilateral mastectomies.
- 5. Added SNOMED data set PXRM BGP BILAT MASTECTOMY to bilateral mastectomy definition (for Problem List only).
- 6. Added SNOMED data set PXRM BGP RIGHT MASTECTOMY to right mastectomy definition (for Problem List only).

- 7. Added SNOMED data set PXRM BGP LEFT MASTECTOMY to left mastectomy definition (for Problem List only).
- 8. Added logic to colorectal cancer screening definition to look at the Problem List.
- 9. Added SNOMED data set PXRM COLORECTAL CANCER to colorectal cancer definition (for Problem List only).
- 10. Added LOINC code 80372-6 to BGP FOBT LOINC CODES taxonomy.

### **Patient List Description**

List of patients 25 through 75 with comprehensive cancer screening, if any.

#### **Measure Source**

Not Available

#### **Measure Past Performance and Long-Term Targets**

None

### **Performance Improvement Tip**

- Providers should ask about and record off-site Pap tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should ask about and record off-site historical colorectal cancer tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy).

```
DU
                             November 25, 2017
                                                                     Page 87
       *** IHS 2017 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
              Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Comprehensive Cancer Screening
                              % PREV YR
                    REPORT
                                             % CHG from BASE
                                                                    % CHG from
                     PERIOD
                                  PERIOD
                                                PREV YR % PERIOD
                                                                       BASE %
Active Clinical
 Pts 24-75 (GPRA
                        761
                                      761
                                                             730
 Dev.)
```

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

<pre># w/ Comp Cancer Screening-No Refusals (GPRA Dev.)</pre>	170	22.3	215	28.3	-5.9	189	25.9	-3.6
A. Female Active								
Clinical Pts 24-75	583		587			570		
A. # Female w/ All Screens	156	26.8	196	33.4	-6.6	171	30.0	-3.2
B. Male Active Clinical Pts 50-75	178		174			160		
B. # Male w/ CRC Screen	14	7.9	19	10.9	-3.1	18	11.3	-3.4

Figure 2-43: Sample Report, Comprehensive Cancer Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Comprehensive Cancer Screening: List of patients 21-80 with comprehensive cancer screening, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR \_\_\_\_\_\_ PATIENT1, DANIELLE 000001 COMMUNITY #1 F 21 06/05/96 AC,PAP PAP: 05/05/16 POV 795.0 PATIENT2,MARIE 000002 COMMUNITY #1 F 51 11/20/66 AC, PAP PATIENT3, MARY ANN 000003 COMMUNITY #1 F 52 08/15/65
AC, PAP, MAM, CRCS PAP: 06/12/17 Lab; MAM: 07/06/16
03/16/12 Proc 45.22
PATIENT4, BOBBIE 000004 COMMUNITY #1 F 53 04/04/64
AC, CRCS CRCS: 07/20/17 POV V76.51 PAP: 06/12/17 Lab; MAM: 07/06/16 CPT 77055; CRCS: PATIENT5, WINONA 000005 COMMUNITY #1 F 57 01/18/60
AC.MAM MAM: 10/01/16 CPT 77052 MAM: 10/01/16 CPT 77052

PATIENT6, HARRY 000006 COMMUNITY #1 M 56 05/09/61

AC, CRCS CRCS: 04/07/12 P PATIENT7, LARRY 000007 COMMUNITY #1 M 57 06/17/60 AC CRCS AC, CRCS PATIENT8, BARRY 000008 COMMUNITY #1 M 63 10/22/54 AC, CRCS CRCS: 02/18/17 CPT 45330

Figure 2-44: Sample Patient List, Comprehensive Cancer Screening

# 2.6.5 Tobacco Use and Exposure Assessment

#### **Denominators**

Active Clinical patients ages 5 and older. Broken down by gender and age groups (5 through 13, 14 through 17, 18 through 24, 25 through 44, 45 through 64, and 65 and older), based on HP 2010 age groups.

Pregnant female User Population patients with no documented miscarriage or abortion.

*User Population patients* ages 5 and older. Broken down by gender.

#### **Numerators**

Patients who have been screened for tobacco use during the Report Period.

Patients identified as current tobacco users during the Report Period, both smokers and smokeless users.

- a. Patients identified as current smokers during the Report Period.
- b. Patients identified as current smokeless tobacco users during the Report Period.

Patients identified as exposed to environmental tobacco smoke (ETS) (second-hand smoke) during the Report Period.

### **Logic Description**

Ages are calculated at beginning of Report Period.

For screening, an additional eight months is included for patients who were pregnant during the Report Period but who had their tobacco assessment prior to that.

CRS uses the following codes to define the denominators and numerators:

	<b>CPT:</b> 59000-59076, 59300,	<b>POV:</b> ICD-9: 640.*3, 641.*3, 642.*3,
Reproductive Factors file set to "Yes"	59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828	643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 665.*3, 665.*3, 665.*3, 665.*3, 665.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 669.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.214, O99.280-O99.284, O99.310-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.344, O99.330-O99.314, O99.320-O99.344, O99.330-O99.344, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.844, O99.840-O99.844, O99.89, O98.311-O98.42, O99.310-O99.354, O99.340-O99.344, O99.340-O99.344, O99.350-O99.354, O99.89, O98.311-O98.42, O99.511-O99.62, O99.711-O99.62, O99.711-O99.62, O99.711-O99.62, O99.711-O99.72, O99.810, O99.834, O99.840-O99.844, O99.89, O98.111-O98.42, O99.511-O98.42, O99.511-O98.42, O99.830, O99.834, O99.840-O99.844, O99.89, O98.311-O98.32, O98.411-O98.42, O99.831, O99.834, O99.840-O99.844, O99.89, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36
Miscarriage (after second pregnancy POV in past 20 months)	59812, 59820, 59821, 59830	<b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9

Subject Defined	CPT Codes	ICD and Other Codes
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267	POV: ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Screened for Tobacco Use (time frame for pregnant patients is past 20 months)	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8453 (old code), G8455-G8457 (old codes), G8402 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z72.0, Z87.891; SNOMED data set PXRM BGP TOBACCO SCREENED (Problem List only)  Patient Education codes: Containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005  Dental code: 1320
Tobacco Users (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), G8455 (old code), G8456 (old code), G8453 (old code), G9276	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*, Z72.0; SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only) Dental code: 1320
Current Smokers (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), G8455 (old code), G8402 (old code), G8453 (old code)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.200, F17.203-F17.210, F17.213-F17.290, F17.293-F17.299, O99.33*; SNOMED data set PXRM BGP TOBACCO SMOKER (Problem List only) Dental code: 1320

Subject Defined	CPT Codes	ICD and Other Codes
Current Smokeless (time frame for pregnant patients is past 20 months)	`	POV or Problem List entry where the status is not Inactive or Deleted: ICD-10: F17.220, F17.223-F17.229; SNOMED data set PXRM BGP TOBACCO SMOKELESS (Problem List only)

For numerator definitions, all existing national Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS-CHEWING/DIP), and TOBACCO (EXPOSURE) Health Factors are listed below with the numerator to which they apply.

Health Factor	Numerator
Ceremonial	Screened (does NOT count as Smoker)
Cessation-Smokeless	Screened; Tobacco Users; Smokeless User
Cessation-Smoker	Screened; Tobacco Users; Smoker
Current Smokeless	Screened; Tobacco Users; Smokeless User
Current Smoker	Screened; Tobacco Users; Smoker
Current Smoker, status unknown	Screened; Tobacco Users; Smoker
Current smoker, every day	Screened; Tobacco Users; Smoker
Current smoker, some day	Screened; Tobacco Users; Smoker
Heavy Tobacco Smoker	Screened; Tobacco Users; Smoker
Light Tobacco Smoker	Screened; Tobacco Users; Smoker
Non-Tobacco User	Screened
Previous Smokeless	Screened
Previous (Former) Smokeless	Screened
Previous Smoker	Screened
Previous (Former) Smoker	Screened
Smoke Free Home	Screened
Smoker In Home	Screened; ETS
Current Smoker & Smokeless	Screened; Tobacco Users; Smoker; Smokeless User
Exposure To Environmental Tobacco Smoke	Screened; ETS

# **Key Logic Changes from CRS Version 16.1**

1. Added SNOMED data set PXRM TOBACCO EVER SMOKED to tobacco-related diagnosis definition (for Problem List only).

# **Patient List Description**

List of patients 5 and older with documented tobacco screening, if any.

#### **Measure Source**

HP 2020 TU-1.1 Cigarette smoking 18 and older; TU-1.2 Smokeless tobacco use 18 and older; TU-11 Exposure to ETS-nonsmokers 3 and older

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance (Screening)	68.7%
IHS FY 2015 Performance (Screening)	67.5%
IHS FY 2014 Performance (Screening)	67.3%
IHS FY 2013 Performance (Screening)	66.6%
IHS FY 2012 Performance (Screening)	64.3%
IHS FY 2011 Performance (Screening)	62.0%
IHS FY 2010 Performance (Screening)	60.0%
IHS FY 2009 Performance (Screening)	57.0%
IHS FY 2008 Performance (Screening)	54.0%
IHS FY 2005 Performance (Screening)	34.0%
IHS FY 2004 Performance (Screening)	27.0%

Performance	Percent
IHS FY 2016 Performance (Tobacco Users)	25.7%
IHS FY 2015 Performance (Tobacco Users)	27.4%
IHS FY 2014 Performance (Tobacco Users)	28.1%
IHS FY 2013 Performance (Tobacco Users)	28.6%
IHS FY 2012 Performance (Tobacco Users)	30.7%
IHS FY 2011 Performance (Tobacco Users)	31.6%
IHS FY 2010 Performance (Tobacco Users)	27.0%
IHS FY 2009 Performance (Tobacco Users)	26.0%
IHS FY 2008 Performance (Tobacco Users)	29.0%
HP 2020 Goals: TU-1.1 (Cigarette smoking 18 and older): 12%; TU-1.2 (Smokeless tobacco use 18 and older): 0.3%; TU-11 (Exposure to ETS-non smokers 18 and older): 68%	

```
DU November 25, 2017 Page 90

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Tobacco Use and Expo	sure Ass	essmen	t (con't)						
	REPORT PERIOD		PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %	
% PREV YR % CHO	G from PERIOD	BASE	% CH PERIOD	G from	n PREV YR %	PERIOD		BASE %	
Active Clinical Pts 5+	1,861		1,921			1,914			
# w/ Tobacco Screening # Tobacco Users w/	358	19.2	1,182	61.5	-42.3	1,288	67.3	-48.1	
% of Total Screened A. # Smokers w/ %	74	20.7	236	20.0	+0.7	297	23.1	-2.4	
of Total Tobacco Users B. # Smokeless Tobacco Users w/ %	70	94.6	227	96.2	-1.6	279	93.9	+0.7	
of Total Tobacco Users # Exposed to ETS/Smoker in home	6	8.1	15	6.4	+1.8	22	7.4	+0.7	
w/ % of Total Screened	27	7.5	109	9.2	-1.7	70	5.4	+2.1	
Male Active Clinical Pts 5+	835		893			896			
# w/ Tobacco Screening # Tobacco Users w/ % of Total	148	17.7	501	56.1	-38.4	548	61.2	-43.4	
Screened A. # Smokers w/ %	39	26.4	136	27.1	-0.8	190	34.7	-8.3	
of Total Tobacco Users B. # Smokeless Tobacco Users w/ %	36	92.3	131	96.3	-4.0	178	93.7	-1.4	
of Total Tobacco Users # Exposed to ETS/Smoker in home	5	12.8	10	7.4	+5.5	13	6.8	+6.0	
w/ % of Total Screened	15	10.1	49	9.8	+0.4	28	5.1	+5.0	
Female Active Clinical Pts 5+	1,026		1,028			1,018			
# w/ Tobacco Screening # Tobacco Users w/	210	20.5	681	66.2	-45.8	740	72.7	-52.2	
% of Total Screened A. # Smokers w/ % of Total Tobacco	35	16.7	100	14.7	+2.0	107	14.5	+2.2	

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Users B. # Smokeless	34	97.1	96	96.0	+1.1	101	94.4	+2.8	
Tobacco Users w/ % of Total Tobacco									
Users # Exposed to	1	2.9	5	5.0	-2.1	9	8.4	-5.6	
ETS/Smoker in home w/ % of Total									
Screened	12	5.7	60	8.8	-3.1	42	5.7	+0.0	

Figure 2-45: Sample Report, Tobacco Use Assessment Tobacco Use and Exposure Assessment

Previous	t Peri Year P	Measure DEMO I od: Jan eriod:	NDIAN H 01, 20 Jan 01	Communi OSPITAL 17 to D	ec 31, to Dec	2017 31, 2016	
Basell			an ui,			., 2010	
Tobacco Use and Exposur	e Asse	ssment	(con't)				
	TOTAL	ACTIVE		AL POPU			
	E 12	1/ 17		Distri 25-44		65.	
	3-13	14-1/	10-24	25-44	45-04	05+	
CURRENT REPORT PERIOD							
# Active Clinical							
<pre># w/ Tobacco Screening % w/ Tobacco Screening</pre>	59 15 0	13 3	18 7	94 17 9			
wy lobaceo beleening	13.0	13.3	10.7	17.0	21.3	20.5	
# Tobacco Users		3	18	22	24	5	
% Tobacco Users w/ % of		16 7	26.0	22.4	22.0	12 0	
Total Screened	3.4	16./	36.0	23.4	23.8	13.9	
A. # Smokers	2	3	18	22	22	3	
A. % Smokers w/ % of							
Total Tobacco Users	100.0	100.0	100.0	100.0	91.7	60.0	
B. # Smokeless	0	0	2	1	3	0	
B. % Smokeless w/ % of							
Total Tobacco Users	0.0	0.0	11.1	4.5	12.5	0.0	
# ETS/Smk Home	1	2	2	6	8	4	
% ETS/Smk Home w/ % of		۷	3	0	0	4	
Total Screened	6.8	11.1	6.0	6.4	7.9	11.1	
PREVIOUS YEAR PERIOD # Active Clinical	204	149	298	536	426	118	
# w/ Tobacco Screening	394 201	83		365		83	
% w/ Tobacco Screening	51.0	55.7				70.3	
# Tobacco Users		7	41	107	64	14	
<pre>% Tobacco Users w/ % of Total Screened</pre>		0 1	27.5	20.2	21.3	16 0	
TOTAL SCIENTED	1.5	0.4	47.5	49.3	21.3	10.9	
A. # Smokers	2	7	41	100	64	13	
A. % Smokers w/ % of							

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

Total Tobacco Users	66.7	100.0	100.0	93.5	100.0	92.9	
B. # Smokeless	1	0	1	10	2	1	
B. % Smokeless w/ % of Total Tobacco Users	33.3	0.0	2.4	9.3	3.1	7.1	
# ETS/Smk Home	11	2	14	37	35	10	
<pre>% ETS/Smk Home w/ % of Total Screened</pre>	5.5	2.4	9.4	10.1	11.6	12.0	
CHANGE FROM PREV YR %							
# w/ Tobacco Screening	-36.0	-42.4	-31.3	-50.2	-46.2	-42.0	
Tobacco Users	+1.9	+8.2	+8.5	-5.9	+2.5	-3.0	
A. # Smokers	+33.3	+0.0	+0.0	+6.5	-8.3	-32.9	
B. # Smokeless	-33.3	+0.0	+8.7	-4.8	+9.4	-7.1	
ETS	+1.3	+8.7	-3.4	-3.8	-3.7	-0.9	

Figure 2-46: Sample Age Breakdown Report, Tobacco Use Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Tobacco Use and Exposure Assessment: List of patients 5 and older with documented tobacco screening, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR \_\_\_\_\_\_ PATIENT1, CHESTER 000001 COMMUNITY #1 M 7 06/05/10 UP, AC 01/10/17 SCREEN 000002 COMMUNITY #1 M 19 07/07/98 ΠP PATIENT3, BEN 000003 COMMUNITY #1 M 22 05/18/95 PATIENT4, MARY 000004 COMMUNITY #2 F 35 03/31/82 UP, AC, PREG 04/10/17 CORRENT 04/10/17 TOTAL 04/10/17 SCREEN, 04/10/17 USER, 04/10/17 SMOKELESS UP,AC,PREG 

 OP,AC,PREG
 04/10/17 SCREEN, 04/10/17 USER, 0

 PATIENT5,HARRY B
 000005 COMMUNITY #2 M 13 09/02/04

 UP
 03/15/17 SCREEN

 PATIENT6,EMERSON
 000006 COMMUNITY #2 M 15 11/19/02

 UP,AC
 05/21/17 SCREEN, 05/21/17 USER, 0

 05/21/17 SCREEN, 05/21/17 USER, 05/21/17 SMOKER, 05/21/17 ETS PATIENT7, EUGENE JAY 000007 COMMUNITY #3 M 29 05/18/88 PATIENT8, ROGER 000008 COMMUNITY #3 M 31 08/04/86
UP,AC 01/21/17 SCREEN, 01/21/17 USER, 0
PATIENT9, ANDREW 000009 COMMUNITY #3 M 42 09/15/75 01/21/17 SCREEN, 01/21/17 USER, 01/21/17 SMOKER

Figure 2-47: Sample Patient List, Tobacco Use Assessment

#### 2.6.6 Tobacco Cessation

### **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 53.2% for the proportion of tobacco-using patients who receive tobacco cessation intervention or quit tobacco use.

#### **Denominators**

Active Clinical patients identified as current tobacco users or tobacco users in cessation. Broken down by gender and age groups (less than (<) 12, 12 through 17, 18 and older (GPRA Denominator).)

*User Population patients* identified as current tobacco users or tobacco users in cessation.

#### **Numerators**

Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid anytime during the Report Period.

**Note**: This numerator does *not* include refusals.

Patients identified as having quit their tobacco use anytime during the Report Period.

Patients who received tobacco cessation counseling, received a prescription for a tobacco cessation aid, or quit their tobacco use anytime during the Report Period. (GPRA Numerator)

**Note**: This numerator does *not* include refusals.

### **Logic Description**

Age is calculated at the beginning of the Report Period.

### **Denominator Logic**

Current Tobacco Users or Tobacco Users in Cessation:

CRS will search first for all health factors in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories documented during the Report Period.

If health factor(s) are found and at least one of them is one of the health factors listed below, the patient is counted as a current tobacco user or tobacco user in cessation. The patient is not counted as receiving cessation counseling.

Tobacco User Health Factors (TUHFs):

- Cessation-Smoker
- Cessation-Smokeless
- Current Smoker
- Current Smokeless
- Current Smoker and Smokeless
- Current Smoker, status unknown
- Current Smoker, every day
- Current Smoker, some day
- Heavy Tobacco Smoker
- Light Tobacco Smoker

If a health factor is found and it is NOT a TUHF, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user.

If no TUHF was found, CRS will then search for any of the following codes documented during the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*, Z72.0; SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only).
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276.

If any of these codes are found, the patient will be considered a tobacco user.

If no TUHF or other tobacco user-defining code listed above was found during the specified timeframe, CRS will then search for the most recent health factor in both the TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories documented during an EXPANDED timeframe of any time prior to the Report Period. For example, a patient with the most recent health factor being documented five years prior to the Report Period.

**Note:** If multiple health factors were documented on the same date and if any of them are TUHFs, all of the health factors will be considered as TUHFs.

If a health factor is found during the expanded timeframe, and is a TUHF, the patient will be considered a potential tobacco user.

If a health factor is found during the expanded timeframe and it is not one of the TUHFs, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a potential tobacco user.

If no health factor was found, CRS will then search for any of the following codes documented through the beginning of the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*, Z72.0; SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only).
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F,
   G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code),
   G9276.

If any of these codes are found, the patient will be considered a potential tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If the patient is considered a potential tobacco user, CRS will then search for diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891; SNOMED data set PXRM BGP QUIT TOBACCO (Problem List only) with a date occurring after the health factor date and through the beginning of the report period. If one of these diagnoses is found, the patient will be considered as having quit their tobacco use and will not be included in the denominator. If a diagnosis is not found, the patient is included as a current tobacco user and will be included in the denominator.

#### **Numerator Logic**

#### **Tobacco Cessation Counseling**

Any of the following documented anytime during the Report Period:

- Patient education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1\* (old codes), 649.00-649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402, G8453, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005
- Clinic code 94 (tobacco cessation clinic)
- Dental code 1320
- CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453

#### **Prescription for Tobacco Cessation Aid**

Any of the following documented anytime during the Report Period:

- Prescription for medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy that does not have a comment of RETURNED TO STOCK.
- Prescription for any medication with name containing "NICOTINE PATCH", "NICOTINE POLACRILEX", "NICOTINE INHALER", or "NICOTINE NASAL SPRAY" that does not have a comment of RETURNED TO STOCK.
- CPT 4001F

#### **Quit Tobacco Use**

Any of the following documented anytime during the Report Period through the end of the Report Period AND after the date of the code found indicating the patient was a current tobacco user.

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891; SNOMED data set PXRM BGP QUIT TOBACCO (Problem List only)
- Health Factor (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (former) smoker, Previous (former) smokeless

### **Key Logic Changes from CRS Version 16.1**

- 1. Added SNOMED data set PXRM BGP QUIT TOBACCO to quit tobacco definition (for Problem List only).
- 2. Added SNOMED data set PXRM BGP CURRENT TOBACCO to tobacco user definition (for Problem List only).

#### **Patient List Description**

List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

#### **Measure Source**

Smoking Cessation Attempts: HP 2020 TU-4

Smoking Cessation Counseling: HP 2020 TU-10

#### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2016 Performance	50.4%
IHS FY 2015 Performance	52.1%
IHS FY 2014 Performance	48.2%
IHS FY 2013 Performance	45.7%
IHS FY 2012 Performance	36.4%
Former definition:	
IHS FY 2012 Performance	35.2%
IHS FY 2011 Performance	29.4%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	24.0%
IHS FY 2008 Performance	21.0%
IHS FY 2007 Performance	16.0%
IHS FY 2006 Performance	12.0%
HP 2020 goal for increasing smoking cessation attempts for adult smokers	80.0%

```
DU November 25, 2017 Page 101

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Tobacco Cessation (con't)
```

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		%	CHG from BASE %	
User Pop Tobacco Users/In Cessation	483		560			436			
<pre># w/ Tobacco   Cessation   Counseling or Rx   for Cessation Aid,   or Quit-No   Refusals</pre>	39	8.1	141	25.2	-17.1	150	34.4	-26.3	
RCIUSAIS	37	0.1	111	23.2	17.1	150	34.4	20.5	
Active Clinical Tobacco Users/In Cessation (GPRA)	424		512			417			
# w/ Tobacco Cessation Counseling or Rx for Cessation									
Aid-No Refusals # Quit # w/ Tobacco Cessation Counseling, Rx for	26 12	6.1 2.8		19.5 8.6			27.1 9.6		
Cessation Aid, or Quit-No Refusals (GPRA)	37	8.7	135	26.4	-17.6	148	35.5	-26.8	
Male Active Clinical Tobacco Users/In Cessation	252		307			253			
# w/ Tobacco Cessation Counseling or Rx for Cessation									
Aid-No Refusals # Quit # w/ Tobacco Cessation	12 8	4.8	52 21	16.9 6.8	-12.2 -3.7	65 19	25.7 7.5		
Counseling, Rx for Cessation Aid, or Quit-No Refusals	20	7.9	72	23.5	-15.5	81	32.0	-24.1	
Female Active Clinical Tobacco Users/In Cessation	172		205			164			
<pre># w/ Tobacco   Cessation   Counseling or Rx   for Cessation   Aid-No Refusals # Quit # w/ Tobacco</pre>	14 4	8.1		23.4		48 21	29.3 12.8		
Cessation			aio Monus						

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Counseling, Rx for Cessation Aid, or									
Quit-No Refusals	17	9.9	63	30.7	-20.8	67	40.9	-31.0	

Figure 2-48: Sample Report, Tobacco Cessation

Tobacco Cessation (con't)				
ACTIVE C	LINICA	L TOBACCO USERS		
	<12	Age Distribution 12-17	18+	
CURRENT REPORT PERIOD AC Tob Users/in Cess	8	16	400	
# w/ Tobacco Cessation Counseling				
or RX for Cessation Aid- No Refusals % w/ Tobacco Cessation Counseling	1	1	24	
or Rx for Cessation Aid- No Refusals	12.5	6.3	6.0	
# Quit % Quit	0.0	0.0	12 3.0	
# w/ Tobacco Cessation Counseling	,			
Rx for Cessation Aid or Quit- No Refusals % w/ Tobacco Cessation Counseling	,	1	35	
Rx for Cessation Aid or Quit- No Refusals	12.5	6.3	8.8	
PREVIOUS YEAR PERIOD AC Tob Users/in Cess	11	23	478	
# w/ Tobacco Cessation Counseling or RX for Cessation Aid-				
No Refusals % w/ Tobacco Cessation Counseling or Rx for Cessation Aid-	4	2	94	
No Refusals	36.4	8.7	19.7	
# Quit % Quit	2 18.2	3 13.0	39 8.2	
# w/ Tobacco Cessation Counseling Rx for Cessation Aid or Quit-	,			
No Refusals % w/ Tobacco Cessation Counseling	6	5	124	
Rx for Cessation Aid or Quit- No Refusals	54.5	21.7	25.9	
CHANGE FROM PREV YR %  W/ Tobacco Cessation Counseling				
# Quit	-23.9 -18.2		-13.7 -5.2	
# w/ Tobacco Cessation				

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
Counseling, Rx for Cessation Aid or Quit-No Refusals -42.0 -15.5 -17.2
```

Figure 2-49: Sample Age Breakdown Report, Tobacco Cessation

UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Tobacco Cessation: List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use. PATIENT NAME HRN COMMUNITY
DENOMINATOR NUMERATOR HRN COMMUNITY SEX AGE DOB PATIENT1, BRITNEY 000001 COMMUNITY #1 F 22 08/04/95
UP, AC COUNSEL/RX: 06/10/17 CPT G0375
PATIENT2, LORETTA 000002 COMMUNITY #1 F 22 09/19/95
UP, AC COUNSEL/RX: 01/13/17 305.1-DP
PATIENT3, HALEY 000003 COMMUNITY #1 F 25 04/01/92
UP, AC COUNSEL/RX: 02/19/17 TO-LA
PATIENT4, ANGEL 000004 COMMUNITY #1 F 30 06/15/87
UP, AC COUNSEL/RX: 03/05/17 CPT 4000F
PATIENT5, JOYCE 000005 COMMUNITY #1 F 31 05/22/86
UP, AC QUIT: PREVIOUS (FORMER) SMOKER 05
PATIENT6, ESTHER 000006 COMMUNITY #1 F 32 09/23/85
UP, AC COUNSEL/RX: 03/05/17 CESSATION M QUIT: PREVIOUS (FORMER) SMOKER 05/31/17 COUNSEL/RX: 03/05/17 CESSATION MED - NICOTINE 14MG TRANSDERMAL PATCH PATIENT7, SARAH 000007 COMMUNITY #1 F 33 06/15/84 UP,AC PATIENT8, PAULA 000008 COMMUNITY #1 F 34 07/04/83 COUNSEL/RX: 03/17/17 TO-QT UP,AC

Figure 2-50: Sample Patient List Tobacco Cessation

## 2.7 Behavioral Health Related Performance Measure Topics

## 2.7.1 Alcohol Screening

## **GPRA Measure Description**

During GPRA Year 2017, establish a baseline for the proportion of patients ages 12 to 75 who receive screening for alcohol use.

#### **Denominators**

Active Clinical Plus BH patients ages 12 through 75. Broken down by age groups: 12-19, 20-24, 25-34, 35-44, 45-54, and 55-75. (GPRA Denominator)

Active Clinical Plus BH patients ages 12 through 75 screened for alcohol use during the Report Period, not including refusals or patient education. Broken down by age groups: 12-19, 20-24, 25-34, 35-44, 45-54, and 55-75.

**Note**: This denominator does *not* include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.

Female Active Clinical patients ages 14 through 46.

Female Active Clinical patients ages 14 through 46 screened for alcohol use during the Report Period.

**Note**: This denominator does *not* include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.

User Population patients ages 12 through 75.

#### **Numerators**

Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

**Note**: This numerator does *not* include refusals or alcohol-related patient education. (GPRA Numerator)

Patients with alcohol-related patient education during the Report Period.

Patients who were screened positive for alcohol use.

Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, or received alcohol-related patient education during the Report Period.

**Note**: This numerator does *not* include refusals.

- a. Patients with alcohol screening during the report period.
- b. Patients with alcohol-related diagnosis or procedure during the report period
- c. Patients with alcohol-related patient education during the report period.

#### **Logic Description**

Ages are calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes
Alcohol Screening	Exam Code: 35
	CPT code: 99408, 99409, G0396, G0397, H0049, H0050, 3016F
	Any CAGE Health Factor POV: ICD-9: V11.3 (history of alcoholism), V79.1 (screening for alcoholism)
	BHS Problem Code: 29.1 (Screening for Alcoholism)
	Measurement in PCC or BHS: AUDT, AUDC, or CRFT
Alcohol-related Diagnosis	POV, Current PCC or BHS Problem List: ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.920-F10.982, F10.99, G62.1; SNOMED data set PXRM BGP ETOH RELATED DX (Problem List only)  BHS POV or Problem Codes: 10, 12.1, 14.2, 17.1, 18.1, 20.1, 22.1, 27, 29
Alcohol-related	Procedure: ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69
Procedure	1100cdd1c. 10D 3. 34.40, 34.33, 34.01 34.03, 34.01 34.03
Alcohol-related Education	Patient Education codes: "AOD-" or "-AOD", "CD-" or "-CD" (old codes), or containing V11.3, V79.1, 303.*, 305.0*, 291.* 357.5*, 99408, 99409, G0396, G0397, H0049, H0050, 3016F, or SNOMED codes 15167005, 18653004, 191471000, 191475009, 191476005, 191477001, 191478006, 191480000, 191802004, 191804003, 191805002, 191811004, 191812006, 191813001, 19303008, 281004, 284591009, 288281000119100, 29212009, 30491001, 34938008, 41083005, 42344001, 53936005, 61144001, 66590003, 7052005, 7200002, 73097000, 78524005, 79578000, 8635005
Positive Screen for	Exam Code: 35 Alcohol Screening result of "Positive"
Alcohol Use	Health Factor: CAGE result of 1/4, 2/4, 3/4 or 4/4
	<b>CPT:</b> G0396, G0397, 99408, 99409
	<b>Measurement Result in PCC:</b> AUDT result of greater than or equal to (>=) 8, AUDC result of greater than or equal to (>=) 4 for men and greater than or equal to (>=) 3 for women, CRFT result of 2-6

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

## **Recommended Brief Screening Tool**

Single Alcohol Screening Question (SASQ) (below).

For Women:

When was the last time you had more than four drinks in one day?

For Men:

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

#### **Alcohol Health Factors**

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

- 1. Have you ever felt the need to Cut down on your drinking?
- 2. Have people Annoyed you by criticizing your drinking?
- 3. Have you ever felt bad or **G**uilty about your drinking?
- 4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?
- 5. Based on how many YES answers are received, document Health Factor:
  - HF-CAGE 0/4 (all "No" answers)
  - HF-CAGE 1/4
  - HF-CAGE 2/4
  - HF–CAGE 3/4
  - HF-CAGE 4/4

#### Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: # of drinks daily

#### **Key Logic Changes from CRS Version 16.1**

- 1. Changed topic to Alcohol Screening from Alcohol Screening (FAS Prevention)
- 2. Moved measures from GPRA Developmental report to Selected Measures report.
- 3. Changed GPRA measure to Universal Alcohol Screening measure.
- 4. Removed User Pop FAS meaures.

- 5. Added new measure with User Pop denominator.
- 6. Added SNOMED data set PXRM BGP ETOH RELATED DX to alcohol-related diagnosis definition (for Problem List only).

## **Patient List Description**

List of patients with documented alcohol screening and result, if any.

#### **Measure Source**

HP 2010 16-17a

## **Measure Past Performance and Long-term Targets**

Performance	Percent
IHS FY 2016 Performance (FAS prevention)	67.2%
IHS FY 2015 Performance (FAS prevention)	66.6%
IHS FY 2014 Performance (FAS prevention)	66.0%
IHS FY 2013 Performance (FAS prevention)	65.7%
IHS FY 2012 Performance (FAS prevention)	63.8%
IHS FY 2011 Performance (FAS prevention)	57.8%
IHS FY 2010 Performance (FAS prevention)	55.0%
IHS FY 2009 Performance (FAS prevention)	52.0%
IHS FY 2008 Performance (FAS prevention)	47.0%
IHS FY 2007 Performance (FAS prevention)	41.0%
IHS FY 2006 Performance (FAS prevention)	28.0%
IHS FY 2005 Performance (FAS prevention)	11.0%
IHS FY 2004 Performance (FAS prevention)	7.0%

DU November 25, 2017 Page 114  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Alcohol Screening (FAS Prevention)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %								
AC+BH ages 12-75 (GPRA)	1,517	1,581	1,582					
# w/ Alcohol Screening/Dx/Proc	-No							

Refusals or Pt Ed (GPRA) # w/ Alcohol-Related	335	22.1	1,014	64.1	-42.1	1,076	68.0	-45.9	
Education	24	1.6	88	5.6	-4.0	36	2.3	-0.7	
AC+BH ages 12-75 w/ Alcohol Screening	295		950			975			
# w/ Positive Alcohol Screen (GPRA Dev.)	83	28.1	217	22.8	+5.3	221	22.7	+5.5	
Female Active Clinical Pts 14-46	537		549			534			
<pre># w/ Alcohol   Screening/Dx/Proc/Pt   Ed-No Refusals</pre>	141	26.3	372	67.8	-41.5	386	72.3	-46.0	
A. # w/ Alcohol Screening w/ % of Total Screened B. # w/	119	84.4	346	93.0	-8.6	359	93.0	-8.6	
Alcohol-Related Dx or Procedure w/ % of Total Screened C. # w/ Alcohol-Related	17	12.1	19	5.1	+6.9	26	6.7	+5.3	
Education w/ % of Total Screened	15	10.6	35	9.4	+1.2	14	3.6	+7.0	
Female Active Clinical Pts 14-46 w/ Alcohol									
Screening	119		346			359			
# w/ Positive Alcohol Screen	29	24.4	66	19.1	+5.3	65	18.1	+6.3	
User Pop Pts 12-75	1,773		1,814			1,813			
# w/ Alcohol Screening/Dx/Proc-No Refusals or Pt Ed	348	19.6	1,054	58.1	-38.5	1,099	60.6	-41.0	

Figure 2-51: Sample Report, Alcohol Screening

```
DU November 25, 2017 Page 95

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Alcohol Screening (con't)

ACTIVE CLINICAL POPULATION
```

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

Age Distribution 12-19 20-24 25-34 35-44 45-54 55-6  CURRENT REPORT PERIOD	7.5
CURRENT REPORT PERIOD	
	13
Total Active Clinical 285 188 319 210 226 28	9
# w/ Alcohol Screening/Dx/	
Proc-No Refusals or Pt Ed 57 43 70 41 62 6.	2
% w/ Alcohol Screening/Dx/	4
Proc-No Refusals	
or Pt Ed 20.0 22.9 21.9 19.5 27.4 21.	5
# w/ Alcohol-Related Education 6 6 5 2 3	2
% w/ Alcohol-Related	4
Education 2.1 3.2 1.6 1.0 1.3 0.	7
# Active Clinical w/ Alcohol Screening 49 37 65 33 56 5	_
Screening 49 37 65 33 56 5	0
# w/ Positive Alcohol	
	7
% w/ Positive Alcohol	
Screen 28.6 29.7 33.8 33.3 32.1 12.	7
PREVIOUS YEAR PERIOD	
Total Active Clinical 307 209 325 213 251 27	<u> </u>
# w/ Alcohol Screening/Dx/	
Proc-No Refusals	
or Pt Ed 157 111 223 153 168 20.	2
% w/ Alcohol Screening/Dx/	
Proc-No Refusals or Pt Ed 51.1 53.1 68.6 71.8 66.9 73.	2
01 FC Ed 31.1 33.1 00.0 71.0 00.9 73.	2
# w/ Alcohol-Related	
Education 45 4 7 11 11 1	)
% w/ Alcohol-Related	
Education 14.7 1.9 2.2 5.2 4.4 3.	0
# Active Clinical w/ Alcohol	
Screening 144 100 205 143 159 19	9
# w/ Positive Alcohol   Screen   21   28   59   41   44   20	1
Screen   21   28   59   41   44   20   28   8   w/ Positive Alcohol	±
Screen 14.6 28.0 28.8 28.7 27.7 12.	1
CHANGE FROM PREV YR %	
w/ Alcohol Screening/Dx/	
Proc-No Refusals or Pt Ed -31.1 -30.2 -46.7 -52.3 -39.5 -51.	7
or Pt Ed -31.1 -30.2 -46.7 -52.3 -39.5 -51.  W/ Alcohol related	1
Educ -12.6 +1.3 -0.6 -4.2 -3.1 -2.5	9
w/ Positive Alcohol	
Screen +14.0 +1.7 +5.1 +4.7 +4.5 +0.	7

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Figure 2-52: Sample Age Breakdown Report, Alcohol Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Alcohol Screening: List of patients with documented alcohol screening and result, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, CHRISTINE S 000001 COMMUNITY #1 F 15 05/25/02 PATIENT2, RITA A 000002 COMMUNITY #1 F 15 07/21/02 UP, AC+BH SCREEN: 03/06/17 POV V11.3 POV V11.3 PATIENT3, DIANE L 000003 COMMUNITY #1 F 15 07/30/02 PATIENT4, ALICIA 000004 COMMUNITY #1 F 15 10/22/02 UP,AC,AC+BH DP,AC,AC+BH
PATIENT5,MELISSA

000005 COMMUNITY #1 F 16 03/11/01
UP,AC+BH
PT ED: 02/13/17 99408-P
PATIENT6,LISA MARIE

000006 COMMUNITY #1 F 16 05/22/01
UP,AC+BH
SCREEN: 10/13/17 HF CAGE 1/4 PATIENT7, RUTH NELLIE 000007 COMMUNITY #1 F 16 07/18/01 PATIENT8, ALISHA DAWN 000008 COMMUNITY #1 F 16 09/09/01 SCREEN: 03/03/17 CPT 3016F UP,AC,AC+BH

Figure 2-53: Sample Patient List, Alcohol Screening

# 2.7.2 Screening, Brief Intervention, and Referral to Treatment (SBIRT)GPRA Measure Description

During GPRA Year 2017, establish a baseline for the proportion of patients ages 9 through 75 who screened positive for risky or harmful alcohol use and who received a Brief Negotiated Interview (BNI) or Brief Intervention (BI) within 7 days of screen.

#### **Denominators**

Active Clinical Plus BH patients ages 9 through 75. Broken down by gender and age groups (9 through 12, 13 through 18, 19 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, and 65 through 75).

Active Clinical Plus BH patients age 9 through 75 years screened positive for risky or harmful alcohol use during the Report Period. Broken down by gender and age groups (9 through 12, 13 through 18, 19 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, and 65 through 75). (GPRA Denominator)

*User Population patients* age 9 through 75 years screened positive for risky or harmful alcohol use during the Report Period.

#### **Numerators**

Patients screened in Ambulatory Care for risky or harmful alcohol use.

- a. Patients screened positive for risky or harmful alcohol use.
- b. Patients provided a Brief Negotiated Interview (BNI) or Brief Intervention (BI) in Ambulatory care within 7 days of screen.

Patients provided a Brief Negotiated Interview (BNI) or Brief Intervention (BI) in Ambulatory Care within 7 days of screen. (GPRA Numerator)

- a. Patients who received a BNI/BI on same day as screen.
- b. Patients who received a BNI/BI 1-3 days after screen.
- c. Patients who received a BNI/BI 4-7 days after screen.
- d. Patients who were referred treatment within 7 days of screen.

#### **Logic Description**

Age of the patient is calculated as of the beginning of the Report Period.

Ambulatory Care definition: Service Category A (Ambulatory).

CRS uses the following codes:

Subject Defined	ICD and Other Codes					
Screening for Risky	Any conducted during an Ambulatory Care visit.					
or Harmful Alcohol	Exam Code: 35					
Use	Any Alcohol Health Factor (i.e., CAGE)					
	POV: V79.1 Screening for Alcoholism					
	<b>CPT:</b> G0396, G0397, H0049, H0050, 99408 (old code), 99409 (old code), 3016F					
	Measurement in PCC: AUDT, AUDC, or CRFT					
Positive Screen for Hazardous Alcohol	Any of the following for the screening conducted during an Ambulatory Care visit:					
Use	Exam Code: 35 Alcohol Screening result of "Positive"					
	Health Factor: CAGE result of 1/4, 2/4, 3/4 or 4/4					
	<b>CPT:</b> G0396, G0397, 99408, 99409					
	<b>Measurement Result in PCC:</b> AUDT result of greater than or equal to (>=) 8, AUDC result of greater than or equal to (>=) 4 for men and greater than or equal to (>=) 3 for women, CRFT result of 2-6					

Subject Defined	ICD and Other Codes
Brief Negotiated Interview/Brief Intervention (BNI/BI)	Any of the following documented at the Ambulatory Care visit or within 7 days of the Ambulatory Care visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:  CPT: G0396, G0397, H0050, 99408 (old code), 99409 (old code), 96150-96155
	<b>Patient Education Code:</b> AOD-BNI or containing G0396, G0397, H0050, 99408, 99409, 96150-96155
Referral to treatment	Patient Education Code: AOD-TX

## **Recommended Brief Screening Tool**

SASQ (below).

For Women:

When was the last time you had more than four drinks in one day?

For Men:

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

#### **Alcohol Health Factors**

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

- 1. Have you ever felt the need to Cut down on your drinking?
- 2. Have people Annoyed you by criticizing your drinking?
- 3. Have you ever felt bad or Guilty about your drinking?
- 4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?

Based on how many YES answers are received, document Health Factor:

- HF–CAGE 0/4 (all No answers)
- HF–CAGE 1/4
- HF-CAGE 2/4

- HF–CAGE 3/4
- HF-CAGE 4/4

#### Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: number of drinks daily

## **Key Logic Changes from CRS Version 16.1**

- 1. Made BNI/BI measure new GPRA measure.
- 2. Added new measure with User Pop denominator.

## **Patient List Description**

List of patients with screening for risky or harmful alcohol use, results of screen, BNI/BI, and referral, if any.

#### **Measure Source**

None

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
N/A	N/A

DU November 25, 2017 Page 117  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Screening, Brief Intervention, and Referral to Treatment (SBIRT)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %									
AC+BH Pts 9-75	1,652		1,720			1,685			
<pre># w/ Screening for Alcohol Use A. # w/ Positive Screen w/ % of</pre>	289	17.5	954	55.5	-38.0	968	57.4	-40.0	
Total Screened B. # w/ BNI/BI in 7 days of screen w/ % of Total	83	28.7	219	23.0	+5.8	221	22.8	+5.9	

Screened	10	3.5	3	0.3	+3.1	5	0.5	+2.9	
Male AC+BH Pts 9-75	741		794			796			
# w/ Screening for Alcohol Use A. # w/ Positive	122	16.5	392	49.4	-32.9	393	49.4	-32.9	
Screen w/ % of Total Screened B. # w/ BNI/BI in 7 days of screen	45	36.9	133	33.9	+3.0	137	34.9	+2.0	
w/ % of Total Screened	5	4.1	2	0.5	+3.6	3	0.8	+3.3	
Female AC+BH Pts 9-75	911		926			889			
# w/ Screening for Alcohol Use A. # w/ Positive Screen w/ % of	167	18.3	562	60.7	-42.4	575	64.7	-46.3	
Total Screened B. # w/ BNI/BI in 7 days of screen	38	22.8	86	15.3	+7.5	84	14.6	+8.1	
w/ % of Total Screened	5	3.0	1	0.2	+2.8	2	0.3	+2.6	

Figure 2-54: Sample Report, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

DU November 25, 2017 Page 95  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Screening, Brief Intervention, and Referral to Treatment (SBIRT) (con't)  AC+BH Pts 9-75  Age Distribution									
	9-12	13-18	_		35-44	45-54	55-64	65-75	
CURRENT REPORT PERIOD AC+BH Pts 9-75				319					
# w/ Screening for Alcohol Use % w/ Screening for Alcohol Use					29 13.8				
A. # w/ Positive Screen w/ % of Total Screened % A. w/ Positive Screen % of Total Screened	w/				11 5.2		5 2.6		
B. # w/ BNI/BI in 7 days of screen w/ % of Total Screened 1 3 4 1 0 1 0 0 % B. w/ BNI/BI in 7 days of screen									

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

w/ % of Total Screened	0.6	1.5	1.7	0.3	0.0	0.4	0.0	0.0	
PREVIOUS REPORT PERIOD	177	222	254	225	212	240	1.01	0.2	
AC+BH Pts 9-75	173	232	254	325	213	249	181	93	
II / G									
# w/ Screening for Alcohol Use	15	116	120	205	142	150	128	69	
% w/ Screening for	13	110	120	205	142	133	120	09	
Alcohol Use	8.7	50.0	47.2	63.1	66.7	63.9	70.7	74.2	
	0.,	50.0		00.1		00.0	, , ,		
A. # w/ Positive Screen									
w/ % of Total Screened	2	14	35	59	41	44	19	5	
% A. w/ Positive Screen	w/								
% of Total Screened	1.2	6.0	13.8	18.2	19.2	17.7	10.5	5.4	
B. # w/ BNI/BI in 7 days									
w/ % of Total Screened			0	1	0	0	0	0	
% B. w/ BNI/BI in 7 days			0 0		0 0	0 0	0 0	0 0	
w/ % of Total Screened	0.0	0.9	0.0	0.3	0.0	0.0	0.0	0.0	
CHANGE FROM PREVIOUS YR	O <sub>2</sub>								
# w/ Screening for	6								
Alcohol Use	-7 5	-32 0	-27 4	-42 7	-52 9	-39 3	-52 9	-52 5	
A. # w/ Positive Screen	, . 5	32.0	2/.1	12.7	34.9	37.3	34.9	24.3	
w/% of Total Screened	-0.6	-1.6	-7.3	-11.3	-14.0	-9.6	-7.9	-3.3	
B. # w/ BNI/BI in 7 days									
w/% of Total Screened			+1.7	+0.0	+0.0	+0.4	+0.0	+0.0	

Figure 2-55: Sample Age Breakdown Report, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient SBIRT: List of patients with screening for risky or harmful alcohol use, results of screen, BNI/BI, and referral, if any. PATIENT NAME DENOMINATOR HRN COMMUNITY SEX AGE DOB NUMERATOR PATIENT1, DARLENE S 000001 COMMUNITY #1 F 33 04/04/83 SCREEN: 03/01/17 CPT G0396 result=Pos; BNI: 03/01/17 Yes [0]; REFERRAL: No PATIENT2, RITA A 000002 COMMUNITY #1 F 33 10/22/83 AC+BH PATIENT3, DIANE L 000003 COMMUNITY #1 F 15 06/02/01 AC+BH PATIENT4, ALICIA 000004 COMMUNITY #1 F 18 08/13/98 SCREEN: 02/27/17 HF CAGE 1/4 result=Pos; BNI: No; AC+BH REFERRAL: No PATIENT5, MELISSA 000005 COMMUNITY #1 F 16 03/01/00 SCREEN: 07/01/17 Meas AUDC result=Pos; BNI: No; REFERRAL: 07/06/17 Yes PATIENT6, LISA MARIE 000006 COMMUNITY #1 F 20 06/02/96 SCREEN: 02/06/17 Ex 35; BNI: No; AC+BH

Figure 2-56: Sample Patient List, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

## 2.7.3 Intimate Partner (Domestic) Violence Screening

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 65.3% for the proportion of female patients ages 14 through 46 who receive screening for domestic violence.

#### **Denominators**

Female Active Clinical patients ages 14 through 46. (GPRA Denominator)

Female User Population patients ages 14 through 46.

#### **Numerators**

Patients screened for intimate partner (domestic) violence at any time during the Report Period.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with documented IPV/DV exam
- b. Patients with IPV/DV related diagnosis
- c. Patients provided with education or counseling about IPV/DV

## **Logic Description**

Age of the patient is calculated at the beginning of the report period. CRS uses the following codes to define numerators.

Subject Defined	CPT Codes	ICD and Other Codes
IPV/DV Screening		Exam: Code 34
		BHS Exam: IPV/DV
IPV/DV Diagnosis		POV or current PCC or BHS Problem List: ICD-9: 995.80-995.83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410; SNOMED data set PXRM BGP IPV DV DX (Problem List only) BHS POV: 43.*, 44.*
IPV/DV Education		Patient education codes: Containing "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, V15.49, or SNOMED 3027571011, 3027627017, 371772001, 406138006, 412732008, 429746005, 431027007, 432527004

Subject Defined	CPT Codes	ICD and Other Codes
IPV/DV Counseling		<b>POV: ICD-9:</b> V61.11; ICD-10: Z69.11

## **Key Logic Changes from CRS Version 16.1**

1. Added SNOMED data set PXRM BGP IPV DV DX to IPV/DV diagnosis definition (for Problem List only).

## **Patient List Description**

List of female patients 14-46 with documented IPV/DV screening, if any.

## **Measure Source**

HP 2010 15-34

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance	65.3%
IHS FY 2015 Performance	63.6%
IHS FY 2014 Performance	63.5%
IHS FY 2013 Performance	62.4%
IHS FY 2012 Performance	61.5%
IHS FY 2011 Performance	55.3%
IHS FY 2010 Performance	53.0%
IHS FY 2009 Performance	48.0%
IHS FY 2008 Performance	42.0%
IHS FY 2007 Performance	36.0%
IHS FY 2006 Performance	28.0%
IHS FY 2005 Performance	13.0%
IHS FY 2004 Performance	4.0%

```
November 25, 2017
                                                                  Page 128
      *** IHS 2017 Selected Measures with Community Specified Report ***
                           DEMO INDIAN HOSPITAL
                Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Intimate Partner (Domestic) Violence Screening (con't)
                   REPORT
                             % PREV YR
                                           % CHG from BASE % CHG from
                                             PREV YR % PERIOD
                   PERIOD
                              PERIOD
                                                                   BASE %
Female Active
```

Clinical Pts 14-46 (GPRA)	537		549			534			
# w/ IPV/DV Screening-No									
Refusals (GPRA) A. # w/ IPV/DV	100	18.6	339	61.7	-43.1	309	57.9	-39.2	
Exam w/ % of Total Screened B. # w/	97	97.0	336	99.1	-2.1	307	99.4	-2.4	
IPV/DV-Related Dx w/ % of Total	-	1 0		1 0			1.0	0.0	
Screened C. # w/ IPV/DV Education w/ % of	1	1.0	6	1.8	-0.8	4	1.3	-0.3	
Total Screened	2	2.0	1	0.3	+1.7	4	1.3	+0.7	
Female User Pop Pts 14-46	610		616			610			
# w/ IPV/DV Screening-No Refusals	102	16.7	348	56.5	-39.8	313	51.3	-34.6	

Figure 2-57: Sample Report, Intimate Partner (Domestic) Violence Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Intimate Partner (Domestic) Violence Screening: List of female patients 14-46 with documented IPV/DV screening, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR PATIENT NAME \_\_\_\_\_ PATIENT1, ELVIRA 000001 COMMUNITY #1 F 13 08/03/04 UP EXAM: 03/18/17 Ex 34 PATIENT2, SHARON KAY 000002 COMMUNITY #1 F 14 05/04/03 000003 COMMUNITY #1 F 15 06/06/02 PATIENT3, KRISTINA PATIENT4, RITA 000004 COMMUNITY #1 F 15 10/24/02 UP,AC EXAM: 05/06/17 Ex 34 PATIENT5, DIANE LOUISE 000005 COMMUNITY #1 F 15 11/18/02 EXAM: 02/24/17 Ex 34 UP EXAM: 02/24/17 Ex 34 PATIENT6, ALICE LILA 000006 COMMUNITY #1 F 15 12/27/02 UP,AC

Figure 2-58: Sample Patient List, Intimate Partner (Domestic) Violence Screening

## 2.7.4 Depression Screening

## **GPRAMA/GPRA Measure Description**

Age 12-17: During GPRA Year 2017, establish a baseline for the proportion of patients ages 12 through 17 who receive annual screening for depression.

Age 18 and older: During GPRA Year 2017, achieve the target rate of 70.0% for the proportion of patients ages 18 and older who receive annual screening for depression.

#### **Denominators**

Active Clinical patients ages 12 through 17. Broken down by gender. (GPRA Denominator)

Active Clinical patients ages 18 and older. Broken down by gender and age group: 65 and older. (GPRAMA Denominator)

User Population patients ages 12 through 17. Broken down by gender.

*User Population patients* ages 18 and older. Broken down by gender and age group: 65 and older.

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. Broken down by gender.

Active CHD patients, defined as Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. Broken down by gender.

#### **Numerators**

Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note**: This numerator does not include refusals. (GPRAMA Numerator)

- a. Patients screened for depression during the Report Period.
- b. Patients with a diagnosis of a mood disorder during the Report Period.
- c. Patients who were screened in a Behavioral Health clinic.

Patients with depression-related education during the Report Period.

**Note:** Depression-related patient education does not count toward the GPRAMA numerator and is included as a separate numerator only.

## **Logic Description**

Age is calculated at beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	ICD and Other Codes
Diabetes	POV: ICD-9: 250.00–250.93; ICD-10: E10.*-E13.*
Coronary Heart Disease	Any of the following:
	<b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9, Z95.5
	2) One or more CABG or PCI procedures
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209
	<b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61
	<b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**
Depression Screening	Exam: Exam Code 36
	<b>POV:</b> ICD-9: V79.0
	<b>CPT</b> : 1220F, 3725F, G0444
	BHS Problem Code: 14.1 (Screening for Depression)
	Measurement in PCC or BHS: PHQ2, PHQ9 or PHQT
Mood Disorders	At least 2 visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.
	<b>POV:</b> ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39 <b>BHS POV:</b> 14, 15

Subject Defined	ICD and Other Codes
Depression-related Patient Education (does not count	Documented education of any of the following during the Report Period:
toward GPRA numerator)	Patient education codes: Containing "DEP-" (depression), 296.2* or 296.3*, "BH-" (behavioral and social health), 290319, 995.5*, or 995.80–995.85, "SB-" (suicidal behavior) or 300.9, or "PDEP-" (postpartum depression) or 648.44, or SNOMED codes 14183003, 15193003, 15639000, 18818009, 191610000, 191611001, 191613003, 191616006, 191659001, 192080009, 19527009, 19694002, 20250007, 231504006, 231542000, 2506003, 25922000, 2618002, 268621008, 28475009, 3109008, 319768000, 320751009, 33078009, 35489007, 36170009, 36474008, 36923009, 370143000, 38451003, 38694004, 39809009, 40379007, 40568001, 42925002, 430852001, 442057004, 48589009, 63778009, 66344007, 67711008, 69392006, 71336009, 73867007, 75084000, 75837004, 76441001, 77486005, 77911002, 78667006, 79298009, 81319007, 83176005, 832007, 84760002, 85080004, 87512008.

## **Recommended Brief Screening Tool**

A sample of a Patient Health Questionnaire (PHQ-2 Scaled Version) appears below.

Over the past 2 weeks, how often have you been bothered by any of the following problems?

- 1. Little interest or pleasure in doing things
  - Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3
- 2. Feeling down, depressed, or hopeless
  - Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3

Total Possible PHQ-2 Score: Range: 0-6

0–2: Negative

3–6: Positive; further evaluation indicated

Provider should note the screening tool used was the PHQ-2 Scaled in the COMMENT section of the Exam Code.

## Key Logic Changes from CRS Version 16.1

- 1. Added measures for ages 12 through 17.
- 2. Created new GPRA measure for age 12 through 17.
- 3. Added PHQT to depression screening definition.

## **Patient List Description**

List of patients with documented depression screening/diagnosed with mood disorder, if any.

#### **Measure Source**

USPSTF (US Preventive Services Task Force), HP 2010 developmental indicator 18 through 6.

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance (age 18+)	67.9%
IHS FY 2015 Performance (age 18+)	67.4%
IHS FY 2014 Performance (age 18+)	66.0%
IHS FY 2013 Performance (age 18+)	65.1%
IHS FY 2012 Performance (age 18+)	61.9%
IHS FY 2011 Performance (age 18+)	56.5%
IHS FY 2010 Performance (age 18+)	52.0%
IHS FY 2009 Performance (age 18+)	44.0%
IHS FY 2008 Performance (age 18+)	35.0%
IHS FY 2007 Performance (age 18+)	24.0%
IHS FY 2006 Performance (age 18+)	15.0%

```
DU November 25, 2017 Page 130

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016
```

Bas	eline Pe	riod:	Jan 01,	Tan 01, 2010 to Dec 31, 2010					
Depression Screening	(con't)								
	REPORT PERIOD		PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts 12-17 (GPRA)	201		214			238			
# w/ Depression Screening or Mood Disorder-No Refusals (GPRA) A. # Screened for Depression w/ % of	8	4.0	47	22.0	-18.0	44	18.5	-14.5	
Total Screened B. # w/ Mood	8	100.0	44	93.6	+6.4	38	86.4	+13.6	
Disorder Dx w/ % of Total Screened C. # Screened in	0	0.0	6	12.8	-12.8	8	18.2	-18.2	
BH Clinic w/ % of Total Screened # w/ Depression	2	25.0	0	0.0	+25.0	2	4.5	+20.5	
Education	1	0.5	3	1.4	-0.9	3	1.3	-0.8	
Active Clinical Pts 18+ (GPRAMA)	1,336		1,382			1,367			
# w/ Depression Screening or Mood Disorder Dx-No Refusals (GPRAMA) A. # Screened for	257	19.2	849	61.4	-42.2	917	67.1	-47.8	
Depression w/ % of Total Screened B. # w/ Mood	232	90.3	818	96.3	-6.1	889	96.9	-6.7	
Disorder Dx w/ % of Total Screened C. # Screened in	27	10.5	60	7.1	+3.4	52	5.7	+4.8	
BH Clinic w/ % of Total Screened	4	1.6	6	0.7	+0.8	68	7.4	-5.9	
# w/ Depression Education	18	1.3	43	3.1	-1.8	26	1.9	-0.6	

Figure 2-59: Sample Report, Depression Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Depression Screening: List of patients with documented depression
screening/diagnosed with mood disorder, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT55, LORETTA LYNN 000055 COMMUNITY #1 F 78 09/05/39

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
PATIENT56, TINA MARIE 000056 COMMUNITY #1 F 78 10/11/39
UP, AC, AD, CHD
                             SCREEN: 05/22/17 Meas PHQ9
                      000057 COMMUNITY #1 F 79 05/06/38
PATIENT57, DANIELLE
                             PT ED: 02/06/17 296.20-DP
UP,AC
PATIENT58, LESLIE ANN 000058 COMMUNITY #1 F 80 08/30/37
UP,AC SCREEN: 04/16/17 POV V79.0
PATIENT59,DONNA SUE 000059 COMMUNITY #1 F 86 03/22/31
UP AC
UP,AC
                             SCREEN: 01/15/17 POV V79.0
PATIENT60, TAYLOR OLIVIA 000060 COMMUNITY #1 F 87 09/08/30
PATIENT61, DENNIS GERALD 000061 COMMUNITY #1 M 18 01/24/99
                             PT ED: 02/01/17 296.20-DP
PATIENT62, JOSHUA DALE 000062 COMMUNITY #1 M 18 06/22/99
UP,AC
```

Figure 2-60: Sample Patient List, Depression Screening

## 2.7.5 Antidepressant Medication Management

## **GPRA Measure Description**

Acute Treatment: During GPRA Year 2017, establish a baseline for the proportion of patients ages 18 and older with acute treatment for depression.

Continuous Treatment: During GPRA Year 2017, establish a baseline for the proportion of patients ages 18 and older with continuous treatment for depression.

#### **Denominators**

As of the 120th day of the Report Period, *Active Clinical Plus BH patients* ages 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

As of the 120th day of the Report Period, *User Population patients* ages 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year. (GPRA Denominator)

#### **Numerators**

Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks). (GPRA Numerator)

Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months). (GPRA Numerator)

## **Logic Description**

Age is calculated at the beginning of the Report Period. To be included in the denominator, patient must have filled a prescription for an antidepressant medication (see list of medications below) within the 121st day of the year prior to the Report Period to the 120th day of the Report Period. For example, if Report Period is July 1, 2016 - June 30, 2017, patient must have filled a prescription during 11/1/2015 - 10/29/2016. In V Medication, Date Discontinued must not be equal to the prescription (i.e. visit) date. The Index Prescription Start Date (IPSD) is the date of the earliest prescription for antidepressant medication filled during that time period.

#### **Denominator Exclusions**

Patients who did not have a diagnosis of major depression in an inpatient, outpatient, ED, intensive outpatient or partial hospitalization setting during the 60 days prior to the IPSD (inclusive) through 60 days after the IPSD (inclusive).

Major depression defined as POV ICD-9: 296.20-296.25, 296.30-296.35, 298.0, 311; ICD-10: F32.0-F32.4, F32.8-F33.3, F33.41, F33.9.

Patients who had a new or refill prescription for antidepressant medication (see list of medications below) within 105 days prior to the Index Prescription Start Date are excluded as they do not represent new treatment episodes.

## Effective Acute Phase Treatment Numerator

For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114-day time frame, the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

#### **Example of Patient Included in Numerator:**

- First RX is Index Rx Date: 11/1/2016, # Days Prescribed=30
- Rx covers patient through 12/1/2016
- Second RX: 12/15/2016, # Days Prescribed=30

- Gap #1 = (12/15/2016-12/1/2016) = 14 days
- Rx covers patient through 1/14/2017
- Third RX: 1/10/2017, # Days Prescribed=30
- No gap days
- Rx covers patient through 2/13/2017
- Index Rx Date 11/1/2016 + 114 days = 2/23/2017
- Patient's 84th treatment day occurs on 2/7/2017, which is less than or equal to (<=) 2/23/2017 and # gap days of 14 is less than 30

## **Example of Patient Not Included in Numerator:**

- First Rx is Index Rx Date: 11/1/2016, # Days Prescribed=30
- Rx covers patient through 12/1/2016
- Second Rx: 12/15/2016, # Days Prescribed=30
- Gap #1 = (12/15/2016-12/1/2016) = 14 days
- Rx covers patient through 1/14/2017
- Third Rx: 2/01/2017, # Days Prescribed=30
- Gap #2 = (2/01/2017 through 1/14/2017) = 18, total # gap days = 32, so patient is not included in the numerator

## Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see list of medications below) filled within 231 days of the Index Prescription Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Prescription Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231 day time frame, the patient is not included in the numerator.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

Antidepressant medications defined with medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS. (Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinepherine reuptake inhibitors (SNRI), and other antidepressants.) Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 16.1**

1. Made two measures new GPRA measures.

## **Patient List Description**

List of patients with new depression DX and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

#### **Measure Source**

HEDIS, HP 2010 18-9b

## Measure Past Performance and Long-Term Targets

Performance	Percent
N/A	N/A

DU November 25, 2017 Page 141  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Antidepressant Medic	cation Mar	nageme	nt (con't	)					
					CHG from PREV YR %				
AC+BH Pts 18+ w/ New Depression Dx and Antidepressant Meds	22		13			23			
# w/ 12-week Treatment Meds # w/ 180-Day	6	27.3	2	15.4	+11.9	7	30.4	-3.2	
Treatment Meds	4	18.2	1	7.7	+10.5	1	4.3	+13.8	
User Pop Pts 18+ w/ New Depression Dx and Antidepressant Meds (GPRA)	22		13			23			

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ 12-week									
Treatment Meds (GPRA)	6	27.3	2	15.4	+11.9	7	30.4	-3.2	
# w/ 180-day	ŭ	27.5	_			·	30.1	3.2	
Treatment Meds			_			_			
(GPRA)	4	18.2	1	7.7	+10.5	1	4.3	+13.8	

Figure 2-61: Sample Report, Antidepressant Medication Management

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Antidepressant Medication Management: List of patients with new depression Dx
and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.
                  HRN COMMUNITY SEX AGE DOB
PATIENT NAME
DENOMINATOR
                          NUMERATOR
PATIENT1, MICHELLE D 000001 COMMUNITY #1 F 22 02/22/95
UP,AC+BH IESD: 06/06/16; NOT APT: DAYS=60, GAP=1; NOT CONPT: DAYS=60, GAP=1
PATIENT2,PAULA KAY 000002 COMMUNITY #1 F 34 01/14/83
IESD: 10/29/16; NOT APT: DAYS=68, GAP=28; CONPT
                          IESD: 04/21/17; NOT APT: DAYS=74, GAP=0; NOT CONPT:
DAYS=74, GAP=0
PATIENT4, KATHLEEN 000004 COMMUNITY #1 F 38 08/03/79
            IESD: 11/15/16; APT; CONPT
UP,AC+BH
```

Figure 2-62: Sample Patient List, Antidepressant Medication Management

## 2.8 Cardiovascular Disease Related Measure Topics

## 2.8.1 Obesity Assessment

#### **Denominators**

Active Clinical patients ages 2 through 74. Broken down by gender and age groups (2 through 5, 6 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74).

User Population patients ages 2 through 74. Broken down by gender.

#### **Numerators**

Patients for whom a Body Mass Index (BMI) could be calculated.

**Note**: This numerator does *not* include refusals.

- 1. For those with a BMI calculated, those considered overweight but not obese using BMI and standard tables
- 2. For those with a BMI calculated, those considered obese using BMI and standard tables
- 3. Total of overweight and obese

Patients with documented refusal during the Report Period.

#### **Logic Description**

Age is calculated at beginning of the Report Period.

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2-18, definitions are based on standard tables. Refusals include REF, NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

#### **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients with current BMI, if any.

#### Measure Source

HP 2020: NWS-9 Obesity in Adults 20+, NWS-10.1 (Obesity in Children 2-5), NWS-10.2 Overweight or Obesity in Children 6-11, NWS-10.3 Overweight or Obesity in Adolescents 12-19, NWS-10.4 Overweight or Obesity in Children 2-19

#### **Measure Past Performance and Long-Term Targets**

Performance	Percent
Assessed as Obese–IHS FY 2012 Performance	47.1%
Assessed as Obese–IHS FY 2011 Performance	46.9%
Assessed as Obese–IHS FY 2010 Performance	47.0%
Assessed as Obese–IHS FY 2009 Performance	47.0%
Assessed as Obese–IHS FY 2008 Performance	46.0%
BMI Measured–IHS FY 2012 Performance	81.6%
BMI Measured–IHS FY 2011 Performance	78.0%
BMI Measured–IHS FY 2010 Performance	76.0%
BMI Measured-IHS FY 2009 Performance	75.0%
BMI Measured–IHS FY 2008 Performance	74.0%
BMI Measured- FY 2005 Performance	64.0%
BMI Measured–IHS FY 2004 Performance	60.0%
HP 2020 Goal: Obesity in Adults 20+ (NWS-9)	30.6%
HP 2020 Goal: Overweight or Obesity in Children 2–5 (NWS-10.1)	9.6%
HP 2020 Goal: Overweight or Obesity in Children 6–11 (NWS-10.2)	15.7%
HP 2020 Goal: Overweight or Obesity in Adolescents 12–19 (NWS-10.3)	16.1%
HP 2020 Goal: Overweight or Obesity in Children 2–19 (NWS-10.4)	14.6%

## **Performance Improvement Tips**

- 1. A Body Mass Index report can be run from your PCC Management Reports menu. This report can be run for all patients or for a specific template of patients that has been pre-defined with a QMan search. The BMI report will provide you with patient height, weight, date weight taken, BMI and NHANES percentile.
- 2. Recent guidelines indicate that height for adults must be taken at least once every 5 years, rather than once after age 18. Your BMI rates may be lower than anticipated because of height data that is over 5 years old.
- 3. If height and weight measurements are being recorded as cm/kg vs. in/lbs ensure providers are *noting* they are cm/kg *and* that data entry is entering the measurements correctly in PCC, as shown below.
  - Use mnemonics of CHT and KWT (vs. HT and WT), or
  - Add "c" after height value and "k" after weight value (e.g. 100c, 50k)

```
DU November 25, 2017 Page 143

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016
```

Ва	aseline Pe	riod:	Jan 01, 2010 to Dec 31, 2010						
Obesity Assessment	(con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts 2-74	1,976		2,056			2,053			
# w/ BMI Calculated-No Refusals	1,400	70.9	1,819	88.5	-17.6	1,840	89.6	-18.8	
A. # Overweight w/ % of Total BMI	299	21 4	407	22 4	-1.0	402	21 8	-0.5	
B. # Obese w/ % of									
Total BMI C. # Overweight/Obese	893	63.8	1,086	59.7	+4.1	1,102	59.9	+3.9	
<pre>w/ % of Total BMI # w/ BMI Refusal</pre>	1,192	85.1	1,493	82.1	+3.1	1,504	81.7	+3.4	
(No BMI)	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Male Active Clinical Pts 2-74	902		966			978			
# w/ BMI Calculated-No Refusals		68.8	842	87.2	-18.3	855	87.4	-18.6	
A. # Overweight w/ % of Total BMI		24.2	197	23.4	+0.8	209	24.4	-0.3	
B. # Obese w/ % of Total BMI C. #	376	60.5	481	57.1	+3.4	483	56.5	+4.1	
Overweight/Obese w/ % of Total BMI	526	84.7	678	80.5	+4.2	692	80.9	+3.8	
# w/ BMI Refusal (No BMI)	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Female Active Clinical Pts 2-74	1,074		1,090			1,075			
# w/ BMI Calculated-No									
Refusals A. # Overweight w/	779	72.5	977	89.6	-17.1	985	91.6	-19.1	
% of Total BMI	149	19.1	210	21.5	-2.4	193	19.6	-0.5	
B. # Obese w/ % of Total BMI C. #	517	66.4	605	61.9	+4.4	619	62.8	+3.5	
Overweight/Obese w/ % of Total BMI	666	85.5	815	83.4	+2.1	812	82.4	+3.1	
# w/ BMI Refusal (No BMI)	0	0.0	0	0.0	+0.0	0	0.0	+0.0	

Figure 2-63: Sample Report, Obesity Assessment

Obesity Assessment (con't)										
	TOTAL	ACTIVE			LATION bution					
	2-5	6-11			25-34		45-54	55-74		
CURRENT REPORT PERIOD										
Total # Active Clin	214	264	282	186	318	208	222	282		
# w/ BMI Calculated										
-No Refusals % w/ BMI Calculated	102	93	122	174	305	197	186	221		
-No Refusals	47.7	35.2	43.3	93.5	95.9	94.7	83.8	78.4		
A. # Overweight w/										
% of Total BMI	20	17	32	43	56	43	40	48		
A. % Overweight w/ % of Total BMI	19.6	18.3	26.2	24.7	18.4	21.8	21.5	21.7		
% OI TOCAT BMI	19.0	10.3	20.2	24.7	10.4	21.0	21.5	21.7		
B. # Obese w/	26	26	ΕO	100	226	140	120	1.40		
% of Total BMI B. % Obese w/	36	36	59	108	226	142	138	148		
% of Total BMI	35.3	38.7	48.4	62.1	74.1	72.1	74.2	67.0		
C. # Overweight or Obes	e w/									
% of Total BMI	56	53	91	151	282	185	178	196		
C. % Overweight or Obes % of Total BMI	e w/ 54.9	57.0	74.6	86.8	92.5	93.9	95.7	88.7		
% OI TOCAT BMI	34.5	57.0	74.0	80.8	92.5	93.9	95.1	00.7		
# w/ BMI Refusal (No BMI)	0	0	0	0	0	0	0	0		
% w/ BMI Refusal	U	U	U	U	U	U	U	U		
(No BMI)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
PREVIOUS YEAR PERIOD										
Total # Active Clin	222	273	305	207	325	211	246	267		
# w/ BMI Calculated -No Refusals	182	204	245	200	312	202	230	244		
% w/ BMI Calculated										
-No Refusals	82.0	74.7	80.3	96.6	96.0	95.7	93.5	91.4		
A. # Overweight w/										
% of Total BMI A. % Overweight w/	43	46	61	55	59	40	51	52		
% of Total BMI	23.6	22.5	24.9	27.5	18.9	19.8	22.2	21.3		
B. # Obese w/										
% of Total BMI	50	93	115	120	232	146	165	165		
B. % Obese w/	27 5	45.6	46.0	60.0	7.4.4	70.3	71 8	67.6		
% of Total BMI	27.5	45.6	46.9	60.0	74.4	72.3	71.7	67.6		
C. # Overweight or Obes		100	4	4	0.01		0.5.5	0.5 =		
% of Total BMI C. % Overweight or Obes		139	176	175	291	186	216	217		
% of Total BMI	51.1	68.1	71.8	87.5	93.3	92.1	93.9	88.9		
# w/ BMI Refusal										
(No BMI)	0	0	0	0	0	0	0	0		
% w/ BMI Refusal (No BMI)	0.0	0.0	0 0	0 0	0.0	0.0	0.0	0.0		
(IAO DIAIT)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Figure 2-64: Sample Report, Age Breakout, Obesity Assessment

Figure 2-65: Sample Patient List, Obesity Assessment

## 2.8.2 Childhood Weight Control

## **GPRA Measure Description**

During GPRA Year 2017, achieve the long-term target rate of 22.8% for the proportion of children with a BMI of 95% or higher.

#### **Denominators**

Active Clinical patients ages 2 through 5 for whom a BMI could be calculated. Broken down by gender and age groups (2, 3, 4, 5). (GPRA Denominator)

*User Population patients* ages 2 through 5 for whom a BMI could be calculated.

#### **Numerators**

Patients with BMI in the 85th to 94th percentile.

Patients with a BMI at or above the 95th percentile. (GPRA Numerator)

Patients with a BMI at or above the 85th percentile.

## **Logic Description**

BMI calculation definition: All patients for whom a BMI could be calculated and who are between the ages of 2 and 5 at the beginning of the Report Period and who do not turn age 6 during the Report Period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be 2 years of age at the beginning of the time period, but is 3 years old at the time of the most current BMI found. That patient will fall into the age 3 group. CRS looks for the most recent BMI in the Report Period. CRS calculates BMI at the time the report is run using NHANES II. A height and weight must be taken on the same day any time during the Report Period. The BMI values for this measure are reported differently than in Obesity Assessment since this age group is children ages 2 through 5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

Patients whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

#### **BMI Standard Reference Data**

Low-High Ages	Sex	BMI >= (OVERWT)	BMI >= (OBESE)	Data Check Limits BMI>	Data Check Limits BMI <
2-2	MALE	17.7	18.7	36.8	7.2
2-2	FEMALE	17.5	18.6	37.0	7.1
3-3	MALE	17.1	18.0	35.6	7.1
3-3	FEMALE	17.0	18.1	35.4	6.8
4-4	MALE	16.8	17.8	36.2	7.0
4-4	FEMALE	16.7	18.1	36.0	6.9
5-5	MALE	16.9	18.1	36.0	6.9
5-5	FEMALE	16.9	18.5	39.2	6.8

#### **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients ages 2 through 5, with current BMI.

## **Measure Source**

CDC, National Center for Health Statistics, HP 2020 NWS-10.1

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance	22.3%
IHS FY 2015 Performance	21.8%
IHS FY 2014 Performance	22.8%
IHS FY 2013 Performance	22.8%
IHS FY 2012 Performance	24.0%
IHS FY 2011 Performance	24.1%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	24.0%
IHS FY 2007 Performance	24.0%
IHS FY 2006 Performance	24.0%
HP 2020 Goal	9.6%

DU *** THE 201	7 Soloatod		mber 25,		nity Chodi	fied Ben		ge 156	
*** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2017 to Dec 31, 2017									
Prev	rious Year E	Period	: Jan 01	, 201	to Dec 3	1, 2016			
В	aseline Per	riod:	Jan 01,	2010 1	to Dec 31,	2010			
Childhood Weight C	ontrol (cor	ı't)							
	REPORT	%	PREV YR	%	CHG from	BASE	용 (	CHG from	
					PREV YR %			BASE %	
Active Clinical Pts 2-5 w/ BMI									
(GPRA)	78		143			153			
# w/ BMI 85-94% # w/ BMI >=95%	23	29.5	32	22.4	+7.1	43	28.1	+1.4	
(GPRA)	27	34.6	43	30.1	+4.5	42	27.5	+7.2	
# w/ BMI >=85%	50	64.1	75	52.4	+11.7	85	55.6	+8.5	
Active Clinical									
Pts Age 2	25		3			15			
# w/ BMI 85-94%	8	32.0	0	0.0	+32.0	2	13.3	+18.7	

# w/ BMI >=95% # w/ BMI >=85%	7 15	28.0 60.0		100.0	-72.0 -40.0	2 4	13.3 26.7	+14.7 +33.3	
Active Clinical									
Pts Age 3	24		46			55			
# w/ BMI 85-94%	8	33.3	10	21.7	+11.6	17	30.9	+2.4	
# w/ BMI >=95%	8	33.3	14	30.4	+2.9	17	30.9	+2.4	
# w/ BMI >=85%	16	66.7	24	52.2	+14.5	34	61.8	+4.8	
Active Clinical									
Pts Age 4	25		53			53			
# w/ BMI 85-94%	6	24.0	15	28.3	-4.3	18	34.0	-10.0	
# w/ BMI >=95%	10	40.0	16	30.2	+9.8	14	26.4	+13.6	
# w/ BMI >=85%	16	64.0	31	58.5	+5.5	32	60.4	+3.6	
Active Clinical									
Pts Age 5	4		41			30			
# w/ BMI 85-94%	1	25.0	7	17.1	+7.9	6	20.0	+5.0	
# w/ BMI >=95%	2	50.0	10	24.4	+25.6	9	30.0	+20.0	
# w/ BMI >=85%	3	75.0	17	41.5	+33.5	15	50.0	+25.0	

Figure 2-66: Sample Report, Childhood Weight Control

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Childhood Weight Control: List of patients ages 2-5, with current BMI. SEX AGE DOB PATIENT NAME HRN COMMUNITY DENOMINATOR NUMERATOR PATIENT1, MELISSA ANN 000001 COMMUNITY #1 F 4 11/12/13 AC Age at BMI: 1, 00,25,25,25,27

PATIENT2,RANDY 000002 COMMUNITY #1 M 2 03/02/15

Age at BMI: 2; 05/06/17 17.96 [O Age at BMI: 4; 08/20/17 16.03 Age at BMI: 2; 05/06/17 17.96 [OVERWEIGHT] AC Age at BMI: 2; 05/06/17 17.96 [OV PATIENT3, PAUL BARRY 000003 COMMUNITY #1 M 2 04/13/15 AC Age at BMI: 2; 08/05/17 19.87 [OV PATIENT4, TYLER 000004 COMMUNITY #1 M 4 04/27/13 AC Age at BMI: 4; 02/19/17 15.67 PATIENT5, SAMUEL III 000005 COMMUNITY #1 M 5 05/22/12 Age at BMI: 2; 08/05/17 19.87 [OBESE] Age at BMI: 5; 11/24/17 19.07 [OBESE] PATIENT21, JOSEPHINE 000021 COMMUNITY #2 F 4 10/10/13 Age at BMI: 4; 05/30/17 15.71

Figure 2-67: Sample Patient List, Childhood Weight Control

# 2.8.3 Weight Assessment and Counseling for Nutrition and Physical Activity

#### **Denominators**

Active Clinical patients ages 3 and older. Broken down by gender and age groups (3 through 11, 12 through 17, 18 and older).

#### **Numerators**

Patients with comprehensive assessment, defined as having BMI documented, counseling for nutrition, and counseling for physical activity during the Report Period.

Patients with BMI documented during the Report Period.

Patients with counseling for nutrition during the Report Period.

Patients with counseling for physical activity during the Report Period.

## **Logic Description**

Age is calculated at the end of the Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes
BMI Documented		BMI: CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.  POV: ICD-9: V85*; ICD-10: Z68.20-Z68.54
Counseling for Nutrition	97802-97804, G0270, G0271, G0447, S9449, S9452, S9470	POV: ICD-9: V65.3; ICD-10: Z71.3  Patient education codes: ending "-N" (nutrition), "-MNT" (medical nutrition therapy), (or old code "-DT" (diet)) or containing V65.3, 97802-97804, G0270, G0271, G0447, S9449, S9452, or S9470.

Subject Defined	CPT Codes	ICD and Other Codes
Counseling for Physical Activity	′	POV: ICD-9: V65.41 Patient education codes: ending "-EX" (exercise) or containing V65.41, G0447, or S9451.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients ages 3 and older with assessments, if any.

#### **Measure Source**

**HEDIS** 

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 143  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Weight Assessment a	Weight Assessment and Counseling for Nutrition and Physical Activity (Con't)								
	REPORT PERIOD	%	PREV YR PERIOD		CHG from PREV YR %				
Active Clinical Pts 3+	2,012		2,087			2,087			
<pre># w/ Comprehensive   Assessment # w/ BMI</pre>	49	2.4	130	6.2	-3.8	166	8.0	-5.5	
Documented # w/ Nutrition	1,428	71.0	1,844	88.4	-17.4	1,867	89.5	-18.5	
Counseling # w/ Physical Activity	118	5.9	265	12.7	-6.8	245	11.7	-5.9	
Counseling	116	5.8	252	12.1	-6.3	232	11.1	-5.4	
Male Active Clinical Pts 3+	Male Active								
# w/ Comprehensive Assessment	16	1.8	44	4.5	-2.8	38	3.9	-2.1	

# w/ BMI									
Documented	630	69.2	848	87.2	-18.1	864	87.5	-18.4	
# w/ Nutrition									
Counseling	42	4.6	96	9.9	-5.3	66	6.7	-2.1	
# w/ Physical									
Activity	36	4.0	95	9.8	-5.8	67	6.8	-2.8	
Counseling	30	4.0	95	9.0	-5.0	0 /	0.0	-2.0	
Female Active									
Clinical Pts 3+	1,101		1,115			1,100			
	,		·			·			
# w/ Comprehensive									
Assessment	33	3.0	86	7.7	-4.7	128	11.6	-8.6	
# w/ BMI									
Documented	798	72.5	996	89.3	-16.8	1,003	91.2	-18.7	
# w/ Nutrition			1.50	15.0	0 0	1.70		0.4	
Counseling	76	6.9	169	15.2	-8.3	179	16.3	-9.4	
# w/ Physical									
Activity Counseling	80	7.3	157	14.1	-6.8	165	15.0	-7.7	
Counsering	80	7.3	15/	14.1	-6.8	105	15.0	- / . /	

Figure 2-68: Sample Report, Weight Assessment and Counseling for Nutrition and Physical Activity

Weight Assessment and Counseli	ng for Nu	utrition and	Physical A	ctivity (con't)					
Active Clinical Pts 3+ 3 - 11 12 - 17 18+									
CURRENT REPORT PERIOD									
Active Clinical Pts 3+	437	212	1,363						
# w/ Comprehensive Assessment	2	1	46						
% w/ Comprehensive Assessment	0.5	0.5	3.4						
# w/ BMI Documented	187	42	1,199						
% w/ BMI Documented	42.8	19.8	88.0						
% w/ Nutrition Counseling	8	6	104						
% w/ Nutrition Counseling	1.8	2.8	7.6						
# w/ Physical Activity									
Counseling	18	8	90						
% w/ Physical Activity Counseling	4.1	3.8	6.6						
		3.0	0.0						
PREVIOUS REPORT PERIOD Active Clinical Pts 3+	456	212	1,419						
Active Cillical Pts 3+	430	212	1,419						
# w/ Comprehensive Assessment	7	20	103						
% w/ Comprehensive Assessment	1.5	9.4	7.3						
# w/ BMI Documented	357	161	1,326						
% w/ BMI Documented	78.3	75.9	93.4						
% w/ Nutrition Counseling	40	22	203						
% w/ Nutrition Counseling	8.8	10.4	14.3						
# w/ Physical Activity									
Counseling	33	39	180						

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

% w/ Physical Activity Counseling	7.2	18.4	12.7	
CHANGE FROM PREVIOUS YR %				
# w/ Comprehensive Assessment	-1.1	-9.0	-3.9	
# w/ BMI Documented	+41.3	+10.4	+80.7	
<pre># w/ Nutrition Counseling # w/ Physical Activity</pre>	+0.3	-6.6	+0.4	
Counseling	+2.6	-5.7	-0.7	

Figure 2-69: Sample Report, Age Breakout, Weight Assessment and Counseling for Nutrition and Physical Activity

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Weight Assessment and Counseling for Nutrition and Physical Activity: List of patients ages 3+ with assessments, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR PATIENT NAME PATIENT1, PAMELA 000001 COMMUNITY #1 F 4 10/15/13 AC PATIENT2,GLENDA 000002 COMMUNITY #1 F 4 12/02/13 BMI: 16.03 AC BMI: 16.03 PATIENT3, SHIRLEY 000003 COMMUNITY #1 F 5 02/03/12 PATIENT4, MARY ANNE 000004 COMMUNITY #1 F 5 02/18/12 COMP ASSESS; BMI: V85.53; NUTR: 03/03/17 CPT 97804; PHY: 03/03/17 DX V65.41 PATIENT5, JACKIE 000005 COMMUNITY #1 F 9 03/16/08 PHY: 08/08/17 OBS-EX PATIENT6, ZINNIA 000006 COMMUNITY #1 F 15 07/21/02 PATIENT7, MARY RYAN 000007 COMMUNITY #1 F 15 09/22/02 BMI: 35.04; PHY: 03/03/17 DX V65.41

Figure 2-70: Sample Patient List, Weight Assessment and Counseling for Nutrition and Physical Activity

## 2.8.4 Nutrition and Exercise Education for At Risk Patients

#### **Denominators**

Active Clinical patients ages 6 and older considered overweight (including obese). Broken down by gender.

a. Active Clinical patients ages 6 and older *considered obese*. Broken down by gender and age groups (6 through 11, 12 through 19, 20 through 39, 40 through 59, 60 years and older).

Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes at least 1 year prior to the end of the Report Period, and at least two visits in the past year, and two diabetes-related visits ever.

#### **Numerators**

Patients provided with medical nutrition therapy during the Report Period.

Patients provided specific nutrition education during the Report Period.

Patients provided specific exercise education during the Report Period.

Patients provided with other related exercise and nutrition (lifestyle) education.

#### **Logic Description**

Age of the patient is calculated at beginning of Report Period.

*Diabetes:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Overweight*: Ages 19 and older, BMI greater than or equal to (>=) 25. Overweight is defined as including both obese and overweight categories calculated by BMI.

Obese: Ages 19 and older, BMI greater than or equal to (>=) 30. For ages 18 and under, the definition is based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years; not required to be recorded on same day.

CRS uses any of the following codes to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes
Medical nutrition therapy		Primary or secondary provider codes: 07, 29 Clinic codes: 67 (dietary) or 36 (WIC)

Subject Defined	CPT Codes	ICD and Other Codes
Nutrition education		POV: ICD-9: V65.3 dietary surveillance and counseling; ICD-10: Z71.3  Patient education codes: ending "-N" (nutrition), "-MNT" (medical nutrition therapy), (or old code "-DT" (diet)) or containing V65.3, 97802-97804, G0270, or G0271.
Exercise education		POV: ICD-9: V65.41 exercise counseling Patient education codes: ending "-EX" (exercise) or containing V65.41.
Related exercise and nutrition education	S9449, S9451, S9452, S9470	Patient education codes: ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00 or 278.01, S9449, S9451, S9452, S9470, or SNOMED codes 111036000, 162863004, 162863004, 162864005, 162864005, 170798000, 190965006, 190966007, 238131007, 238132000, 238133005, 238134004, 238136002, 248311001, 248312008, 270486005, 275947003, 276792008, 290439001, 292464007, 293481008, 294493008, 295509007, 296526005, 297500005, 298464002, 360566006, 363247006, 408512008, 413487000, 414438005, 414916001, 414917005, 414918000, 414919008, 414920002, 415530009, 444862003, 444862003, 44772007, 450451007, 48499001, 5036006, 53146006, 62999006, 703316004, 705131003, 80660001, 82793005.

# **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

A list of at risk patients with education, if any.

#### **Measure Source**

HP 2010 19-17

# **Measure Past Performance and Long-Term Targets for Diabetic Education**

Performance	Percent
HP 1997 data	42.0%

DU *** IHS 2017		Measu DEMC	INDIAN H	Commu OSPIT	AL	-		age 160 **	
Previo Bas	ous Year I seline Per	eriod:	l: Jan 01 Jan 01,	, 2010 2010	Dec 31, 20 6 to Dec 31, to Dec 31,	1, 2016 2010			
Nutrition and Exerc					ient				
					CHG from PREV YR %				
Overweight Active Clinical Pts 6+	1,136		1,400			1,395			
<pre># w/ Medical   Nutrition Therapy # w/ Specific</pre>	5	0.4	14	1.0	-0.6	29	2.1	-1.6	
Nutrition Educ # w/ Exercise Educ	78 77	6.9 6.8	184 186	13.1 13.3	-6.3 -6.5	213 184	15.3 13.2		
# w/ Other Exercise or Nutrition Educ	64	5.6	153	10.9	-5.3	133	9.5	-3.9	
Male Overweight Active Clinical									
Pts 6+	499		631			630			
# w/ Medical Nutrition Therapy # w/ Specific	3	0.6	8	1.3	-0.7	10	1.6	-1.0	
Nutrition Educ # w/ Exercise Educ # w/ Other	22 24	4.4	65 68	10.3	-5.9 -6.0	54 45	8.6 7.1	-4.2 -2.3	
Exercise or Nutrition Educ	21	4.2	59	9.4	-5.1	36	5.7	-1.5	
Female Overweight Active Clinical	627		760			765			
Pts 6+	637		769			765			
<pre># w/ Medical   Nutrition Therapy # w/ Specific</pre>	2	0.3	6	0.8	-0.5	19	2.5	-2.2	
Nutrition Educ # w/ Exercise Educ # w/ Other Exercise or	56 53	8.8	119 118	15.5 15.3	-6.7 -7.0	159 139	20.8	-12.0 -9.8	
	43	6.8	94	12.2	-5.5	97	12.7	-5.9	

Figure 2-71: Sample Report, Nutrition and Exercise Education for At Risk Patients

Nutrition and Exercise Educat	ion for A	At Risk Pa	atient (co	on't)		
TOTAL OF	BESE ACTIV	VE CLINICA Age Dis	AL POPULAT			
	6-11	_	20-39	40-59	60+	
CURRENT REPORT PERIOD						
# w/ Medical Nutrition	36	59	416	256	90	
Therapy	0	0	1	2	1	
% w/ Medical Nutrition Therapy	0.0	0.0	0.2	0.8	1.1	
	0.0	0.0	0.2	0.0		
# w/ Specific Nutrition Educ Provided	2	3	17	28	15	
% w/ Specific Nutrition Educ	F 6	F 1	4 1	10.0	16.7	
Provided	5.6	5.1	4.1	10.9	16.7	
# w/ Exercise Educ % w/ Exercise Educ	6 16.7	3 5.1	18 4.3	26 10.2	11 12.2	
	10./	2.1	1.3	10.2	12.2	
# w/ Other Exercise or Nutrition Educ	1	3	13	23	11	
% w/ Other Exercise or						
Nutrition Educ	2.8	5.1	3.1	9.0	12.2	
PREVIOUS YEAR PERIOD	0.3	115	420	205	0.2	
# w/ Medical Nutrition	93	115	430	305	93	
Therapy % w/ Medical Nutrition	1	1	5	2	2	
Therapy	1.1	0.9	1.2	0.7	2.2	
# w/ Specific Nutrition Educ						
Provided	2	12	40	53	35	
<pre>% w/ Specific Nutrition Educ Provided</pre>	2.2	10.4	9.3	17.4	37.6	
# w/ Exercise Educ % w/ Exercise Educ	4 4.3	16 13.9	$\begin{array}{c} 49 \\ 11.4 \end{array}$	59 19.3	17 18.3	
# w/ Other Exercise or						
Nutrition Educ	2	11	34	56	20	
% w/ Other Exercise or Nutrition Educ	2.2	9.6	7.9	18.4	21.5	
CHANGE FROM PREV YR % # w/ Medical Nutrition						
Therapy	-1.1	-0.9	-0.9	+0.1	-1.0	
<pre># w/ Specific Nutrition Ed # w/ Exercise Educ</pre>	+3.4 +12.4	-5.4 -8.8	-5.2 -7.1	-6.4 -9.2	-21.0 -6.1	
# w/ Other Exercise or	.0.6	4 5	4 0		0 2	
Nutrition Educ	+0.6	-4.5	-4.8	-9.4	-9.3	

Figure 2-72: Sample Age Breakout Report, Nutrition and Exercise Education for At Risk Patients

Figure 2-73: Sample Patient List, Nutrition, and Exercise Education for At Risk Patients

## 2.8.5 Physical Activity Assessment

#### **Denominators**

Active Clinical patients ages 5 and older. Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older).

Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older).

User Population patients ages 5 and older. Broken down by gender.

Numerator 1 (User Population Patients assessed for physical activity during the Report Period). Broken down by gender.

#### **Numerators**

Patients assessed for physical activity during the Report Period.

Patients from Numerator 1 who have received exercise education following their physical activity assessment.

Patients from Numerator 1 who have set at least one exercise goal following their physical activity assessment.

## **Logic Description**

Age of the patient is calculated at beginning of Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	ICD and Other Codes
Physical Activity Assessment	<b>Health Factors</b> : Any health factor for category Activity Level documented during the Report Period.
Exercise education	POV: V65.41 exercise counseling
	Patient education codes: ending "-EX" (exercise) or containing V65.41.
Exercise goal	Patient Goal: Goal Type of "Physical Activity" and Goal Status of "Goal Set"

# **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients with physical activity assessment and any exercise education or goals.

DU November 25, 2017 Page 171  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Physical Activity As	ssessment								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts 5+	1,861		1,921			1,914			
<pre># w/ Physical Activity Assessment # w/ Exercise Educ</pre>	4	0.2	14	0.7	-0.5	2	0.1	+0.1	
w/ % of Total Assessed	2	50.0	3	21.4	+28.6	0	0.0	+50.0	
# w/ Exercise Goal w/ % of Total Assessed	1	25.0	0	0.0	+25.0	0	0.0	+25.0	
Male Active									

Clinical Pts 5+	835		893			896			
#/ Ph									
# w/ Physical									
Activity Assessment	2	0.2	7	0.8	-0.5	1	0.1	+0.1	
# w/ Exercise Educ	4	0.2	,	0.0	-0.5	1	0.1	+0.1	
w/ % of Total									
Assessed	1	50.0	1	14.3	+35.7	0	0.0	+50.0	
# w/ Exercise Goal	_	50.0	_	11.5	133.7	O	0.0	130.0	
w/ % of Total									
Assessed	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
1.55 655 64	ŭ	0.0	ŭ	0.0		· ·	0.0		
Female Active									
Clinical Pts 5+	1,026		1,028			1,018			
# w/ Physical									
Activity									
Assessment	2	0.2	7	0.7	-0.5	1	0.1	+0.1	
# w/ Exercise Educ									
w/ % of Total									
Assessed	1	50.0	2	28.6	+21.4	0	0.0	+50.0	
# w/ Exercise Goal									
w/ % of Total	_		_						
Assessed	1	50.0	0	0.0	+50.0	0	0.0	+50.0	

Figure 2-74: Sample Report, Physical Activity Assessment

Physical Activity Asses	Physical Activity Assessment (con't)									
	TOTAL	ACTIVE	-		-					
	5-11	12-19		Distri 25-34		45-54	55-74	75+ yrs		
CURRENT REPORT PERIOD Total # AC Pts 5+ # w/ Physical Activity	327	282	186	318	208	222	282	36		
Assessment	2	0	0	0	0	0	1	1		
% w/ Physical Activity Assessment	0.6	0.0	0.0	0.0	0.0	0.0	0.4	2.8		
<pre># w/ Exercise Educ w/</pre>	1	0	0	0	0	0	0	1		
% of Total Assessed	50.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0		
<pre># w/ Exercise Goal w/</pre>	1	-	0	0	0.0	0.0	0.0	0		
	30.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
PREVIOUS YEAR PERIOD Total # AC Pts 5+ # w/ Physical Activity	329	305	207	325	211	246	267	31		
Assessment	0	2	1	3	2	1	5	0		
% w/ Physical Activity Assessment	0.0	0.7	0.5	0.9	0.9	0.4	1.9	0.0		
# w/ Exercise Educ w/										

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

% of Total Assessed % w/ Exercise Educ w/	0	0	0	0	1	0	2	0	
% w/ Exercise Educ w/ % of Total Assessed	0.0	0.0	0.0	0.0	50.0	0.0	40.0	0.0	
# w/ Exercise Goal w/									
% of Total Assessed	0	0	0	0	0	0	0	0	
% w/ Exercise Goal w/									
% of Total Assessed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
CHANGE FROM PREV YR %									
# w/ Physical Activity									
Assessment	+0.6	-0.7	-0.5	-0.9	-0.9	-0.4	-1.5	+2.8	
# w/ Exercise Educ w/									
% of Total Assessed	+50.0	+0.0	+0.0	+0.0	-50.0	+0.0	-40.0	+100.0	
# w/ Exercise Goal w/									
% of Total Assessed	+50.0	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0	+0.0	

Figure 2-75: Sample Age Breakout Report, Physical Activity Assessment

```
UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Physical Activity Assessment: List of patients with physical activity
assessment and any exercise education.
PATIENT NAME
               HRN COMMUNITY SEX AGE DOB
NUMERATOR
DENOMINATOR
______
PATIENT1, MISTY DAWN 000001 COMMUNITY #1 F 5 03/13/12
UP,AC
                       PHYS ACT: 08/08/17 VERY ACTIVE; EXER ED: 08/08/17 OBS-
EX
PATIENT2, RITA ANN 000002 COMMUNITY #1 F 15 06/12/02
UP,AC
                           PHYS ACT: 03/06/17 SOME ACTIVITY; EXER ED: 03/06/17
TO-EX
PATIENT3, RHONDA SUE 000003 COMMUNITY #1 F 22 06/07/95 UP, AC PHYS ACT: 04/02/17 ACTIVE; EXER 1
                            PHYS ACT: 04/02/17 ACTIVE; EXER ED: 04/02/17 V65.41
PATIENT4, MARY

000004 COMMUNITY #1 F 28 01/16/89

UP, AC

PHYS ACT: 11/12/17 SOME ACTIVITY
                            PHYS ACT: 11/12/17 SOME ACTIVITY;
PATIENT5, JOSEPH HENRY 000005 COMMUNITY #1 M 12 10/10/05
UP,AC PHYS ACT: 08/02/17 SOME ACTIVITY PATIENT6,BOB 000006 COMMUNITY #1 M 17 11/19/00
                            PHYS ACT: 08/02/17 SOME ACTIVITY;
                           PHYS ACT: 05/05/17 INACTIVE; EXER ED: 05/05/17 OBS-EX
UP,AC
```

Figure 2-76: Sample Patient List, Physical Activity Assessment

# 2.8.6 Comprehensive Health Screening

#### **Denominators**

Active Clinical patients ages 2 and older.

Active Clinical patients ages 12 through 75.

Active Clinical patients ages 18 and older.

Female Active Clinical patients ages 14 through 46.

Active Clinical patients ages 5 and older.

Active Clinical patients ages 2 through 74.

Active Clinical patients ages 20 and older.

Active Clinical patients ages 5 and older.

#### **Numerators**

ALL Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and Intimate Partner Violence/Domestic Violence (IPV/DV) screening, BMI calculated, and tobacco use, blood pressure, and physical activity assessed.

**Note**: This does *not* include refusals.

Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and blood pressure assessed.

**Note**: This does *not* include physical activity assessment and does *not* include refusals.

Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

**Note**: This numerator does *not* include refusals or alcohol-related patient education.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note**: This numerator does *not* include refusals.

IPV/DV Screening: Patients screened for IPV/DV at any time during the Report Period.

**Note**: This numerator does *not* include refusals.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report Period.

BMI Available: Patients for whom a BMI could be calculated.

**Note**: This numerator does *not* include refusals.

BP Assessed: Patients with blood pressure value documented at least twice in prior two years.

Physical Activity Assessed: Patients assessed for physical activity during the Report Period.

## **Logic Description**

Age of the patient is calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes					
Alcohol Screening	Exam Code: 35					
	<b>CPT code:</b> 99408, 99409, G0396, G0397, H0049, H0050, 3016F					
	Any CAGE Health Factor					
	<b>POV:</b> ICD-9: V11.3 (history of alcoholism), V79.1 (screening for alcoholism)					
	BHS Problem Code: 29.1 (Screening for Alcoholism)					
	Measurement in PCC or BHS: AUDT, AUDC, or CRFT					
Alcohol-related Diagnosis	POV, Current PCC or BHS Problem List: ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.99, G62.1; SNOMED data set PXRM BGP ETOH RELATED DX (Problem List only)  BHS POV: 10, 27, 29					
Alcohol-related Procedure	<b>Procedure:</b> ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69					

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

Depression screening definition: CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes				
Depression Screening	Exam: Exam Code 36				
	<b>POV:</b> ICD-9: V79.0				
	<b>CPT:</b> 1220F, 3725F, G0444				
	BHS Problem Code: 14.1 (Screening for Depression)				
	Measurement in PCC or BHS: PHQ2 or PHQ9				
Mood Disorders	At least two visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.  POV: ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39  BHS POV: 14, 15				

IPV/DV screening definition: CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
IPV/DV Screening	Exam: Code 34
	BHS Exam: IPV/DV
IPV/DV Diagnosis	POV or current PCC or BHS Problem List: ICD-9: 995.80-995.83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410; SNOMED data set PXRM BGP IPV DV DX (Problem List only)  BHS POV: 43.*, 44.*
IPV/DV Education	Patient education codes: Containing "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, V15.49, or SNOMED 3027571011, 3027627017, 371772001, 406138006, 412732008, 429746005, 431027007, 432527004
IPV/DV Counseling	<b>POV:</b> ICD-9: V61.11; ICD-10: Z69.11

Tobacco screening definition: CRS uses the following codes to define the numerator.

Subject Defined	CPT Codes	ICD and Other Codes
Screened for Tobacco Use	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z72.0, Z87.891; SNOMED data set PXRM BGP TOBACCO SCREENED (Problem List only) Patient Education codes: Containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00- 649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005 Dental code: 1320 Health Factor categories: Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE)

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

Blood pressure definition: Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 Blood Pressures documented in the past 2 years. If 3 BPs are not available, use the mean of last 2 BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

*Physical Activity Assessment definition:* CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
	<b>Health Factors</b> : Any health factor for category Activity Level documented during the Report Period.

### **Key Logic Changes from CRS Version 16.1**

- 1. Added SNOMED data set PXRM TOBACCO EVER SMOKED to tobaccorelated diagnosis definition (for Problem List only).
- 2. Added SNOMED data set PXRM BGP ETOH RELATED DX to alcohol-related diagnosis definition (for Problem List only).
- 3. Added SNOMED data set PXRM BGP IPV DV DX to IPV/DV diagnosis definition (for Problem List only).

## **Patient List Description**

List of patients with assessments received, if any.

```
DU November 25, 2017 Page 181

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Comprehensive Health	Screeni	ng						
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		%	CHG from BASE %
Active Clinical Pts 2+	2,012		2,087			2,087		
<pre># w/ Comp Health   Screening-No   Refusals # w/ Comp Health   Screening-No   Refusals or Phys</pre>	79	3.9	154	7.4	-3.5	154	7.4	-3.5
Activity	289	14.4	1,163	55.7	-41.4	1,212	58.1	-43.7
Active Clinical Pts 12-75	1,503		1,567			1,576		
# w/ Alcohol Screening/Dx/Proc-No Refusals or Pt Ed	334	22.2	1,013	64.6	-42.4	1,076	68.3	-46.1
Active Clinical Pts 18+	1,333		1,378			1,367		
# w/ Depression Screening or Mood Disorder Dx-No Refusals	257	19.3	848	61.5	-42.3	917	67.1	-47.8
Female Active Clinical Pts 14-46	537		549			534		
# w/ IPV/DV Screening-No Refusals	100	18.6	339	61.7	-43.1	309	57.9	-39.2
Active Clinical Pts 5+	1,861		1,921			1,914		
# w/ Tobacco Screening	358	19.2	1,182	61.5	-42.3	1,288	67.3	-48.1
Active Clinical Pts 2-74	1,976		2,056			2,053		
# w/ BMI Calculated-No Refusals	1,400	70.9	1,819	88.5	-17.6	1,840	89.6	-18.8
Active Clinical Pts 20+	1,252		1,287			1,265		
# w/ BPs Documented w/in 2 yrs	1,084	86.6	1,155	89.7	-3.2	1,141	90.2	-3.6

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Active Clinical Pts 5+	1,861		1,921		-	1,914			
# w/ Physical Activity Assessment	4	0.2	14	0.7	-0.5	2	0.1	+0.1	

Figure 2-77: Sample Report, Comprehensive Health Screening

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Comprehensive Health Screening: List of patients with assessments
received, if any.
PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR
PATIENT1, SANDRA KAY 000001 COMMUNITY #1 F 15 08/18/02
                          ALL COMP HEALTH: ALC: 03/06/17 POV V11.3; IPV:
03/06/17 Ex 34; TOB: 09/05/17 NEVER SMOKED; BMI: 17.49; PHYS ACT: 03/06/17 SOME
ACTIVITY
PATIENT2, CAITLYN
                     000002 COMMUNITY #1 F 16 03/19/01
AC PATIENT3, BRITNEY 000003 COMMUNITY #1 F 16 07/24/01
                             TOB: 10/26/17 CESSATION-SMOKER
PATIENT4, LORETTA 000004 COMMUNITY #1 F 17 05/12/00
AC ALC: 10/14/17 HF CAGE 1/4
PATIENT5, HALEY 000005 COMMUNITY #1 F 18 07/22/99
BMI: 19.79; BP: 125/67
PATIENT6, BRITTANY 000006 COMMUNITY #1 F 19 12/16/98
                        BMI: 19.79; BP: 125/67
                            ALC: 10/30/17 CPT G0397; TOB: 08/11/17 CURRENT SMOKER,
STATUS UNKNOWN; BMI: 21.01
```

Figure 2-78: Sample Patient List, Comprehensive Health Screening

# 2.8.7 Cardiovascular Disease and Blood Pressure Control Denominators

Active Clinical patients ages 18 and older. Broken down by gender.

User Population patients ages 18 and older. Broken down by gender.

Active CHD patients, defined as Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. Broken down by gender.

#### **Numerators**

Patients with blood pressure value documented during the Report Period.

#### **Logic Description**

Age of the patient is calculated at beginning of the Report Period.

CRS uses the following codes to define the CHD denominator.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	Any of the following:  1) POV: ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9, Z95.5  2) One or more CABG or PCI procedures
CABG	POV: ICD-9: V45.81; ICD-10: Z95.1  CPT: 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209  Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61  CPT: 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607  Procedure: ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

Blood pressure definition: CRS uses mean of last 3 Blood Pressures documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs, or one BP if there is only one documented. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 18 and older or who have CHD with blood pressure value, if any.

## **Measure Source**

HP 2020 HDS-5

## **Measure Past Performance and Long-Term Targets**

Measure	Percent
HP 2020 goal for adults with high blood pressure (140/90)	26.9%

DU November 25, 2017 Page 196  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Cardiovascular Disease and Blood Pressure Control								
					CHG from PREV YR %			
Active Clinical Pts 18+	1,333		1,378			1,367		
# w/ BPs Documented	858	64.4	1,163	84.4	-20.0	1,162	85.0	-20.6
Male Active Clinical Pts 18+	588		634			633		
# w/ BPs Documented	335	57.0	508	80.1	-23.2	515	81.4	-24.4
Female Active Clinical Pts 18+	745		744			734		
# w/ BPs Documented	523	70.2	655	88.0	-17.8	647	88.1	-17.9
User Pop Pts 18+	1,574		1,601			1,569		

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ BPs Documented	880	55.9	1,227	76.6	-20.7	1,192	76.0	-20.1	
Male User Pop Pts 18+	739		765			745			
# w/ BPs Documented	348	47.1	543	71.0	-23.9	529	71.0	-23.9	
Female User Pop Pts 18+	835		836			824			
# w/ BPs Documented	532	63.7	684	81.8	-18.1	663	80.5	-16.7	

Figure 2-79: Sample Report, CVD and Blood Pressure Control

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Cardiovascular Disease and Blood Pressure Control: List of Patients 18+ or who have CHD with blood pressure value, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, SANDRA KAY 000001 COMMUNITY #1 F 21 03/12/96 UP,AC PATIENT2, EVELYN 000002 COMMUNITY #1 F 21 05/19/96 /3080F PATIENT3, MICHELLE 000003 COMMUNITY #1 F 22 02/15/95 UP.AC 125/67
PATIENT4, CAITLYN 000004 COMMUNITY #1 F 22 08/12/95
UP, AC, IHD 131/67 PATIENT5, BRITNEY JANE 000005 COMMUNITY #1 F 22 10/01/95 UP,AC 102/56 PATIENT6, KATHRYN ANNE 000006 COMMUNITY #1 F 22 10/16/95 UP,AC 161/90
PATIENT7,RHONDA 000007 COMMUNITY #1 F 22 11/23/95
UP,AC 153/05

Figure 2-80: Sample Patient List, CVD and Blood Pressure Control

# 2.8.8 Controlling High Blood Pressure (Million Hearts) GPRA Measure Description

During GPRA Year 2017, achieve the target rate of 59.7% for the proportion of patients with BP less than (<) 140/90.

#### **Denominator**

User Population patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD or current diagnosis of pregnancy. Broken down by age groups 18 through 59 and 60 through 85 (Million Hearts (NQF 0018)).

#### **Numerators**

Patients with blood pressure less than (<) 140/90, i.e., the systolic value is less than (<) 140 AND the diastolic value is less than (<) 90 (Million Hearts (NQF 0018)). Patients with blood pressure less than (<) 150/90 (i.e., the systolic value is less than (<) 150 AND the diastolic value is less than (<) 90).

## **Logic Description**

Age of the patient is calculated at the end of the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses the last blood pressure documented during the Report Period. If a patient has more than one blood pressure documented on the same day, CRS will first look for a blood pressure less than (<) 140/90 on that day, and if not found, will look for a blood pressure less than (<) 150/90.

CRS uses the following codes to define ESRD, hypertension, and pregnancy.

Subject Defined	CPT Codes	ICD and Other Codes
ESRD	36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939, 90947, 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308-G0327 (old code), G0393 (old code), G9231, S2065, or S9339	Diagnosis (POV or Problem List entry where the status is not Deleted): ICD-9: 585.6, V42.0, V45.1, (old code), V45.11, V45.12, V56.*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2; SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)  Procedure: ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*

Subject Defined	CPT Codes	ICD and Other Codes
Hypertension		POV or Problem List entry where the status is not Inactive or Deleted ever through the first 6 months of the Report Period, and at least one hypertension POV during Report Period: ICD-9: 401.*; ICD-10: I10; SNOMED data set PXRM ESSENTIAL HYPERTENSION (Problem List only)
Pregnancy - Any of the following: 1) The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period, or 2) At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes".	CPT: 59000-59076, 59300, 59320, 59400- 59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828	POV or Problem diagnosis:. ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O99.344, O99.310-O99.314, O99.320-O99.324, O99.310-O99.314, O99.320-O99.324, O99.310-O99.314, O99.320-O99.324, O99.310-O99.344, O99.350-O99.354, O99.411-O99.12, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.844, O99.89, O99.814, O99.820, O99.844, O99.89, O99.811-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36  Procedure:. ICD-9: 72.*, 73.*, 74.*
Miscarriage	59812, 59820, 59821,	POV: ICD-9: 630, 631, 632, 633*, 634*; ICD-
	59830	10: O03.9

Subject Defined	CPT Codes	ICD and Other Codes
Abortion	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260- S2267	POV: ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z

#### **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to ESRD definition to look at the Problem List.
- 2. Added SNOMED data set PXRM END STAGE RENAL DISEASE to ESRD definition (for Problem List only).
- 3. Added SNOMED data set PXRM ESSENTIAL HYPERTENSION to hypertension definition (for Problem List only).
- 4. Updated logic for patients with more than one blood pressure on a single day to first look for blood pressure less than (<) 140/90 and if not found, look for blood pressure less than (<) 150/90.

#### **Patient List Description**

List of patients with hypertension and BP value, if any.

#### **Measure Source**

Not Available

#### **Measure Past Performance and Long-Term Targets**

Performance	Percent	
IHS FY 2016 Performance	59.2%	
IHS FY 2015 Performance	58.5%	
IHS FY 2014 Performance	59.5%	

```
Page 200
DH
                            November 25, 2017
       *** IHS 2017 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Controlling High Blood Pressure - Million Hearts
                                  PREV YR
                                                                    % CHG from
                    REPORT
                                             % CHG from BASE
                    PERIOD
                                  PERIOD
                                                PREV YR % PERIOD
                                                                       BASE %
```

User Pop Pts 18-85 w/ HTN Dx (GPRA)	302		403			380		
# w/ BP <140/90 (GPRA)	145	48.0	218	54.1	-6.1	211	55.5	-7.5
User Pop Pts 18-59 w/ HTN Dx	202		284			267		
# w/ BP <140/90	93	46.0	153	53.9	-7.8	138	51.7	-5.6
User Pop Pts 60-85 w/ HTN Dx	100		119			113		
# w/ BP <150/90	66	66.0	89	74.8	-8.8	81	71.7	-5.7

Figure 2-81: Sample Report, Controlling High Blood Pressure (Million Hearts)

Figure 2-82: Sample Patient List, Controlling High Blood Pressure (Million Hearts)

# 2.8.9 Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

## **GPRA Measure Description**

During GPRA Year 2017, establish a baseline for the proportion of at-risk patients who receive statin therapy.

#### **Denominators**

*User Population patients* ages 40 through 75 with diabetes or age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190. Broken down by age groups 21 through 39, 40 through 75, 76 and older. (GPRAMA Denominator)

*User Population patients* ages 40 through 75 with diabetes.

*User Population patients* ages 40 through 75 with diabetes or age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190, including denominator exclusions.

#### **Numerators**

Patients who are statin therapy users during the Report Period or who receive an order (prescription) to receive statin therapy at any point during the Report Period. (GPRAMA Numerator)

Patients with any of the listed denominator exclusions.

a. Patients with documented allergy, intolerance, or other adverse effect to statin medication.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

## **Denominator Logic**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file.

Cardiovascular Disease (CVD) diagnosis defined as any of the following:

Subject Defined	ICD and Other Codes
Coronary Heart Disease (CHD)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 410.0-413.*, 414.0-414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9, Z95.5; SNOMED data set PXRM ISCHEMIC HEART DISEASE (Problem List only)
Acute Myocardial Infarction (AMI)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 410.0*-410.9*, 412; ICD-10: I21.*, I22.*, I23.*, I25.2; SNOMED data set PXRM BGP AMI (Problem List only)
Ischemic Vascular Disease (IVD)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 411.*, 413.*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, 445.*; ICD-10: I20.*, I24.*, I25.1*, I25.5-I25.812, I65.*, I66.*, I70.1, I70.201-I70.299, I70.92, I74.*, I75.*; SNOMED data set PXRM BGP IVD (Problem List

Subject Defined	ICD and Other Codes
	only)
Ischemic Stroke or Transient Ischemic Attack (TIA)	Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.*; SNOMED data set PXRM BGP ISCHEMIC STROKE TIA (Problem List only)
CABG	POV: ICD-9: V45.81; ICD-10: Z95.1 CPT: 33510-33514, 33516-33519, 33521-33523, 33530, 33533- 33536, 33572, 35500, 35600, S2205-S2209 Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61 CPT: 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 Procedure: ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05 (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**
Other Revascularization	CPT: 37220, 37221, 37224-37231

CRS uses the following to define the tests:

Subject Defined	LOINC Codes	Taxonomy
LDL Done	Yes	DM AUDIT LDL CHOLESTEROL TAX
LDL greater than or equal to (=>) 190		Tests in above taxonomy with LDL greater than or equal to (=>) 190
LDL less than (<) 70		Tests in above taxonomy with LDL less than (<) 70

In the LOINC Codes column, specific LOINC codes used by CRS are located in the *CRS Technical Manual*.

#### **Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- 1. Patients with documented allergy, intolerance, or other adverse effect to statin medication.
- 2. Patients who have an active diagnosis of pregnancy or who are breastfeeding.
- 3. Patients with a diagnosis of cirrhosis of the liver during the Report Period or the year prior to the Report Period.
- 4. Patients who are receiving palliative care.
- 5. Patients with end-stage renal disease (ESRD).
- 6. Patients with diabetes whose most recent LDL result is less than (<) 70 and who have never had an LDL result greater than or equal to (>=) 190 and who are not taking statin therapy.

CRS uses the following codes to define contraindications to statins.

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		See below for definition
Acute Alcoholic Hepatitis		POV or Problem List entry where the status is not Inactive or Deleted during the Report Period: ICD-9: 571.1; ICD-10: K70.10, K70.11; SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
NMI Refusal		Refusal: NMI refusal for any statin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

#### Adverse Drug Reaction/Allergy to Statins

#### ICD and Other Codes

Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period

Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period

Myopathy/Myalgia, defined as any of the following during the Report Period: **POV or Problem List entry where the status is not Inactive or Deleted:** ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1; SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)

Any of the following occurring anytime ever:

POV: ICD-9: 995.0-995.3 AND E942.9

Entry in ART (Patient Allergies File): "statin" or "statins"

Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

**Problem List entry where the status is not Deleted**: SNOMED data set PXRM BGP ADR STATIN

Subject Defined	ICD and CPT Codes
Pregnancy	Any of the following: 1) The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period, or 2) At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with:  POV or Problem List: ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 658.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: 009.00-010.02, 010.111-010.12, 010.211-010.22, 010.311-010.32, 010.411-024.12, 024.311-024.32, 024.41*, 024.811-024.82, 024.911-024.92, 025.10-025.2, 026.00-026.62, 026.711-026.72, 026.811-026.93, 029.011-030.33, 031.*-048.*, 060.0*, 061.*-066.*, 068, 069.*, 071.00-071.1, 071.89, 071.9, 074.0-075.81, 075.89, 075.9, 076-077.*, 088.011-088.02, 088.111-088.12, 088.211-088.22, 088.311-088.32, 088.811-088.82, 090.3, 091.011-091.019, 091.111-091.119, 091.211-091.219, 092.011-092.019, 092.20, 092.29, 098.011-098.02, 098.111-098.12, 098.211-098.22, 098.311-098.32, 098.411-098.42, 098.511-098.52, 099.611-098.62, 098.711-099.12, 099.210-099.214, 099.280-099.284, 099.310-099.314, 099.320-099.324, 099.314, 099.334, 099.344, 099.340-099.344, 099.350-099.324, 099.311-098.02, 099.111-099.02, 099.111-099.72, 099.810, 099.814, 099.89, 099.111-099.62, 099.711-099.72, 099.810, 099.814, 099.89, 099.111-098.62, 099.711-099.22, 099.810, 099.814, 099.830, 099.834, 099.840-099.844, 099.89, 099.111-098.42, 098.510, 599.54, 099.810, 099.814, 099.89, 099.510, 599.54, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82, 099.834, 099.834, 099.834, 099.840-099.844, 099.89, 099.81, 099.824, 099.830, 099.834, 099.840-099.844, 099.89, 099.81, 099.824, 099.830, 099.834, 099.840-099.844, 099.89, 099.81, 099.811, 099.82, 099.811, 099.82, 099.811, 099.82
	The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes".
Abortion	CPT: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267  POV: ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z,
	0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z

Miscarriage	<b>CPT:</b> 59812, 59820, 59821, 59830
	<b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9
Breastfeeding	POV: ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
	<b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period

*Cirrhosis of the liver definition*: Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-9: 571.2, 571.5, 571.6; ICD-10: K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81; SNOMED data set PXRM BGP CIRRHOSIS (Problem List only).

Palliative care visit definition: POV ICD-9: V66.7; ICD-10: Z51.5.

ESRD diagnosis/treatment definition: Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only); (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

#### **Numerator Logic**

Statin therapy user definition: CPT 4013F

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

#### **Key Logic Changes from CRS Version 16.1**

1. New topic for CRS v17.0.

## **Patient List Description**

List of patients 40 through 75 with diabetes or 21 and older with CVD or LDL greater than or equal to (>=) 190 with statin therapy or exclusion, if any.

## **Measure Source**

HHS Statin Therapy eMeasure

## **Measure Past Performance and Long-Term Targets:**

Performance	Percent	
N/A	N/A	

Previ	eport Per ous Year	Measu DEMC iod: J Period	) INDIAN H Jan 01, 20 H: Jan 01	Commus OSPIT 17 to , 201		017 1, 2016		age 15 **	
Statin Therapy for	the Preve	ntion	and Treat	ment	of Cardiova	ascular	Disea	se	
	REPORT PERIOD				CHG from PREV YR %				
UP Pts 40-75 w/DM or 21+ w/CVD or LDL>=190 (GPRAMA)	404		395			391			
# w/ Statin Rx (GPRAMA)	97	24.0	103	26.1	-2.1	135	34.5	-10.5	
UP Pts 21-39 w/ CVD or LDL>=190	13		12			6			
# w/ Statin Rx	3	23.1	2	16.7	+6.4	4	66.7	-43.6	
UP Pts 40-75 w/ CVD or LDL>=190	116		126			129			
# w/ Statin Rx	41	35.3	43	34.1	+1.2	52	40.3	-5.0	
UP Pts 76+ w/ CVD or LDL>=190	21		18			20			
# w/ Statin Rx	5	23.8	3	16.7	+7.1	3	15.0	+8.8	
UP Pts 40-75 w/ DM	338		329			321			
# w/ Statin Rx	82	24.3	92	28.0	-3.7	114	35.5	-11.3	
UP Pts 40-75 w/DM									

or 21+ w/CVD or LDL>=190, incl exclusions	498		476			443			
# w/ Exclusions A. # w/ Allergy/ADR w/ %	94	18.9	81	17.0	+1.9	52	11.7	+7.1	
of Total Exclusions	22	23.4	39	48.1	-24.7	22	42.3	-18.9	

Figure 2-83: Sample Report, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Statin Therapy for the Prevention and Treatment of Cardiovascular Disease: List of patients 40-75 with diabetes or 21+ with CVD or LDL >=190 with statin therapy or exclusion, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR PATIENT NAME PATIENT1, DEBORAH 000001 COMMUNITY #1 F 35 11/11/81
UP, AD (CHD) Statin: 02/27/17 SIMVASTATIN 40MG TABLET
PATIENT2, TARA 000002 COMMUNITY #1 F 51 02/10/65 UP (DM) UP (DM)
PATIENT3,BOBBIE 000003 COMMUNITY #1 F 52 05/06/64
UP,AD (DM,CHD) Exclusion: 02/02/13 ESRD
PATIENT4,WINONA 000004 COMMUNITY #1 F 53 07/21/63
UP,AD (DM) Statin: 01/08/17 SIMVASTATIN 4
PATIENT5,NADINE 000005 COMMUNITY #1 F 61 08/12/55 Statin: 01/08/17 SIMVASTATIN 40MG TABLET UP, AD (DM) UP,AD (DM)
PATIENT6,RUTH 000006 COMMUNITY #1 F 64 06/30/52 Exclusion: 02/15/17 ADR/Allergy POV 995.2 UP (CHD)

Figure 2-84: Sample Patient List, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

# 2.8.10 Appropriate Medication Therapy after a Heart Attack

#### **Denominator**

Active Clinical patients aged 35 and older discharged for an AMI during the first 51 weeks of the Report Period and were not readmitted for any diagnosis within 7 days of discharge. Broken down by gender.

### **Numerators**

Patients with active prescription for or who have a contraindication/previous adverse reaction to *beta-blockers*.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *ACEIs/ARBs*.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *statins*.

**Note**: This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with active prescriptions for *all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin), and/or who have a contraindication/previous adverse reaction.

**Note**: This numerator does *not* include refusals.

#### **Logic Description**

Age is calculated at the beginning of the Report Period.

Acute Myocardial Infarction (AMI) definition: POV ICD-9: 410.0\*-410.9\*, 412; ICD-10: I21.\*, I22.\*, I23.\*, I25.2 with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.

**Denominator Exclusions** 

Patients meeting any of the following conditions will be excluded from the denominator.

- 1. Patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death."
- 2. Patients readmitted for any diagnosis within 7 days of discharge.
- 3. Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
- 4. Patients with a Provider Narrative beginning with "Consider"; "Doubtful"; "Maybe"; "Possible"; "Perhaps"; "Rule Out"; "R/O"; "Probable"; "Resolved"; "Suspect"; "Suspicious"; or "Status Post."

Numerator Logic

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below:

- 1. An active prescription (not discontinued as of [discharge date plus (+) 7 days] and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within 7 days after discharge. "Active" prescription defined as: Days Prescribed greater than (>) ((Discharge Date plus (+) 7 days) Order Date); *or*
- 2. Have a contraindication/previous adverse reaction to the indicated medication.

Contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy will be counted in subnumerator B.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

### **Beta-Blocker Numerator Logic**

Beta-blocker medication codes defined with medication taxonomy BGP PQA BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.)

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta- Blockers (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		POV or Problem List entry where the status is not Deleted: 1 diagnosis of ICD-9: 458*; ICD-10: I95.*; SNOMED data set PXRM BGP HYPOTENSION (Problem List only)
Heart Block greater than (>)1 Degree		POV or Problem List entry where the status is not Deleted: 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6; SNOMED data set PXRM BGP OVER 1 DEG HEART BLK (Problem List only)
Sinus Bradycardia		POV or Problem List entry where the status is not Deleted: 1 diagnosis of ICD-9: 427.81; ICD-10: I49.5, R00.1; SNOMED data set PXRM BGP SINUS BRADYCARDIA (Problem List only)

COPD		POV: 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta- blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during hospital stay through 7 days after discharge date	Refusal: NMI (not medically indicated) refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to beta-blockers.

## Adverse Drug Reaction/Allergy to Beta-Blockers

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
Entry in ART (Patient Allergies File): "beta block*"
Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "beta block*", "bblock*" or "b block*"
Problem List entry where the status is not Deleted: SNOMED data set PXRM BGP ADR BETA BLOCKER

## ASA (aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated DM AUDIT ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge		Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS
Hemorrhage		POV or Problem List entry where the status is not Deleted: ICD-9: 459.0; ICD-10: R58; SNOMED data set PXRM BGP HEMORRHAGE (Problem List only)
NMI Refusal	G8008 (old code) at least once during hospital stay through 7 days after discharge date	Refusal: NMI (not medically indicated) refusal for any aspirin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ASA/other anti-platelets.

# Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

ICD and Other Codes
<b>POV</b> : ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*
Entry in ART (Patient Allergies File): "aspirin"
Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ASA" or "aspirin"
Problem List entry where the status is not Deleted: SNOMED data set PXRM BGP ADR ASA

## **ACEI/ARB Numerator Logic**

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

CRS uses the following codes to define contraindications to ACE inhibitors.

Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)	ICD and Other Codes
Pregnancy	See below for definition
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
	Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis	POV or Problem List entry where the status is not Deleted: ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22; SNOMED data set PXRM BGP MOD SEV AORTIC STEN (Problem List only)
NMI Refusal	Refusal: NMI (not medically indicated) refusal for any ACE inhibitor at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ACE inhibitors.

# **Adverse Drug Reaction/ Allergy to ACE Inhibitors**

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
<b>Entry in ART (Patient Allergies File):</b> "ace inhibitor" or "ACEI"
Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ace i*" or "ACEI"
Problem List entry where the status is not Deleted: SNOMED data set PXRM BGP ADR ACEI

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)	ICD and Other Codes
Pregnancy	See below for definition
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
	Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis	POV or Problem List entry where the status is not Deleted: ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22; SNOMED data set PXRM BGP MOD SEV AORTIC STEN (Problem List only)
NMI Refusal	Refusal: NMI refusal for any ARB at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ARBs.

# Adverse Drug Reaction/Allergy to ARBs

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6
Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB"
Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Angiotensin Receptor Blocker" or "ARB"
Problem List entry where the status is not Deleted: SNOMED data set PXRM BGP ADR ARB

# **Statins Numerator Logic**

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	ICD and Other Codes
Pregnancy	See below for definition
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
	Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Acute Alcoholic Hepatitis	POV or Problem List entry where the status is not Deleted during the Report Period: ICD-9: 571.1; ICD-10: K70.10, K70.11; SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
NMI Refusal	<b>Refusal:</b> NMI refusal for any statin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

# **Adverse Drug Reaction/Allergy to Statins**

ICD and Other Codes
Site-Populated Lab Taxonomy or LOINC Taxonomy:
DM AUDIT ALT TAX, with ALT and/or AST greater than
(>) 3x the Upper Limit of Normal (ULN) (i.e., Reference
High) on 2 or more consecutive visits during the Report
Period

#### ICD and Other Codes

Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period

POV or Problem List entry where the status is not Deleted: Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1; SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)

POV: ICD-9: 995.0-995.3 AND E942.9

Entry in ART (Patient Allergies File): "statin" or "statins"

Entry in Problem List (where status is not Deleted) or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

**Problem List entry where the status is not Deleted:** SNOMED data set PXRM BGP ADR STATIN

Subject Defined	ICD and CPT Codes
Pregnancy - Any of the following: 1) The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period, or 2) At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes".	POV or Problem List: ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 666.*3, 667.*3, 665.*3, 668.*3, 669.*3, 667.*3, 678.*3, 678.*3, 678.*3, 678.*3, 678.*3, 678.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.11-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.201, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O99.311-O98.32, O98.411-O98.42, O98.511-O98.52, O99.611-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.841-O99.820, O99.844, O99.89, O99.811-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.841-O99.820, O99.844, O99.89, O99.844, O99.89, O99.844, O99.89, O99.811-O98.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36.  Procedure: ICD-9: 72.*, 73.*, 74.* CPT: 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828
Abortion	CPT: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267  POV: ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Miscarriage	CPT: 59812, 59820, 59821, 59830 POV: ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9

## **All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

## **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to Hypotension definition to look at the Problem List.
- 2. Added SNOMED data set PXRM BGP HYPOTENSION to hypotension definition (for Problem List only).
- 3. Added logic to Heart block >1 degree definition to look at the Problem List.
- 4. Added SNOMED data set PXRM BGP OVER 1 DEG HEART BLK to heart block > 1 degree definition (for Problem List only).
- 5. Added logic to Sinus bradycardia definition to look at the Problem List.
- 6. Added SNOMED data set PXRM BGP SINUS BRADYCARDIA to sinus bradycardia definition (for Problem List only).
- 7. Added logic to Hemorrhage definition to look at the Problem List.
- 8. Added SNOMED data set PXRM BGP HEMORRHAGE to hemorrhage definition (for Problem List only).
- 9. Added logic to Moderate or severe aortic stenosis definition to look at the Problem List.
- 10. Added SNOMED data set PXRM BGP MOD SEV AORTIC STEN to moderate or severe aortic stenosis definition (for Problem List only).
- 11. Added logic to Acute Alcoholic Hepatitis definition to look at the Problem List.
- 12. Added SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS to acute alcoholic hepatitis definition (for Problem List only).
- 13. Added logic to Myopathy/Myalgia definition to look at the Problem List.
- 14. Added SNOMED data set PXRM BGP MYOPATHY MYALGIA to myopathy/myalgia definition (for Problem List only).
- 15. Updated adverse drug reaction/documented beta blocker allergy logic to clarify that Problem List entry status is not Deleted.

- 16. Added SNOMED data set PXRM BGP ADR BETA BLOCKER to beta blocker adverse reaction definition (for Problem List only).
- 17. Updated adverse drug reaction/documented ASA/other anti-platelet allergy logic to clarify that Problem List entry status is not Deleted.
- 18. Added SNOMED data set PXRM BGP ADR ASA to ASA/aspirin adverse reaction definition (for Problem List only).
- 19. Updated adverse drug reaction/documented ACEI allergy logic to clarify that Problem List entry status is not Deleted.
- 20. Added SNOMED data set PXRM BGP ADR ACEI to ACEI adverse reaction definition (for Problem List only).
- 21. Updated adverse drug reaction/documented ARB allergy logic to clarify that Problem List entry status is not Deleted.
- 22. Added SNOMED data set PXRM BGP ADR ARB to ARB adverse reaction definition (for Problem List only).
- 23. Updated adverse drug reaction/documented statin allergy logic to clarify that Problem List entry status is not Deleted.
- 24. Added SNOMED data set PXRM BGP ADR STATIN to statin adverse reaction definition (for Problem List only).

## **Patient List Description**

List of patients with AMI, with appropriate medication therapy, if any.

## **Measure Source**

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

# Measure Past Performance and Long-Term Targets

None

```
DU November 25, 2017 Page 216

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Appropriate Medication Therapy after a Heart Attack
```

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		% C	CHG from BASE %
Active Clinical Pts 35+ Hospitalized for AMI	15		0			0		
<pre># w/ Beta-Blocker   Rx/Contra/ADR-No   Refusals A. # w/   Beta-Blocker Rx w/</pre>	7	46.7	0	0.0	) +46.7	0	0.0	+46.7
% of Total B. # w/ Contra/ADR	4	57.1	0	0.0	+57.1	0	0.0	+57.1
w/ % of Total	3	42.9	0	0.0	) +42.9	0	0.0	+42.9
# w/ ASA Rx/Contra/ADR-No Refusals A. # w/ ASA Rx w/	3	20.0	0	0.0	) +20.0	0	0.0	+20.0
% of Total B. # w/ Contra/ADR	1	33.3	0	0.0	+33.3	0	0.0	+33.3
w/ % of Total	2	66.7	0	0.0	+66.7	0	0.0	+66.7
# w/ ACEI/ARB Rx/Contra/ADR-No Refusals	12	80.0	0	0.0	0.08+	0	0.0	+80.0
A. # w/ ACEI/ARB Rx w/ % of Total B. # w/ Contra/ADR	7	58.3	0	0.0	+58.3	0	0.0	+58.3
w/ % of Total	5	41.7	0	0.0	+41.7	0	0.0	+41.7
<pre># w/ Statin   Rx/Contra/ADR-No   Refusals</pre>	10	66.7	0	0.0	) +66.7	0	0.0	+66.7
A. # w/ Statin Rx w/ % of Total	2	20.0	0	0.0		0	0.0	+20.0
B. # w/ Contra/ADR w/ % of Total	8	80.0	0	0.0	0.08+	0	0.0	+80.0
# w/ Rx/Contra/ADR of All Meds-No								
Refusals	3	20.0	0	0.0	+20.0	0	0.0	+20.0

Figure 2-85: Sample Report, Appropriate Medication Therapy after a Heart Attack

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Appropriate Medication Therapy after a Heart Attack: List of patients with AMI, with appropriate medication therapy, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR

```
PATIENT1, CECELIA 000001 COMMUNITY #1 F 37 08/18/80

AC BETA: 06/30/17 Contra 2/3 heart block POV 426.3

PATIENT2, KATHLEEN 000002 COMMUNITY #1 F 38 12/15/79

AC ACEI/ARB: Contra pregnant; STATIN: Contra pregnant

PATIENT3, KIMBERLY A 000003 COMMUNITY #1 F 49 02/27/68

AC ASA: 11/16/17 CLOPIDOGREL BISULFATE 75MG TAB;

ACEI/ARB: 01/14/17 Contra BF-HC; STATIN: 01/14/17 Contra BF-HC

PATIENT4, TIMOTHY JOHN 000004 COMMUNITY #1 M 57 04/30/60

AC ACEI/ARB: 06/01/17 Contra NMI CAPTOPRIL 25MG TABS

PATIENT5, FELIPE 000005 COMMUNITY #1 M 57 09/12/60

AC

PATIENT6, JAMES DALTON 000006 COMMUNITY #1 M 77 06/14/40

AC ALL MEDS: BETA: 07/23/17 Contra CPT G8011; ASA:

07/23/17 Contra CPT G8008; ACEI/ARB: 07/27/15 Contra POV 396.0; STATIN: 06/05/17 SIMVASTATIN 40MG TAB
```

Figure 2-86: Sample Patient List: Appropriate Medication Therapy after a Heart Attack

# 2.8.11 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation

## **Denominator**

*User Population patients* ages 18 and older who have a documented diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation any time prior to the end of the Report Period.

## **Numerators**

Patients who received a prescription for anticoagulant during the Report Period.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes to define ischemic stroke or transient ischemic attack with atrial fibrillation.

Subject Defined	ICD and Other Codes
Ischemic Stroke or TIA with Atrial Fibrillation	POV: ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.* AND ICD-9: 427.31; ICD-10: I48.0-I48.2, I48.91 (atrial fibrillation)

Anticoagulant Therapy: Patient must receive a prescription for Warfarin, aspirin, or other anti-platelet during the Report Period to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

*Warfarin Medication:* Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

Aspirin Medication: Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

Other Anti-Platelet/Anticoagulant Medication: Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

# **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

#### **Measure Source**

None

## **Measure Past Performance and Long-Term Targets**

None

```
DU
                             November 25, 2017
                                                                    Page 248
       *** IHS 2017 Selected Measures with Community Specified Report
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial
Fibrillation
                    REPORT
                              % PREV YR
                                            % CHG from BASE
                                                                   % CHG from
                    PERIOD
                                 PERIOD
                                               PREV YR % PERIOD
                                                                      BASE %
User Pop Pts 18+
w/ Stroke/TIA and
 Atrial Fib
                         5
```

# w/ Anticoagulant						
Rx	5 100.0	1 100.0	+0.0	1 100.0	+0.0	

Figure 2-87: Sample Report, Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge: List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR

PATIENT1, SHERRY 000001 COMMUNITY #1 F 38 05/14/79

UP DX: 10/23/10 THERAPY: 01/17/17 ASA PATIENT2, CODY JACK 000002 COMMUNITY #1 M 31 04/28/86

UP DX: 05/01/14 THERAPY: 01/30/17 ASA PATIENT3, TIMOTHY ALLEN 000003 COMMUNITY #1 M 33 04/13/84

UP DX: 02/02/17 THERAPY: 06/10/17 WARF PATIENT4, TRACE 000004 COMMUNITY #1 M 37 05/16/80

UP DX: 03/01/16 THERAPY: 04/17/17 ASA
```

Figure 2-88: Sample Patient List: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

# 2.8.12 Heart Failure and Evaluation of LVS Function

## **Denominator**

Active Clinical patients ages 18 and older discharged with heart failure during the Report Period.

#### **Numerators**

Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.

## **Logic Description**

Age of the patient is calculated as of the hospital admission date.

Denominator exclusions are defined as any of the following:

1. Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).

- 2. Patients with a Discharge Type of Transferred or Irregular or containing "Death."
- 3. Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

CRS uses the following codes to define the denominator and numerators.

## **Denominator Exclusions**

Subject Defined	CPT Codes	ICD and Other Codes
Comfort Measures		POV: ICD-9: V66.7 (Encounter for palliative care); ICD-10: Z51.5 documented during hospital stay
LVAD/Heart Transplant		Procedure: ICD-9: 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68; ICD-10: 02HA**Z, 02PA*RZ, 02RK0JZ, 02RL0JZ, 02UA4JZ, 02WA0JZ, 02WA0QZ, 02WA0RZ, 02WA3QZ, 02WA3RZ, 02WA4QZ, 02WA4RZ, 02YA0Z*, 5A02*10, 5A02*16, 5A02*1D documented during hospital stay

## **Denominator Definition**

Subject Defined	CPT Codes	ICD and Other Codes
Heart Failure		POV (Primary Diagnosis only): ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, 997.1; ICD-10: I11.0, I13.0, I13.2, I50.* and with Service Category H (hospitalization).  NOTE: If a patient has multiple admissions matching these criteria during the Report Period, the earliest admission will be used.

# Numerator Definition (Evaluation of LVS Function): Any of the codes listed below

Subject Defined	CPT Codes	ICD and Other Codes
Ejection Fraction (ordered or documented anytime one year prior to discharge date)	78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314–93318, 93350, 93543, 93555	Measurement: "CEF" Procedure: ICD-9: 88.53, 88.54; ICD-10: B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ

Subject Defined	CPT Codes	ICD and Other Codes
RCIS Order for Cardiovascular Disorders Referral (ordered		ICD Diagnostic Category: "Cardiovascular Disorders" AND one of the following:
during the hospital stay but no later than the hospital discharge date)		CPT Categories: "Evaluation and/or Management," "Non-surgical Procedures" or "Diagnostic Imaging"
Other Procedures (documented anytime one year prior to discharge date)		Echocardiogram: Procedure ICD-9: 88.72, 37.28, 00.24; ICD-10: B245YZZ, B245ZZ4, B245ZZZ, B246YZZ, B246ZZZ, B24BZZZ, B24BZZZ, B24BZZZ
		<b>Nuclear Medicine Test</b> : Procedure ICD-9: 92.2*;
		Cardiac Catheterization with a Left Ventriculogram: Procedure ICD-9: 37.22, 37.23, 88.53, 88.54; ICD-10: 4A02*N7, 4A02*N8, B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ

# **Key Logic Changes from CRS Version 16.1**

None.

# **Patient List Description**

List of Active Clinical heart failure patients 18 and older who received evaluation of LVS function, if any.

## **Measure Source**

CMS HF-2

# **Measure Past Performance and Long-Term Targets**

None

Pre	17 Selected  Report Peri	Meas DEM od: erio	O INDIAN H Jan 01, 20 d: Jan 01	Comm OSPI 17 t , 20	TAL o Dec 31, 2 16 to Dec 3	2017 31, 2016		Page 255 ***
Heart Failure and	Baseline Per  Evaluation				to Dec 31,	2010		
	REPORT PERIOD	%	PREV YR PERIOD	0/0	CHG from PREV YR %		%	CHG from BASE %
Active Clinical 18+ w/ Heart								

Failure Dx	2	0	0	
Patients w/ Eval of LVS Function	1 50.0	0 0.0	+50.0 0	0.0 +50.0

Figure 2-89: Sample Report, Heart Failure and Evaluation of LVS Function

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Heart Failure and Evaluation of LVS Function: List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any. HRN COMMUNITY SEX AGE DOB PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, JOAN 000164 COMMUNITY #1 F 36 08/12/81 AC Admission: 06/01/17 LVS: NOT DOCTOR PATIENT2, SARAH 000127 COMMUNITY #1 F 35 10/09/82 Admission: 06/01/17 LVS: NOT DOCUMENTED AC Admission: 06/01/17 LVS: 06/03/17 PATIENT3, JOHN 000151 COMMUNITY #1 M 36 12/16/81 Admission: 06/01/17 LVS: 06/03/17 Proc 88.72 Admission: 05/01/17 LVS: 05/01/17 Meas CEF 40 AC Admission: 05/01/1/ LVS: 05/01/1 PATIENT4, ROGER 000125 COMMUNITY #1 M 47 08/01/70 Admission: 06/01/17 LVS: NOT DOCUMENTED PATIENT5, DANIEL 000129 COMMUNITY #1 M 57 07/12/60 Admission: 06/01/17 LVS: 06/01/17 CPT 78468

Figure 2-90: Sample Patient List: Heart Failure and Evaluation of LVS Function

# 2.9 STD-Related Measure Topics

# 2.9.1 HIV Screening

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 41.9% for the proportion of patients who have ever been screened for HIV.

#### **Denominators**

*Pregnant Active Clinical female patients* with no documented miscarriage or abortion and with no recorded HIV diagnosis ever.

*User Population patients* ages 13 through 64 with no recorded HIV diagnosis prior to the Report Period. (GPRA Denominator).

## **Numerators**

Patients who were screened for HIV during the past 20 months.

**Note**: This numerator does *not* include refusals.

Patients who were screened for HIV during the Report Period. (GPRA Developmental Numerator)

**Note**: This numerator does *not* include refusals.

Patients who were screened for HIV at any time before the end of the Report Period. (GPRA Numerator)

**Note**: This numerator does *not* include refusals.

Count only: Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen. (GPRA Developmental Numerator)

**Note**: This numerator does not include refusals.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Pregnancy definition: Any of the following: 1) The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period, or 2) At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.

The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes". The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

HIV Screening definition: For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

**Notes:** The time frame for screening for the pregnant patients denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Pregnancy (at least 2 visits in past 20 months with 1 during the Report Period or the Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period)	CPT: 59000- 59076, 59300, 59320, 59400- 59426, 59510, 59612, 59618, 59620, 76801- 76828	POV: ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 665.*3, 657.*3, 658.*3, 665.*3, 665.*3, 667.*3, 663.*3, 665.*3, 666.*3, 667.*3, 663.*3, 665.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.92, O11.1-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.344, O99.30-O99.344, O99.30-O99.334, O99.840-O99.344, O99.30-O99.344, O99.30-O99.334, O99.30-O		
Miscarriage (after second pregnancy POV in past 20 months)	59812, 59820, 59821, 59830	<b>POV</b> : ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260—S2267	POV: ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z		
HIV Diagnosis (documented any time prior to the end of the Report Period)		POV or Problem List entry where the status is not Deleted: ICD-9: 042, 042.0–044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73; SNOMED data set PXRM HIV (Problem List only)		
HIV Screening	86689, 86701- 86703, 87390, 87391, 87534- 87539		Yes	BGP HIV TEST TAX

# **Key Logic Changes from CRS Version 16.1**

- 1. Changed logic for HIV to include inactive problems on the Problem List.
- 2. Added SNOMED data set PXRM HIV to HIV diagnosis definition (for Problem List only).

# **Patient List Description**

List of pregnant patients (any age) or User Population patients 13-64 with documented HIV test, if any.

## **Measure Source**

HP 2020 HIV-14.3

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance (HIV screen ever)	41.9%

Performance	Percent
IHS FY 2015 Performance (Prenatal HIV screen)	86.6%
IHS FY 2014 Performance (Prenatal HIV screen)	88.0%
IHS FY 2013 Performance (Prenatal HIV screen)	87.7%
IHS FY 2012 Performance (Prenatal HIV screen)	85.8%
IHS FY 2011 Performance (Prenatal HIV screen)	80.0%

Performance	Percent
IHS FY 2010 Performance (Prenatal HIV screen)	78.0%
IHS FY 2009 Performance (Prenatal HIV screen)	76.0%
IHS FY 2008 Performance (Prenatal HIV screen)	75.0%
IHS FY 2007 Performance (Prenatal HIV screen)	74.0%
IHS FY 2006 Performance (Prenatal HIV screen)	65.0%
IHS FY 2005 Performance (Prenatal HIV screen)	54.0%
HP 2020 Goal (Prenatal HIV screen)	74.1%

Previo	eport Per ous Year	Measu DEMC iod: J Period	INDIAN Han 01, 20	Commun OSPITA 17 to , 201	nity Specif	017 1, 2016		ge 256 *
HIV Screening								
	REPORT PERIOD				CHG from PREV YR %			
Pregnant Active Clinical Pts w/ No HIV Ever	40		62			65		
# w/ HIV Screening-No Refusals	22	55.0	47	75.8	-20.8	42	64.6	-9.6
User Pop Pts 13-64 w/ No HIV (GPRA Dev.)	1,617		1,667			1,680		
# w/ HIV Screening-No Refusals (GPRA								
Dev.) # w/ HIV Screening	41	2.5	107	6.4	-3.9	90	5.4	-2.8
Ever-No Refusals (GPRA) # HIV Screens for User Pop Pts w/ No Prior HIV-No	431	26.7	419	25.1	+1.5	339	20.2	+6.5
Refusals (GPRA Dev.)	44		121		-77	104		-60

Figure 2-91: Sample Report, HIV Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

```
HIV Screening: List of pregnant patients or User Population patients with documented HIV test or refusal, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1, HELEN MARY 000001 COMMUNITY #1 F 12 09/08/05
UP 03/31/17 Lab; Screen Count: 1
PATIENT2, CECELIA 000002 COMMUNITY #1 F 19 10/10/98
UP
PATIENT15, BRENDA G 000015 COMMUNITY #2 F 30 12/03/87
UP 03/14/17 CPT 87534; 02/14/17 CPT 86689; Screen Count: 2
PATIENT16, ALYSHA 000016 COMMUNITY #2 F 33 06/09/84
UP, AC PREG 08/25/17 Lab; Screen Count: 1
```

Figure 2-92: Sample Patient List, HIV Screening

# 2.9.2 HIV Quality of Care

#### **Denominator**

*User Population patients* ages 13 and older with at least two direct care visits (i.e., not Contract/PRC) with HIV diagnosis during the Report Period, including one HIV diagnosis in last 6 months.

#### **Numerators**

Patients who received CD4 test only (without HIV viral load) during the Report Period.

Patients who received HIV viral load only (without CD4) during the Report Period.

Patients who received both CD4 and HIV viral load during the Report Period.

Total patients receiving any test.

Patients who received at least one prescription for an Antiretroviral medication.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
HIV		POV: ICD-9: 042, 042.0-044.9 (old codes), 079.53, V08, 795.71; ICD- 10: B20, B97.35, R75, Z21, O98.711- O98.73		
CD4	86359, 86360 86361, G9214		Yes	BGP CD4 TAX
HIV Viral Load	87536, 87539, G9242, G9243		Yes	BGP HIV VIRAL LOAD TAX
Antiretroviral medication				BGP PQA ANTIRETROVIRAL MEDS - Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 16.1**

1. Added LOINC code 43275-7 to BGP CD4 LOINC CODES taxonomy.

# **Patient List Description**

List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

## **Measure Source**

HP 2010 developmental measure 13–13a Viral Load Testing

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS 2020 goal for viral load testing	Nearly 100%
IHS 2020 baseline for CD4 testing	Nearly 100%

```
DU November 25, 2017 Page 258

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

HIV Quality of Care

REPORT * PREV YR * CHG from BASE * CHG from PERIOD PERIOD PREV YR * PERIOD BASE *

User Pop Pts 13+
```

w/ HIV Dx	5	1	1
# w/ CD4 Only # w/ Viral Load	1 20.0	0 0.0 +20.0	0 0.0 +20.0
Only # w/ Both CD4 and	2 40.0	0 0.0 +40.0	0 0.0 +40.0
Viral Load	2 40.0	0 0.0 +40.0	0 0.0 +40.0
# w/ Any Tests	5 100.0	0 0.0 +100.0	0 0.0 +100.0
# w/ ART Rx	1 20.0	1 100.0 -80.0	1 100.0 -80.0

Figure 2-93: Sample Report HIV Quality of Care

Figure 2-94: Sample Patient List, HIV Quality of Care

# 2.9.3 Hepatitis C Screening

## **Denominator**

*User Population patients* born between 1945 and 1965 with no recorded Hep C diagnosis.

User Population patients with documented positive Ab result or Hep C diagnosis ever

*User Population patients* born between 1945-1965 with documented positive Ab result or Hep C diagnosis ever.

*User Population patients* with positive Hepatitis C confirmation result ever.

*User Population patients* born between 1945-1965 with positive Hepatitis C confirmation result ever.

#### **Numerators**

Patients screened for Hepatitis C ever (Ab test).

- a. Patients with a positive result.
- b. Patients with a negative result.

Patients with documented positive Ab result ever.

Patients with documented Hep C diagnosis ever.

Patients who were given a Hepatitis C confirmation test.

- a. Patients with a positive result.
- b. Patients with a negative result.

Patients who ever had a negative confirmation test twelve weeks or greater after a positive confirmation test (cured).

a. Patients who had a negative confirmation test twelve weeks or greater after their most recent positive confirmation test (currently cured).

## **Logic Description**

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hepatitis C diagnosis (documented any time prior to the end of the Report Period)		POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 070.41, 070.44, 070.51, 070.54, 070.70-070.71, V02.62; ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21, Z22.52; SNOMED data set PXRM HEPATITIS C (Problem List only)		
Hepatitis C Screening (Ab Test)	86803		Yes	BGP HEP C TEST TAX

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hepatitis C Confirmation Test (documented any time prior to the end of the Report Period)	86804, 87520, 87521, 87522, G9203, G9207, G9209		Yes	BGP HEP C CONF TEST TAX
If patient has more than one confirmatory test, CRS will first look for a test with a positive result, and if none is found, then will look for a test with a negative result. If there is no test with a result, CRS will use the first test documented.				

For patients ever cured numerator, there must be twelve or more weeks between a positive and negative confirmation test result.

Positive Ab test result defined as a result starting with ">" or containing "Pos", "React", or "Detec".

Negative Ab test result defined as a result starting with "<", or containing "Neg", "Non", "Not", or "None".

Positive confirmation test result defined as any number greater than zero, a result starting with ">" or "<", or containing "Pos", "React", or "Detec".

Negative confirmation test result defined as a result containing "Neg", "Non", "Not", or "None".

# **Key Logic Changes from CRS Version 16.1**

- 1. Added SNOMED data set PXRM HEPATITIS C to Hep C diagnosis definition (for Problem List only).
- 2. Updated logic for positive and negative Ab and confirmation test result definitions.

3. Removed LOINC codes 10676-5, 11011-4, 11259-9, 16937-5, 20416-4, 20571-6, 29609-5, 32286-7, 34703-9, 34704-7, 38180-6, 41996-0, 42003-4, 42617-1, 47252-2, 48574-8, 48575-5, 48576-3, 48796-7, 49372-6, 49376-7, 49380-9, 49605-9, 49758-6, 49846-9, 50023-1, 5010-4, 5011-2, 5012-0, 51655-9, and 6422-0 from BGP HEP C TEST LOINC CODES taxonomy.

# **Patient List Description**

List of patients with documented Hepatitis C screening or confirmatory test ever, if any.

DU			mber 25,					age 258	
*** IHS 2017	Selected		res with			fied Rep	ort *	* *	
		iod: J	an 01, 20	17 to	Dec 31, 20				
					6 to Dec 31				
Bā	seline Pe	r10a; 	Jan UI,	ZUIU 1	to Dec 31,	 			
Hepatitis C Screeni	.ng								
					CHG from				
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
UP Pts born									
1945-1965 w/ No Hep C	445		471			482			
пер с	113		7/1			402			
# w/ Hep C									
Screening A. # w/ Positive	66	14.8	63	13.4	+1.5	48	10.0	+4.9	
Result w/ % of									
Total Screened	45	68.2	41	65.1	+3.1	26	54.2	+14.0	
B. # w/ Negative Result w/ % of									
Total Screened	14	21.2	16	25.4	-4.2	17	35.4	-14.2	
User Pop Pts w/ Hep C	255		233			128			
пер с	233		233			120			
# w/ Positive Ab									
result		91.4 13.7		90.6	+0.8 -1.7	98	76.6	+14.8 -16.7	
# w/ Hep C Dx # w/ Confirmation	35	13.7	30	13.5	-1.7	39	30.5	-16.7	
Test	27	10.6	23	9.9	+0.7	16	12.5	-1.9	
A. # w/ Positive									
Result w/ % of Total Screened	12	44 4	9	39 1	+5.3	8	50 0	-5.6	
B. # w/ Negative	12			57.1	, 5 , 5	3	33.0	3.0	
Result w/ % of						_			
Total Screened	12	44.4	12	52.2	-7.7	7	43.8	+0.7	
UP Pts born									
1945-1965 w/ Hep C	66		63			50			

# w/ Positive Ab									
result	49	74.2	46	73.0	+1.2	30	60.0	+14.2	
# w/ Hep C Dx	20	30.3	21	33.3	-3.0	23	46.0	-15.7	
# w/ Confirmation									
Test	15	22.7	12	19.0	+3.7	9	18.0	+4.7	
A. # w/ Positive									
Result w/ % of Total Screened	5	33.3	1	33.3	+0.0	5	55.6	-22.2	
B. # w/ Negative	J	33.3	-	33.3	+0.0	J	33.0	-22,2	
Result w/ % of									
Total Screened	7	46.7	6	50.0	-3.3	3	33.3	+13.3	
User Pop Pts w/									
positive Hep C									
confirmation	12		9			8			
# Ever Cured	2	16.7	1	11.1	+5.6	0	0.0	+16.7	
A. # Currently	۷	10.7	1	11.1	+3.0	U	0.0	+10.7	
Cured	1	8.3	1	11.1	-2.8	0	0.0	+8.3	
UP Pts born									
1945-1965 w/									
positive Hep C									
confirmation	5		4			5			
# Ever Cured	1	20.0	0	0.0	+20.0	0	0.0	+20.0	
A. # Currently		20.0	U	0.0	TZU.U	U	0.0	720.0	
Cured	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
2 2	,			0.0		_			

Figure 2-95: Sample Report Hepatitis C Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Hepatitis C Screening: List of patients with documented Hepatitis C screening ever, if any. PATIENT NAME DENOMINATOR HRN COMMUNITY SEX AGE DOB NUMERATOR PATIENT1, MARY 000001 COMMUNITY #1 F 50 05/15/67 Ab Test Pos: 10/08/11 Lab Test (Loinc 5198); Conf: 06/15/15 Lab Result=NEG PATIENT2, TANYA 000002 COMMUNITY #1 F 52 08/07/65 Hep C Dx: 12/12/13 POV V02.62 UP, HEP PATIENT15, JOHN 000015 COMMUNITY #2 M 65 02/03/52 Screen: 02/08/17 result=NEG 000016 COMMUNITY #2 M 66 01/15/51 PATIENT16, HAROLD Hep C Dx: 11/22/16 POV 070.54; Ab Test Pos: 10/12/16 Lab Test (Loinc 5198); Conf: 11/10/16 Lab Result=POS; Currently Cured

Figure 2-96: Sample Patient List, Hepatitis C Screening

# 2.9.4 Chlamydia Testing

## **Denominators**

Female Active Clinical patients ages 16 through 25. Broken down by age groups (16 through 20, 21 through 25).

Female User Population patients ages 16 through 25. Broken down by age groups (16 through 20, 21 through 25).

#### **Numerators**

Patients tested for Chlamydia during the Report Period.

Patients with documented refusal during the Report Period.

# **Logic Description**

Age is calculated at beginning of the Report Period. The following codes are used to determine a test for Chlamydia.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Chlamydia Test	86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228	<b>POV</b> : ICD-9: V73.88, V73.98	Yes	BGP CHLAMYDIA TESTS TAX
Refusals	86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228			V Lab Chlamydia Test

# **Key Logic Changes from CRS Version 16.1**

- 1. Added refusal measures and corresponding logic.
- 2. Added LOINC codes 80363-5 and 80364-3 to BGP CHLAMYDIA LOINC CODES taxonomy.

## **Patient List Description**

List of patients with documented Chlamydia screening or refusal, if any.

#### Measure Source

HP 2020 STD-4, annual screening for genital Chlamydia–females enrolled in commercial MCOs (aged 25 years and under); STD-3, annual screening for genital Chlamydia–females enrolled in Medicaid MCOs (aged 25 years and under).

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
HP 2020 goal for Females 16 through 20 with Medicaid (STD-3.1)	57.9%
HP 2020 goal for Females 21 through 24 with Medicaid (STD-3.2)	65.3%
HP 2020 goal for Females 16 through 20 with Commercial Health Insurance (STD-4.1)	44.1%
HP 2020 goal for Females 21 through 24 with Commercial Health Insurance (STD-4.2)	47.9%

Previo	eport Per ous Year	Measu DEMC iod: J Period	INDIAN Han 01, 20	Commun OSPITA 17 to , 201	AL Dec 31, 20 6 to Dec 31	017 1, 2016		age 260 **	
Bas	seline Pe 	riod: 	Jan 01,	2010	to Dec 31, 	2010 			
Chlamydia Testing									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Female Active Clinical Pts 16-25	211		217			213			
# w/ Chlamydia Screen	20	13.7	5.0	27 2	-13.4	5.0	22 5	-9.7	
# w/ Refusal		0.0			+0.0				
A. Female Active Clinical Pts 16-20	101		113			120			
# w/ Chlamydia Screen # w/ Refusal		10.9			-11.2 +0.0				
B. Female Active Clinical Pts 21-25	110		104			93			
# w/ Chlamydia Screen # w/ Refusal		16.4			-16.3 +0.0			-18.0 +0.0	
Female User Pop Pts 16-25	240		245			241			
# w/ Chlamydia Screen # w/ Refusal		12.1		24.5	-12.4 +0.0		20.7		
A. Female User Pop Pts 16-20	117		129			140			

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Chlamydia Screen # w/ Refusal	11 0	9.4	25 0	19.4	-10.0 +0.0	18 0	12.9	-3.5 +0.0	
B. Female User Pop Pts 21-25	123		116			101			
# w/ Chlamydia Screen # w/ Refusal	18	14.6	35 0	30.2	-15.5 +0.0	32 0	31.7	-17.0 +0.0	

Figure 2-97: Sample Report Chlamydia Testing

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Chlamydia Testing: List of patients with documented Chlamydia screening or refusal, if any. HRN COMMUNITY SEX AGE DOB PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, MELISSA ANNE 000001 COMMUNITY #1 F 16 08/12/01 UP,AC PATIENT2, LISA MARIE 000002 COMMUNITY #1 F 16 10/18/01 04/04/17 Lab test UP,AC 04/04/17 Lab test PATIENT3,CRYSTAL LEE 000003 COMMUNITY #1 F 17 01/16/00 UP,AC 07/25/17 Lab test
PATIENT4,DANIELLE 000004 COMMUNITY #1 F 18 03/22/99 UP,AC 06/01/17 CPT 87490 PATIENT5, KELLYE 000005 COMMUNITY #1 F 19 09/12/98 UP,AC 03/15/17 Refused CPT 86631

Figure 2-98: Sample Patient List, Chlamydia Testing

# 2.9.5 Sexually Transmitted Infection Screening

## **Denominators**

HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

#### **Numerators**

Count only: Number of *Active Clinical patients* who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

Count only: Number of separate key STI incidents for Active Clinical patients during the defined period.

*Number of needed HIV/AIDS screenings* performed from one month prior to the date of first STI diagnosis of each incident through 2 months after.

**Note**: This numerator does *not* include refusals.

Patients with documented HIV screening refusal during the Report Period.

# **Logic Description**

Key STIs are Chlamydia, Gonorrhea, HIV/AIDS, and Syphilis. Key STI diagnoses are defined with the following codes.

STI	ICD and Other Codes
Chlamydia	<b>POV</b> : ICD-9: 079.88, 079.98, 099.41, 099.50-099.59; ICD-10: A56.*, A74.81-A74.9
Gonorrhea	<b>POV</b> : ICD-9: 098.0-098.89; ICD-10: A54.*, O98.2*
HIV/AIDS	<b>POV</b> : ICD-9: 042, 042.0-044.9, 079.53, 795.71, V08; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73
Syphilis	<b>POV</b> : ICD-9: 090.0-093.9, 094.1-097.9; ICD-10: A51.*-A53.*

Logic for Identifying Patients Diagnosed with Key STI:

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

*Logic for Identifying Separate Incidents of Key STIs*:

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs 2 months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

Example of Patient with Multiple Incidents of Single STI:

Visit	Total Incidents
08/01/16: Patient screened for Chlamydia	0
08/08/16: Patient diagnosed with Chlamydia	1
10/15/16: Patient diagnosed with Chlamydia	2

Visit	Total Incidents
10/25/16: Follow-up for Chlamydia	2
11/15/16: Patient diagnosed with Chlamydia	2
03/01/17: Patient diagnosed with Chlamydia	3

## Denominator Logic for Needed Screenings:

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed HIV screening tests denominator, the count will be derived from the number of separate non-HIV STI incidents. HIV screening tests are recommended for the following key STIs: Chlamydia, Gonorrhea, Syphilis.

"Needed" screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

- 1. Only one screening for HIV is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening is needed for HIV/AIDS.
- 2. A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

## Numerator Logic:

To be counted in the numerator, each needed screening in the denominator must have a corresponding laboratory test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through 2 months after the STI incident.

Key STI screening	gs are defin	ed with the	following codes.
-------------------	--------------	-------------	------------------

STI	ICPI COMPS	ICD and Other Codes	LOINC Codes	Taxonomy
HIV/AIDS	86689, 86701– 86703, 87390– 87391, 87534– 87539		Yes	BGP HIV TEST TAX
HIV Refusals	86689, 86701- 86703, 87390- 87391, 87534- 87539			V Lab HIV Test

# **Key Logic Changes from CRS Version 16.1**

1. Added refusal measures and corresponding logic.

# **Patient List Description**

List of patients diagnosed with one or more STIs during the defined time period with related screenings or refusal.

## **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 266  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Sexually Transmitted Infection (STI) Screening (con't)							
	REPORT PERIOD	PREV Y PERIOI		CHG from PREV YR			
Total # of AC Pts w/ Key STI Dx Total # of Male AC	18	2	24	-6	28		-10
Pts w/ Key STI Dx Total # of Female AC Pts w/ Key STI	7		8	-1	12		-5
Dx Total # Key STI Incidents for Active Clinical	11	<u>:</u>	L6	-5	16		-5
Pts	19	2	27	-8	31		-12
HIV/AIDS Screens Needed for Key STIs-AC Pts (GPRA Dev.)	9	:	26		31		
# Needed HIV/AIDS Screens Performed-No Refusals (GPRA							
Dev.) # w/ HIV Screening Refusal	_	0.0	9 34.6			0.0	

HIV/AIDS Screens Needed for Key STIs-Male AC Pts	2		8			12			
# Needed HIV/AIDS Screens Performed-No									
Refusals	1	50.0	3	37.5	+12.5	1	8.3	+41.7	
# w/ HIV Screening Refusal	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
HIV/AIDS Screens Needed for Key STIs-Female AC Pts	7		18			19			
# Needed HIV/AIDS Screens Performed-No									
Refusals	3	42.9	6	33.3	+9.5	9	47.4	-4.5	
# w/ HIV Screening Refusal	0	0.0	0	0.0	+0.0	0	0.0	+0.0	

Figure 2-99: Sample Report Sexually Transmitted Infection (STI) Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Sexually Transmitted Infection (STI) Screening: List of patients diagnosed with one or more STIs during the defined time period with related screenings or refusal. HRN COMMUNITY SEX AGE DOB PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, DIANE 000001 COMMUNITY #1 F 15 02/12/02 UP;AC Visit 1) 02/12/17 POV: HIV 042. 1) N/APATIENT2, LEIGHANN 000002 COMMUNITY #1 F 18 06/18/99 UP;AC Visit 1) 11/02/17 POV: GC 098.89 1) HIV-Y 12/02/17 CPT [87390] PATIENT3, WHITNEY 000003 COMMUNITY #1 F 25 12/15/92 UP; AC Visit 1) 06/17/17 POV: CHL 078.89 1) HIV-N PATIENT4, NANCY 000004 COMMUNITY #1 F 29 08/28/88 UP;AC Visit 1) 03/01/17 POV: CHL 079.88 1) HIV-Contraind Prior DX 04/11/09 POV: HIV [079.53] PATIENT5, JOHN 000005 COMMUNITY #1 M 40 10/22/77 UP; AC Visit 1) 06/15/17 POV: GC 098.89; 2) 07/15/17 POV: HIV 042. 1) HIV-N; 2) N/A PATIENT6, NORMAN 000006 COMMUNITY #1 M 42 07/29/75 UP;AC Visit 1) 10/11/17 POV: CHL 079.98, 10/11/17 POV: GC 098.891) HIV-N

Figure 2-100: Sample Patient List, Sexually Transmitted Infection (STI) Screening

# 2.10 Other Clinical Measures Topics

# 2.10.1 Asthma

#### **Denominators**

All *Active Clinical patients*. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

Patients who have had two asthma-related visits during the Report Period or with persistent asthma. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

#### **Numerators**

Patients who have had two asthma-related visits during the Report Period or with persistent asthma.

Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the Report Period.

Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period.

Patients from Numerator 1 who have a Severity of 1.

Patients from Numerator 1 who have a Severity of 2.

Patients from Numerator 1 who have a Severity of 3.

Patients from Numerator 1 who have a Severity of 4.

Patients from Numerator 1 who have no documented Severity.

## **Logic Description**

Age is calculated at beginning of Report Period.

Asthma visits definition: Diagnosis (POV) ICD-9: 493.\*; ICD-10: J45.\*.

Persistent asthma definition: Any of the following:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\*; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at *any* time before the end of the Report Period
- Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period, or

• Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented *any* time before the end of the Report Period.

Severity definition: Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for ICD-9: 493.\*; ICD-10: J45.\*; SNOMED data set PXRM ASTHMA or in V Asthma.

*Hospitalizations definition*: Service Category H with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

ER and Urgent Care definition: Clinic codes 30 or 80 with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

# **Key Logic Changes from CRS Version 16.1**

- 1. Added SNOMED data set PXRM ASTHMA to asthma diagnosis definition.
- 2. Added SNOMED data set PXRM ASTHMA PERSISTENT to persistent asthma definition.

# **Patient List Description**

List of patients diagnosed with asthma and any asthma-related hospitalizations.

## **Measure Source**

HP 2020 RD-2

## Measure Past Performance and Long-Term Targets

Measure	Target			
HP1998 baseline for hospitalizations for asthma:				
Under 5	45.6 per 10,000			
5-64	12.5 per 10,000			
65 and older	17.7 per 10,000			
HP 2020 goal for hospitalizations for asthma:				
Under 5	18.1 per 10,000			
5-64	8.6 per 10,000			
65 and older	20.3 per 10,000			

```
DU November 25, 2017 Page 289

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Asthma (con't)	DEDODE	90	DDEU VD	0.	and from	DAGE	0.	aua forem	
	REPORT PERIOD	6	PREV YR PERIOD	6	CHG from PREV YR %		6	CHG from BASE %	
Active Clinical Pts	2,100		2,223			2,207			
# w/ Asthma A. Active Clinical	63	3.0	149			127			
Pts <15 B. Active Clinical	16	25.4	43	28.9	-3.5	40	31.5	-6.1	
Pts 15-34 C. Active Clinical	14	22.2	43	28.9	-6.6	34	26.8	-4.5	
Pts 35-64 D. Active Clinical	30	47.6	53	35.6	+12.0	42	33.1	+14.5	
Pts 65+	3	4.8	10	6.7	-1.9	11	8.7	-3.9	
Active Clinical Pts w/ Asthma	63		149			127			
# w/ Asthma									
Hospitalization A. Active Clinical	4	6.3	1	0.7	+5.7	0	0.0	+6.3	
Pts <15 B. Active Clinical	1	25.0	1	100.0	-75.0	0	0.0	+25.0	
Pts 15-34 C. Active Clinical	2	50.0	0	0.0	+50.0	0	0.0	+50.0	
Pts 35-64 D. Active Clinical	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Pts 65+	1	25.0	0	0.0	+25.0	0	0.0	+25.0	
# w/ ER/UC visit A. Active Clinical	4	6.3	4	2.7	+3.7	1	0.8	+5.6	
Pts <15 B. Active Clinical	1	25.0	1	25.0	+0.0	0	0.0	+25.0	
Pts 15-34	1	25.0	0	0.0	+25.0	0	0.0	+25.0	
C. Active Clinical Pts 35-64	2	50.0	3	75.0	-25.0	1	100.0	-50.0	
D. Active Clinical Pts 65+	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# w/ Severity 1	2	3.2	2	1.3		1			
# w/ Severity 2	3	4.8	1			1			
# w/ Severity 3	1	1.6	1	0.7		1	0.8		
<pre># w/ Severity 4 # w/ No Severity</pre>	2 55	3.2 87.3	2 143	1.3		0 124	0.0 97.6	+3.2	
# W/ NO BEVELLEY	33	37.3	113	50.0	0.7	141	57.0	10.5	

Figure 2-101: Sample Report, Asthma

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Asthma: List of patients diagnosed with asthma and any asthma-related hospitalizations/ER/Urgent Care visits.

PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
PATIENT1, GENEVA 000001 COMMUNITY #1 F 47 05/19/70
                           Severity 4 on visit 02/02/17; ER/UC: 11/02/17;
Severity: 4
PATIENT2, JACKIE
                      000002 COMMUNITY #1 F 69 06/07/48
                          Severity 2 on PL; Severity: 2
PATIENT3, PAULINE
                      000003 COMMUNITY #1 F 70 08/11/47
AC
                           2 Dx PCC: 03/01/17, 03/03/17; ER/UC: 10/01/17;
Severity: 1
PATIENT4, WILLIAM R
                      000004 COMMUNITY #1 M 7 06/05/10
                           2 Dx PCC: 05/05/17, 06/06/17; Hospital: 05/05/17;
ER/UC: 06/06/17
PATIENT5, ZACHARY
                      000005 COMMUNITY #1 M 11 02/06/06
                           2 Dx PCC: 03/20/17, 08/08/17
PATIENT42, JOSEPHINE
                      000042 COMMUNITY #2 F 4 06/11/13
                           2 Dx PCC: 07/01/17, 09/19/17; Severity: 2
```

Figure 2-102: Sample Patient List, Asthma

## 2.10.2 Asthma Assessments

#### **Denominators**

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

#### **Numerator**

Patients with asthma management plan during the Report Period.

Patients with severity documented at any time before the end of the Report Period.

Patients with control documented during the Report Period.

Patients who were assessed for number of symptom free days during the Report Period.

Patients with number of symptom free days score of 0 through 5.

Patients with number of symptom free days score of 6 through 12.

Patients with number of symptom free days score of 13 through 14.

Patients who were assessed for number of school/work days missed during the Report Period.

Patients with number of school/work days missed score of 0 through 2.

Patients with number of school/work days missed score of 3 through 7.

Patients with number of school/work days missed score of 8 through 14.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3; SNOMED data set PXRM BGP EMPHYSEMA (Problem List only).

COPD definition: Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8; SNOMED data set PXRM BGP COPD (Problem List only).

## Persistent asthma definition:

- 1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with primary diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
- 2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9:
     493.\*; ICD-10: J45.\*; SNOMED data set PXRM ASTHMA with Severity of
     2, 3 or 4 at any time before the end of the Report Period
  - Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period, or
  - c. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Asthma management plan definition: Patient Education code ASM-SMP.

Severity documented definition:

Meeting any of the following criteria below:

- 1. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at ANY time before the end of the Report Period or
- 2. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the Report Period.

*Control documented definition:* POV ICD-9: 493.\*; ICD-10: J45.\* with Asthma Control recorded in the V Asthma file.

*Number of symptom free days definition:* The most recent V Measurement documented during the Report Period.

*Number of school/work days missed definition:* The most recent V Measurement documented during the Report Period.

## **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to Emphysema definition to look at the Problem List.
- 2. Added SNOMED data set PXRM BGP EMPHYSEMA to emphysema diagnosis definition.
- 3. Added logic to COPD definition to look at the Problem List.
- 4. Added SNOMED data set PXRM BGP COPD to COPD diagnosis definition.
- 5. Added SNOMED data set PXRM ASTHMA to asthma diagnosis definition.
- 6. Added SNOMED data set PXRM ASTHMA PERSISTENT to persistent asthma definition.

## **Patient List Description**

List of asthmatic patients with assessments, if any.

## **Measure Source**

None

## **Measure Past Performance and Long-term Targets**

None

DU November 25, 2017 Page 295  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Asthma Assessments									
	REPORT PERIOD	%	PREV YR PERIOD		CHG from BA			HG from ASE %	
Active Clinical Pts 5+ w/ Persistent Asthma	23		51			40			
# w/ Management Plan # w/ Severity	2	8.7	0	0.0	+8.7	0	0.0	+8.7	
Documented # w/ Control	5	21.7	3	5.9	+15.9	2	5.0	+16.7	

Documented	1	4.3	1	2.0	+2.4	0	0.0	+4.3	
# w/ Symptom Free Days Assessed	4	17.4	0	0.0	+17.4	0	0.0	+17.4	
# w/ Symptom Free Days 0-5	2	8.7	0	0.0	+8.7	0	0.0	+8.7	
# w/ Symptom Free	2	0.7	O	0.0	,	Ü	0.0	10.7	
Days 6-12 # w/ Symptom Free	1	4.3	0	0.0	+4.3	0	0.0	+4.3	
Days 13-14	1	4.3	0	0.0	+4.3	0	0.0	+4.3	
# w/ School/Work Days Missed									
Assessed	3	13.0	0	0.0	+13.0	0	0.0	+13.0	
# w/ School/Work	1	4.3	0	0.0	+4.3	0	0.0	+4.3	
Days Missed 0-2 # w/ School/Work	1	4.3	U	0.0	+4.3	U	0.0	+4.3	
Days Missed 3-7	1	4.3	0	0.0	+4.3	0	0.0	+4.3	
# w/ School/Work Days Missed 8-14	1	4.3	0	0.0	+4.3	0	0.0	+4.3	

Figure 2-103: Sample Report, Asthma Assessments

November 25, 2017 Page 95  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL,  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Asthma Assessments (con't)									
Active Clinical Pts 5+ w/Persistent Asthma 5-14 15-34 35-64 65+									
CURRENT REPORT PERIOD Active Clinical Pts 5+ w/ Persistent Asthma	2	5	16	0					
# w/ Management Plan % w/ Management Plan	0.0	0.0		0					
<pre># w/ Severity Documented % w/ Severity Documented</pre>				0					
% w/ Control Documented % w/ Control Documented	0.0	0.0	1 6.3						
<pre># w/ Symptom Free Days Assessed % w/ Symptom Free Days Assessed</pre>		1 20.0	3 18.8	0					
# w/ Symptom Free Days 0-5 % w/ Symptom Free Days 0-5	0.0	0.0	2 12.5	0					
# w/ Symptom Free Days 6-12 % w/ Symptom Free Days 6-12	0.0	0.0	1 6.3	0 0.0					
<pre># w/ Symptom Free Days 13-14 % w/ Symptom Free Days 13-14</pre>	0.0	1 20.0	0.0	0 0.0					
# w/ School/Work Days									

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

Missed	0	1	2	0	
% w/ School/Work Days Missed	0.0	20.0	12.5	0.0	
# w/ School/Work Days					
Missed 0-2	0	0	1	0	
% w/ School/Work Days	0.0	0.0		2 2	
Missed 0-2	0.0	0.0	6.3	0.0	
# w/ School/Work Days					
Missed 3-7	0	0	1	0	
% w/ School/Work Days					
Missed 3-7	0.0	0.0	6.3	0.0	
# w/ School/Work Days					
Missed 8-14	0	1	0	0	
% w/ School/Work Days					
Missed 8-14	0.0	20.0	0.0	0.0	

Figure 2-104: Sample Age Breakdown Report, Asthma Assessments

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Asthma Assessments: List of asthmatic patients with assessments, if any.
PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR
PATIENT1, GENEVA 000001 COMMUNITY #1 F 47 06/15/70
UP, AC Severity 4 in V Asthma 02/02/17 Severity: 4; Symptom Free Days: 03/01/17 [12];
Days Missed: 03/01/17 [0]
PATIENT2, JACKIE 000002 COMMUNITY #1 F 69 02/25/48
UP,AC Severity >1 on PL for 493.00 Severity: 2
PATIENT3, PAULINE 000003 COMMUNITY #1 F 70 06/22/47
UP,AC Severity >1 on PL for 493.00 Mgmt Plan: 06/01/17; Severity: 3
PATIENT4, WILLIAM R 000004 COMMUNITY #1 M 7 04/11/10
UP,AC 4 meds
PATIENT5, ZACHARY 000005 COMMUNITY #1 M 11 06/18/06
AC Severity 4 in V Asthma 04/04/17 Severity: 4; Control: 05/06/17
PATIENT42, JOSEPHINE 000042 COMMUNITY #2 F 4 07/24/13
AC DX ON HOSP/OR ER ON 05/05/17 DX ON HOSP/OR ER ON 06/03/17 Control: 10/03/17;
Symptom Free Days: 07/01/17 [3]; Days Missed: 07/01/17 [3]
```

Figure 2-105: Sample Patient List, Asthma Assessments

# 2.10.3 Medication Therapy for Persons with Asthma

#### **Denominators**

Active Clinical patients ages 5-50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) who had two or more prescriptions for a LABA during the Report Period. Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

#### **Numerators**

Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting beta2 agonist inhaler during the same 90-day period during the Report Period.

Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

Patients who were prescribed two or more controller therapy medications during the Report Period.

Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period.

Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

*Emphysema definition:* Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3; SNOMED data set PXRM BGP EMPHYSEMA (Problem List only).

COPD definition: Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8; SNOMED data set PXRM BGP COPD (Problem List only).

## Persistent asthma definition:

- 1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with Primary Diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
- 2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\*; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at any time before the end of the Report Period
  - Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period, or
  - c. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

To be included in the Suboptimal Control and Absence of Controller Therapy numerators, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totaling at least four canisters in one 90-day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

#### *Controller Therapy definition:*

At least one non-discontinued prescription of controller therapy medications during the same 90 day period.

Controller therapy medications defined with medication taxonomy BGP PQA CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide, Budesonide-Formoterol, Ciclesonide, Flunisolide, Fluticasone, Fluticasone-Salmeterol, Formoterol, Mometasone, Mometasone-Formoterol, Montelukast, Salmeterol, Theophylline, Zafirlukast, Zileuton). Medications must not have a comment of RETURNED TO STOCK.

Inhaled corticosteroid medications defined with medication taxonomy BGP PQA ASTHMA INHALED STEROIDS. (Medications are: Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Mometasone, Triamcinolone, Budesonide-formoterol, Mometasone-formoterol.) Medications must not have a comment of RETURNED TO STOCK.

Long-Acting Beta-2 Agonist (LABA) medications defined with medication taxonomy BGP ASTHMA LABA MEDS. (Medications are: Formoterol, Salmeterol, Fluticasone-salmeterol, Budesonide-formoterol, Mometasone-formoterol) Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to Emphysema definition to look at the Problem List.
- 2. Added SNOMED data set PXRM BGP EMPHYSEMA to emphysema diagnosis definition.
- 3. Added logic to COPD definition to look at the Problem List.
- 4. Added SNOMED data set PXRM BGP COPD to COPD diagnosis definition.
- 5. Added SNOMED data set PXRM ASTHMA to asthma diagnosis definition.
- 6. Added SNOMED data set PXRM ASTHMA PERSISTENT to persistent asthma definition.

# **Patient List Description**

List of patients with asthma with suboptimal control and controller therapy, if any.

#### **Measure Source**

PQA (Pharmacy Quality Alliance)

## **Measure Past Performance and Long-term Targets**

None

Rep Previou	November 25, 2017 Page 299  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Medication Therapy fo			CHG from BASE PREV YR % PERIOD	% CHG from BASE %					
Active Clinical Pts 5-50 w/ Asthma	16	40	29						
<pre># w/ Suboptimal   Control # w/ Absence of</pre>	3 18.8	1 2.5	+16.3 0	0.0 +18.8					

Controller Therapy	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Active Clinical Pts 5+ w/ Persistent Asthma	23		51			40			
<pre># w/ 2+ Controller Rx # w/ 2+ Inhaled Steroid Rx</pre>		47.8 8.7	13 5		+22.3		25.0	+22.8	
Active Clinical Pts 5+ w/ persistent asthma and LABA Rx	5		6			7			
# w/o 2+ Inhaled Steroid Rx	5	100.0	6	100.0	+0.0	7	100.0	+0.0	

Figure 2-106: Sample Report, Medication Therapy for Persons with Asthma

November 25, 2017 Page 95  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010										
Medication Therapy for Persons with Asthma (con't)										
Active Clinical Pts 5+  w/ Persistent Asthma  5-14 15-34 35-64 65+  CURRENT REPORT PERIOD										
Active Clinical Pts 5+ w/ Persistent Asthma	2	5	16	0						
<pre># w/ 2+ Controller Rx % w/ 2+ Controller Rx</pre>	0	1 20 0	10 62 5	0						
% W/ Z+ Concluded KA	0.0	20.0	02.5	0.0						
# w/ 2+ Inhaled Steroid Rx % w/ 2+ Inhaled Steroid Rx		0.0								
PREVIOUS REPORT PERIOD Active Clinical Pts 5+										
w/ Persistent Asthma	6	16	28	1						
# w/ 2+ Controller Rx % w/ 2+ Controller Rx	1 16.7	4 25.0	8 28.6	0.0						
<pre># w/ 2+ Inhaled Steroid Rx % w/ 2+ Inhaled Steroid Rx</pre>	1 16.7	1 6.3	3 10.7	0.0						
CHANGE FROM PREVIOUS YR % # w/ 2+ Controller Rx # w/ 2+ Inhaled	-16.7	-5.0	+33.9	+0.0						
Steroid Rx	-16.7	-25.0	-16.1	+0.0						

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

BASELINE REPORT PERIOD Active Clinical Pts 5+ w/ Persistent Asthma	3	17	16	3	
# w/ 2+ Controller Rx % w/ 2+ Controller Rx	0.0	3 17.6	6 37.5	1 33.3	
# w/ 2+ Inhaled Steroid Rx % w/ 2+ Inhaled Steroid Rx	0.0	0.0	1 6.3	0.0	
CHANGE FROM BASELINE YR % # w/ 2+ Controller Rx # w/ 2+ Inhaled	+0.0	+2.4	+25.0	-33.3	
Steroid Rx	+0.0	-17.6	-25.0	-33.3	

Figure 2-107: Sample Age Breakdown Report, Medication Therapy for Persons with Asthma

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Medication Therapy for Persons with Asthma: List of patients with asthma with asthma medications, if any. PATIENT NAME PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR \_\_\_\_\_\_ PATIENT1, GWEN 000001 COMMUNITY #1 F 5 10/10/12 AC, Severity 4 in V Asthma 02/02/17 PATIENT2, ALICE 000002 COMMUNITY #1 F 6 06/17/11 AC, Severity >1 on PL for 493.00 SABA: 06/15/17 ALBUTEROL 90MCG/INHALATION MDI(4) PATIENT3, GENEVA 000003 COMMUNITY #1 F 47 05/05/70 AC, Severity 2 in V Asthma 03/03/17 2+ CONT: 06/01/17 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/17 FLUTICASONE PROPIONATE 110MCG INHALER; 2+ STEROID: 06/01/17 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/17 FLUTICASONE PROPIONATE 110MCG TNHALER PATIENT22, MELANIE 000022 COMMUNITY #1 F 47 10/02/70 AC, Severity >1 on PL for 493.00 PATIENT27, RANDALL 000027 COMMUNITY #1 M 6 04/17/11 AC, Severity >1 on PL for 493.00 LABA2+ CONT: 03/03/17 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/17 MOMETASONE/FORMOTEROL 100/5MCG INH; 2+ STEROID: 03/03/17 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/17 MOMETASONE/FORMOTEROL 100/5MCG INH

Figure 2-108: Sample Patient List, Medication Therapy for Persons with Asthma

# 2.10.4 Proportion of Days Covered by Medication Therapy Denominators

Active Clinical patients ages 18 and older who had two or more prescriptions for beta-blockers during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for RAS Antagonists and no documented history of ESRD or one or more prescriptions for ARB/Neprilysin inhibitor combination medications during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for calcium channel blockers (CCB) during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for biguanides and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for sulfonylureas and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for thiazolidinediones and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for DiPeptidyl Peptidase (DPP)-IV Inhibitors and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for Diabetes All Class medications and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for statins during the Report Period

Active Clinical patients ages 18 and older who had two or more prescriptions for non-warfarin oral anticoagulants during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for antiretroviral agents during the Report Period.

#### **Numerators**

Patients with proportion of days covered (PDC) greater than or equal to (>=)80% during the Report Period.

Patients with a gap in medication therapy greater than or equal to (>=)30 days.

Patients with proportion of days covered (PDC) greater than or equal to (>=)90% during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the report period.

To be included in the denominator, patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

For the Non-warfarin anticoagulants measures, the two unique dates of service must be at least 180 days apart and the patient must have received greater than 60 days' supply of the medication during the Report Period. Patients who received one or more prescriptions for warfarin, low molecular weight heparin (LMWH), heparin or an SC Factor Xa inhibitor (defined by medication taxonomy BGP PQA WARFARIN) will be excluded from the denominator.

The Index Prescription Start Date is the date when the medication was first dispensed within the Report Period. For all measures except Non-warfarin anticoagulants, this date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

The medications in the measures are defined with medication taxonomies:

- BGP PQA BETA BLOCKER MEDS: Beta-blocker medications (Acebutolol HCL, Atenolol, Betaxolol HCL, Bisoprolol fumarate, Carvedilol, Labetalol HCL, Metoprolol succinate, Metoprolol tartrate, Nadolol, Nebivolol HCL, Penbutolol sulfate, Pindolol, Propranolol HCL, Timolol maleate); Beta-blocker combination products (Atenolol-chlorthalidone, Bisoprolol-HCTZ, Nadolol-bendroflumethiazide, Metoprolol-HCTZ, Propranolol-HCTZ)
- BGP PQA RASA MEDS: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril); Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, Fosinopril-HCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Quinapril-HCTZ, Trandolapril-verapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ, Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipine-HCTZ, Valsartan-HCTZ, Telmisartan-amlodipine, Telmisartan-HCTZ, Valsartan-HCTZ, Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Aliskiren-valsartan)

- BGP PQA CCB MEDS: Calcium-Channel Blocker medications (Amlodipine besylate, Diltiazem HCL, Felodipine, Isradipine, Nicardipine HCL, Nifedipine (long acting only), Verapamil HCL, Nisoldipine); CCB Combination Products (Amlodipine besylate-benazepril HCL, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Akiskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Telmisartan-amlodipine, Amlodipine-olmesartan, Trandolapril-verapamil HCL, Amlodipine-atorvastatin, Olmesartan-amlodipine-HCTZ)
- BGP PQA BIGUANIDE MEDS: Biguanides (Metformin); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-Metformin, Canagliflozin-Metformin)
- BGP PQA SULFONYLUREA MEDS: Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride)
- BGP PQA THIAZOLIDINEDIONE MEDS: Thiazolidinediones (Pioglitazone, Rosiglitazone); Combination Products (Rosiglitazone-metformin, Pioglitazonemetformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride, Alogliptinpioglitazone)
- BGP PQA DPP IV MEDS: DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptin-pioglitazone, Linagliptin-empagliflozin)
- BGP PQA DIABETES ALL CLASS: Biguanide medications (see list above); Sulfonylurea medications (see list above); Thiazolidinedione medications (see list above); DPP-IV Inhibitor medications (see list above); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-Metformin, Linagliptin-empagliflozin, Canagliflozin-Metformin)
- BGP PQA STATIN MEDS: Statins (Lovastatin, Rosuvastatin, Fluvastatin, Atorvastatin, Pravastatin, Pitavastatin); Combination Products (Niacin-lovastatin, Atorvastatin-amlodipine, Niacin-simvastatin, Sitagliptin-simvastatin, Ezetimibe-simvastatin, Ezetimibe-atorvastatin)
- BGP PQA NON-WARFARIN ANTICOAG: (Apixaban, Dabigatran, Rivaroxaban, Edoxaban)
- BGP PQA WARFARIN: (Warfarin, Dalteparin, Fondaparinux, Enoxaparin, Heparin, Tinzaparin)

- BGP PQA ANTIRETROVIRAL MEDS: Single Agents (Enfuvirtide, Maraviroc, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Dolutegravir, Raltegravir, Delavirdine, Efavirenz, Etravirine, Nevirapine, Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine, Rilpivirine, Elvitegravir); Combination Agents (Lopinavir-Ritonavir, Lamivudine-zidovudine, Darunavir-Cobicistat, Atazanavir-Cobicistat, Abacavir-Lamivudine-Zidovudine, Efavirenz-emtricitabine-Tenofovir, Emtricitabine-tenofovir, Abacavir-lamivudine, Emtricitabine-rilpivirine-Tenofovir, Elvitegravir-cobicistat-emtricitabine-tenofovir, Abacavir-dolutegravir-lamivudine)
- BGP PQA ARB NEPRILYSIN INHIB: ARB/Neprilysin Inhibitor Combinations (Sacubitril/Valsartan)

ESRD diagnosis/treatment definition: Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only); (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

For each PDC numerator:

Proportion of days covered = # of days the patient was covered by at least one drug in the class / # of days in the patient's measurement period.

#### *Measurement Period definition:*

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

**Note**: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4.

## **Example of Proportion of Days Covered:**

- Report Period: January 1 through December 31, 2017
- 1st Rx is Index Rx Start Date: 3/1/17, Days' Supply=90
- Rx covers patient through 5/29/17
- 2nd Rx: 5/26/17, Days' Supply=90
- Rx covers patient through 8/27/17
- 3rd Rx: 9/11/17, Days' Supply=180
- Gap = (9/11/17 8/27/17) = 15 days
- Rx covers patient through 3/8/18
- Patient's measurement period: 3/1/17 through 12/31/17 = 306 Days
- Days patient was covered: 3/1/17 through 8/27/17 + 9/11/17 through 12/31/17 = 292 Days
- PDC = 292 / 306 = 95%

## For each Gap numerator:

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days' supply between consecutive medication fills.

#### Example of Medication Gap greater than or equal to (>=) 30 Days:

- Report Period: January 1 through December 31, 2017
- 1st Rx: 4/1/17, Days' Supply=30
- Rx covers patient through 4/30/17
- 2nd Rx: 7/1/17, Days' Supply=90
- Gap #1 = (7/1/17 4/30/17) = 61 days
- Rx covers patient through 9/28/17
- 3rd Rx: 10/1/17, Days' Supply=90
- Gap #2 = (10/1/17 9/28/17) = 2 days
- Rx covers patient through 12/29/17
- Gap #1 greater than or equal to (>=) 30 days, therefore patient will be included in the numerator for that medication.

## **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to RASA denominator to exclude patients with one or more prescriptions for ARB/Neprilysin inhibitor combination medications during the Report Period.
- 2. Added logic to ESRD definition to look at the Problem List.
- 3. Added SNOMED data set PXRM END STAGE RENAL DISEASE to ESRD definition (for Problem List only).

## **Patient List Description**

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

### **Measure Source**

PQA (Pharmacy Quality Alliance)

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 314  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Proportion of Days	Covered by Med	ication Th	erapy						
	REPORT % PERIOD			CHG from PREV YR %			CHG from BASE %		
Active Clinical Pts w/ Beta-Blockers	74	87			86				
# w/ PDC >=80%	1 1.4	40	46.0	-44.6	24	27.9	-26.6		
# w/ Gap >=30 days									
Active Clinical Pts w/ RAS									
Antagonists	218	326			327				
# w/ PDC >=80% # w/ Gap >=30 days				-30.5 +36.8			-26.1 +32.4		
Active Clinical Pts w/ CCBs	34	49			48				

# w/ PDC >=80% # w/ Gap >=30 days	1 2.9 34 100.0	15 30.6 31 63.3		2 25.0 5 72.9	
Active Clinical Pts w/ Biguanides	137	237	24	9	
# w/ PDC >=80% # w/ Gap >=30 days	1 0.7 137 100.0	59 24.9 168 70.9		4 17.7 4 77.9	-16.9 +22.1
Active Clinical Pts w/				_	
Sulfonylureas	106	160	17	b	
# w/ PDC >=80% # w/ Gap >=30 days	1 0.9 106 100.0	55 34.4 96 60.0	-33.4 3 +40.0 13	7 21.1 3 76.0	-20.2 +24.0
Active Clinical Pts w/	2	0	1.0	7	
Thiazolidinediones	3	0	12	/	
# w/ PDC >=80% # w/ Gap >=30 days	0 0.0 3 100.0	0 0.0 0 0.0		5 27.6 1 63.8	
Active Clinical Pts w/ DPP-IV Inhibitors	3	90		0	
# w/ PDC >=80% # w/ Gap >=30 days	0 0.0 3 100.0	2 2.2 88 97.8		0.0	+0.0 +100.0
Active Clinical Pts w/ Diabetes All Class	191	273	29	0	
				-	
# w/ PDC >=80% # w/ Gap >=30 days	4 2.1 188 98.4	149 54.6 122 44.7	-52.5 13 +53.7 15		
Active Clinical Pts w/ Statins	106	156	18	1	
# w/ PDC >=80% # w/ Gap >=30 days	2 1.9 105 99.1	56 35.9 93 59.6	-34.0 4 +39.4 12		-24.6 +31.1
Active Clinical Pts w/ Non-Warfarin Oral					
Anticoagulants	1	0		0	
# w/ PDC >=80% # w/ Gap >=30 days	1 100.0 1 100.0	0 0.0 0 0.0		0.0	+100.0 +100.0
Active Clinical Pts w/ Antiretroviral					
Agents	3	1		1	
# w/ PDC >=90%	2 66.7	1 100.0	-33.3	1 100.0	-33.3

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

Figure 2-109: Sample Report, Proportion of Days Covered by Medication Therapy

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Proportion of Days Covered by Medication Therapy: List of patients 18 and
older prescribed medication therapy medication with proportion of days
covered and gap days.
PATIENT NAME
                     HRN COMMUNITY SEX AGE DOB
DENOMINATOR
                            NUMERATOR
Patient75, PAULA KAY 000075 COMMUNITY #1 F 34 11/12/83
                            CCB: IXRD: 03/24/17 [282] Days=228 >80 GAP=52
AC CCB: IXRD: 03/24/17 [282] Days=2.
Patient76,CRSCT 000076 COMMUNITY #1 F 36 01/16/81
                            CCB: IXRD: 06/01/17 [213] Days=180 >80 GAP=31
AC
Patient77, CRSAC 000077 COMMUNITY #1 F 44 03/03/73
                       RASA: IXRD: 06/05/17 [209] Days=60 <80 GAP=118
Patient78, DEBORA ELLEN 000078 COMMUNITY #1 F 45 05/05/72
                        BB: IXRD: 07/23/17 [161] Days=126 <80; RASA: IXRD:
01/29/17 [336] Days=267 <80 GAP=31; BIG: IXRD: 01/29/17 [336] Days=272 >80
Patient79,STELLA LYNN 000079 COMMUNITY #1 F 46 06/22/71
                           BB: IXRD: 01/21/17 [344] Days=299 >80 GAP=38; CCB:
IXRD: 01/21/17 [344] Days=299 >80 GAP=38
Patient80, TARA MARIE 000080 COMMUNITY \#1 F 51 11/08/66
                      BB: IXRD: 08/25/17 [128] Days=56 <80 GAP=70; RASA:
IXRD: 01/16/17 [350] Days=314 >80; CCB: IXRD: 01/16/17 [350] Days=218 <80 GAP=103
Patient81, CRSNK 000081 COMMUNITY #1 F 51 11/23/66
                            SULF: IXRD: 09/01/17 [121] Days=120 >80
```

Figure 2-110: Sample Patient List, Proportion of Days Covered by Medication Therapy

# 2.10.5 Primary Medication Non-adherence

#### **Denominator**

Number of e-prescriptions for newly initiated drug therapy for chronic medications for *Active Clinical patients* ages 18 and older.

#### Numerator

Number of medications returned to stock within 30 days.

## **Logic Description**

Age is calculated at beginning of the Report Period.

To be included in the denominator, the e-prescription must be for a chronic medication during the Report Period.

**Denominator Exclusions** 

- 1. Any prescription where there is a prescription dispensing record in the preceding 180 days for the same drug.
- 2. Any duplicate medications, defined as any medication that has been e-prescribed twice in a 30-day period with no prescription fill in between the e-prescriptions.
- 3. Any prescription sent to an outside pharmacy, as it is not possible to know if the medication was returned to stock.

Chronic medications are defined with medication taxonomies:

- BGP PQA ASTHMA INHALED STEROIDS: (Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Mometasone, Budesonide-formoterol, Mometasone-formoterol)
- BGP PQA COPD: (Tiotropium, Indacaterol, Olodaterol, Umeclidinium, Ipratropium-albuterol, Roflumilast, Fluticasone-vilanterol, Ipratropium, Aclidinium, Umeclidinium-vilanterol, Tiotropium-olodaterol)
- BGP POA DIABETES ALL CLASS: Biguanides (Metformin); Biguanide Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-Metformin, Canagliflozin-Metformin); Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Sulfonylurea Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride); Thiazolidinediones (Pioglitazone, Rosiglitazone); Thiazolidinedione Combination Products (Rosiglitazone-metformin, Pioglitazone-metformin, Rosiglitazoneglimepiride, Pioglitazone-glimepiride, Alogliptin-pioglitazone); DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); DPP-IV Inhibitor Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptinpioglitazone, Linagliptin-empagliflozin); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-Metformin, Linagliptin-empagliflozin, Canagliflozin-Metformin)

- BGP PQA RASA MEDS: Angiotensin Converting Enzyme Inhibitors
   (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril,
   Quinapril, Ramipril, Trandolopril); Antihypertensive Combinations (Amlodipinebenazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, FosinoprilHCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Quinapril-HCTZ, Trandolaprilverapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan,
   Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive
   Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-valsartanHCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ,
   Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipineHCTZ, Olmesartan-HCTZ, Telmisartan-amlodipine, Telmisartan-HCTZ,
   Valsartan-HCTZ); Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor
   Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ,
   Aliskiren-HCTZ, Aliskiren-valsartan)
- BGP PQA STATIN MEDS: Statins (Lovastatin, Rosuvastatin, Fluvastatin, Atorvastatin, Pravastatin, Pitavastatin); Combination Products (Niacin-lovastatin, Atorvastatin-amlodipine, Niacin-simvastatin, Sitagliptin-simvastatin, Ezetimibe-simvastatin, Ezetimibe-atorvastatin)

To be included in the numerator, the e-prescription medication must have a comment of RETURNED TO STOCK within 30 days of the prescription date (i.e., visit date).

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.

## **Measure Source**

PQA (Pharmacy Quality Alliance)

## **Measure Past Performance and Long-Term Targets**

None

```
DU November 25, 2017 Page 316

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Primary Medication Non-adherence (con't)									
	REPORT PERIOD	%	PREV YR PERIOD		CHG from BAS PREV YR % PER			CHG from BASE %	
# e-Prescriptions for AC 18+	198		514			600			
# Med Returned to Stock	8	4.0	35	6.8	-2.8	25	4.2	-0.1	

Figure 2-111: Sample Report, Primary Medication Non-adherence

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Primary Medication Non-adherence: List of patients 18 and older with an
e-prescription for chronic medications, with returned to stock, if any.
                     HRN
PATIENT NAME
                            COMMUNITY
                                        SEX AGE DOB
DENOMINATOR
                           NUMERATOR
PATIENT1, ANDREA MARY 000001 COMMUNITY #1 F 33 08/02/84
AC 1) 03/25/17 IPRATROPRIUM BR / ALBUTEROL SO4 INH1) 03/25/17 IPRATROPRIUM BR /
ALBUTEROL SO4 INH-RTS
PATIENT2, VIRGINIA A 000002 COMMUNITY #1 F 34 06/29/83
AC 1) 03/25/17 ROSIGLITAZONE 4MG TAB
PATIENT3, MICHAELA 000003 COMMUNITY #1 F 37 04/15/80
AC 1) 03/25/17 CAPTOPRIL 50MG TABS
PATIENT4, DIANE LOUISE 000006 COMMUNITY #1 F 41 01/09/76
AC 1) 04/09/17 IPRATROPRIUM BR / ALBUTEROL SO4 INH; 2) 04/09/17 CAPTOPRIL 50MG
TABS1) 04/09/17 IPRATROPRIUM BR / ALBUTEROL SO4 INH-RTS
PATIENT5, ALYSHA 000008 COMMUNITY #1 F 55 09/28/62
AC 1) 08/14/17 ROSIGLITAZONE 4MG TAB
PATIENT6, SHELLY 000009 COMMUNITY #1 F 62 04/19/55
AC 1) 06/25/17 CAPTOPRIL 50MG TABS
```

Figure 2-112: Sample Patient List, Primary Medication Non-adherence

# 2.10.6 Medications Education

#### **Denominators**

Active Clinical patients with medications dispensed at their facility during the Report Period.

All *User Population patients* with medications dispensed at their facility during the Report Period.

#### Numerator

Patients who were provided patient education about their medications in any location.

## **Logic Description**

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility. The purpose of this definition is to ensure that sites are not being held responsible for educating patients about medications received elsewhere that may be recorded in RPMS. CRS assumes that the appropriate facility is the one the user has logged onto to run the report.

**Note:** If a site's system identifier, i.e., ASUFAC code, has changed during the period between the Baseline start date and the Current Year end date, due to compacting/contracting or other reasons, your report may display zeros (0s) or very low counts for some time periods.

CRS uses the following patient education codes to define the numerator:

Medication Education	Any Patient Education code containing "M-" or "-M" (medication)
	or
	DMC-IN (Diabetes Medicine-Insulin)
	FP-DPO (Family Planning–Depot Medroxyprogesterone
	Injections
	FP-OC (Family Planning-Oral Contraceptives)
	FP-TD (Family Planning-Transdermal (Patch))
	*-NEB (*Nebulizer)
	*-MDI (*Metered Dose Inhalers)

# **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients receiving medications with medication education, if any.

## **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

Measure	Target
IHS 2020 Goal	75.0%

DU November 25, 2017 Page 316
-------------------------------

*** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Medications Educat	ion (con't	)							
					CHG from PREV YR %				
Active Clinical Pts Receiving Medications	139		209			195			
# Receiving Medication Educ	85	61.2	174	83.3	-22.1	154	79.0	-17.8	
User Pop Pts Receiving Medications	151		241			216			
# Receiving Medication Educ	91	60.3	183	75.9	-15.7	163	75.5	-15.2	

Figure 2-113: Sample Report, Medications Education

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Medications Education: List of patients receiving medications with med education or refusal, if any COMMUNITY SEX AGE DOB PATIENT NAME HRN DENOMINATOR NUMERATOR PATIENT1, ANDREA MARY 000001 COMMUNITY #1 F 0 05/15/17 UP.AC PATIENT2, VIRGINIA A 000002 COMMUNITY #1 F 0 05/23/17 UP 08/06/17 HTN-M 08/06/17 HTN-M PATIENT3, MICHAELA 000003 COMMUNITY #1 F 0 10/22/17
UP 03/10/17 M-I
PATIENT4, MISTY 000004 COMMUNITY #1 F 5 04/18/12
UP, AC 05/16/17 M-DI 05/16/17 M-DI PATIENT5, RITA ANN 000005 COMMUNITY #1 F 15 06/14/02 UP.AC UP,AC UP,AC 07/05/17 M-I PATIENT6, DIANE LOUISE 000006 COMMUNITY #1 F 15 06/23/02 08/21/17 M-I 000007 COMMUNITY #1 F 15 08/15/02 PATIENT7, ALICIA UP,AC PATIENT8, ALYSHA 000008 COMMUNITY #1 F 16 05/07/01 UP,AC PATIENT9, SHELLY 000009 COMMUNITY #1 F 18 09/17/99 UP,AC 03/12/17 PP-M

Figure 2-114: Sample Patient List, Medications Education

# 2.10.7 Medication Therapy Management Services

#### **Denominators**

Active Clinical patients greater than or equal to (=>)18 with medications dispensed at their facility during the Report Period.

#### Numerator

Patients who received medication therapy management (MTM) during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the report period.

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility.

*Medication Therapy Management (MTM) definition*: 1) CPT 99605 through 99607 or 2) Clinic codes: D1, D2, D5.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients greater than or equal to (>=) 18 receiving medications with medication therapy management, if any.

#### **Measure Source**

None

## **Measure Past Performance and Long-Term Targets**

None

```
DU November 25, 2017 Page 316

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Medications Therapy Management Services (con't)
```

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts 18+ Receiving Medications	121		158			144			
# w/ MTM	2	1.7	5	3.2	-1.5	3	2.1	-0.4	

Figure 2-115: Sample Report, Medications Therapy Management Services

Figure 2-116: Sample Patient List, Medications Therapy Management Services

# 2.10.8 Public Health Nursing

### **Denominator**

*User Population patients.* 

#### **Numerators**

For User Population only, the number of patients in the denominator served by Public Health Nurses (PHNs) in any setting, including Home.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting.

For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME Setting.

Count only: *Number of visits to User Population patients* by PHNs in any setting, including Home

- Number of visits to patients ages 0 to 28 days (Neonate) in any setting.
- Number of visits to patients ages 29 days to 12 months (infants) in any setting.
- Number of visits to patients ages 1 through 64 years in any setting
- Number of visits to patients ages 65 and older (Elders) in any setting
- Number of PHN driver/interpreter (Provider Code 91) visits

Count only: Number of visits to User Population patients by PHNs in Home setting

- Number of Home visits to patients age 0 to 28 days (Neonate)
- Number of Home visits to patients age 29 days to 12 months (Infants)
- Number of Home visits to patients ages 1 through 64 years
- Number of Home visits to patients aged 65 and over (Elders).
- Number of PHN driver/interpreter (Provider Code 91) visits in a HOME setting.

## **Logic Description**

PHN visit is defined as any visit with primary or Secondary Provider Code 13 or 91. Home visit defined as: (1) Clinic 11 and a primary or Secondary Provider Code 13 or 91 or (2) Location Home (as defined in Site Parameters) and a primary or Secondary Provider Code 13 or 91.

## **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of patients with PHN visits documented.

Numerator codes in patient list: All PHN = Number of PHN visits in any setting; Home = Number of PHN visits in home setting; Driver All = Number of PHN driver/interpreter visits in any setting; Driver Home = Number of PHN driver/interpreter visits in home setting.

## **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

Performance	All PHN visits	PHN Home Visits
IHS FY 2005 Performance	438,376	Not Reported
IHS FY 2004 Performance	423,379	192,121
IHS FY 2003 Performance	359,089	160,650
IHS FY 2002 Performance	343,874	156,263

DU *** IHS 2017	Selected	Measu		Commu		fied Rep		age 317 **
Re	port Per		INDIAN Han 01, 20		аL Dec 31, 20	017		
Previo	us Year	Period	l: Jan 01	, 201	6 to Dec 31	1, 2016		
Bas	seline Pe	riod:	Jan 01,	2010	to Dec 31,	2010		
Public Health Nursin	ıg (con't	)						
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop Pts	2,466		2,561			2,516		
# Served by PHNs in Any Setting	270	15 /	002	20 2	22.0	004	39.5	-24.1
# Served by PHN Drivers/Interpreter		13.4	902	30.3	-23.0	994	39.3	-24.1
in Any Setting	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# Served by PHNs in a Home Setting	162	6.6	458	17.9	-11.3	515	20.5	-13.9
# Served by PHN Drivers/Interpreter	`S							
in a Home Setting Total # PHN Visits	0	0.0	0	0.0	+0.0	0	0.0	+0.0
- Any Setting	857		3,947		-3,090	2,613		-1,756
A. Ages 0-28 days	0		0		+0	0		+0
B. Ages 29 days-12 months	21		62		-41	21		+0
C. Ages 1-64 years	694		3,340			5 2,254		-1,560
D. Ages 65+	142		545		•	338		-196
E.								
Driver/Interpreter								
Visits - Any	0		0		. 0	0		. 0
Setting	U		0		+0	0		+0
Total # PHN Visits								
- Home Setting	346		1,353			7 1,181		-835
A. Ages 0-28 days	0		0		+0	0		+0
B. Ages 29 days-12 months	1		1.0		-18	14		-13
C. Ages 1-64 years	1 254		19 1,030		-18 -776			-13 -682
D. Ages 65+	25 <del>4</del> 91		304		-213			-140
E.	7.		501		213	201		110
Driver/Interpreter								
Visits - Home								

Setting	0	0	+0	0	+0	
---------	---	---	----	---	----	--

Figure 2-117: Sample Report, Public Health Nursing

Figure 2-118: Sample Patient List, Public Health Nursing

# 2.10.9 Breastfeeding Rates

## **GPRA Measure Description**

During GPRA Year 2017, achieve the target rate of 36.4% for the proportion of 2-month olds who are mostly or exclusively breastfeeding.

#### **Denominators**

Active Clinical patients who are 30 to 394 days old

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 2 months (45 to 89 days) (GPRA Denominator)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 6 months (165 to 209 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 9 months (255 to 299 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 1 year (350 to 394 days)

*User Population patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of 2 *months* (45 to 89 days)

#### **Numerators**

Patients who were screened for infant feeding choice at least once

Patients who were screened for infant feeding choice at the age of 2 months (45 to 89 days)

Patients who were screened for infant feeding choice at the age of 6 months (165 to 209 days)

Patients who were screened for infant feeding choice at the age of 9 months (255 to 299 days)

Patients who were screened for infant feeding choice at the age of 1 year (350 to 394 days)

Patients who, at the age of 2 months (45 to 89 days), were either exclusively or mostly breastfed (GPRA Numerator)

Patients who, at the age of 6 months (165 to 209 days), were either exclusively or mostly breastfed

Patients who, at the age of 9 months (255–299 days), were either exclusively or mostly breastfed

Patients who, at the age of 1 year (350 to 394 days), were either exclusively or mostly breastfed

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period. Therefore, this measure may include patients up to 25 months old if they were within the eligible age range on the first day of the report period, and will not include any patients that were born after the first day of the report period. Patients born after the first day of the report period will be included in the following report period.

Infant feeding choice definition: The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as half breastfed and half formula and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of 2 months (i.e., 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days value of mostly breastfed will be used. The other exact ages are 180 days for 6 months, 270 days for 9 months, and 365 days for 1 year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at 6 months and was exclusively breastfeeding but was not screened at 2 months, then the patient will only be counted in the 6 months numerator.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 30 to 394 days old, with infant feeding choice value, if any.

Note: "DO" represents "Days Old."

#### **Measure Source**

HP 2020, MICH-21.4 Exclusive breastfeeding-through 3 months, MICH-21.5 Exclusive breastfeeding-through 6 months.

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2016 Performance	35.2%
IHS FY 2015 Performance	35.7%
IHS FY 2014 Performance	35.1%
IHS FY 2013 Performance	29.0%
IHS FY 2012 Performance	30.3%
IHS FY 2011 Performance	26.7%
IHS FY 2010 Performance	33%
IHS FY 2008 Performance	28%
HP 2020 goal for breastfeeding through 3 months of age	44.3%
HP 2020 goal for breastfeeding through 6 months of age	23.7%

```
DU
                             November 25, 2017
                                                                     Page 321
       *** IHS 2017 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Breastfeeding Rates
                    REPORT
                                  PREV YR
                                             % CHG from BASE
                                                                    % CHG from
                    PERIOD
                                  PERIOD
                                                PREV YR % PERIOD
                                                                       BASE %
```

Active Clinical Pts 30-394 days	38		54			48			
# w/ Infant Feeding Choice Screening	17	44.7	14	25.9	+18.8	0	0.0	+44.7	
# w/ Screening @ 2	2	5.3		0.0	+5.3		0.0	+5.3	
mos # w/ Screening @ 6			0			0			
mos # w/ Screening @ 9	5	13.2	2	3.7	+9.5	0	0.0	+13.2	
mos # w/ Screening @ 1	3	7.9	3	5.6	+2.3	0	0.0	+7.9	
yr	2	5.3	1	1.9	+3.4	0	0.0	+5.3	
AC Pts 30-394 days Screened @ 2 mos									
(GPRA)	2		0			0			
# @ 2 mos Exclusively/Mostly Breastfed (GPRA)	2 1	100.0	0	0.0	+100.0	0	0.0	+100.0	
AC Pts 30-394 days Screened @ 6 mos	5		2			0			
# @ 6 mos Exclusively/Mostly Breastfed	1	20.0	1	50.0	-30.0	0	0.0	+20.0	
AC Pts 30-394 days Screened @ 9 mos	3		3			0			
# @ 9 mos Exclusively/Mostly Breastfed	0	0.0	2	66.7	-66.7	0	0.0	+0.0	
AC Pts 30-394 days Screened @ 1 yr	2		1			0			
# @ 1 year Exclusively/Mostly Breastfed	1	50.0	0	0.0	+50.0	0	0.0	+50.0	
UP Pts 30-394 days Screened @ 2 mos	3		0			0			
# @ 2 mos Exclusively/Mostly Breastfed	3 [	100.0	0	0.0	+100.0	0	0.0	+100.0	

Figure 2-119: Sample Report, Breastfeeding Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
Breastfeeding Rates: List of patients 30-394 days old, with infant feeding choice value, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1, AMANDA DEBRA 000001 COMMUNITY #1 F 0 01/07/17
AC SCIR: 33 DO, 02/09/17 MOSTLY BREASTFEEDING
PATIENT2, LEROY JAMES 000002 COMMUNITY #1 M 1 12/03/16
AC SCIR: 2 MOS: 48 DO, 01/20/17 EXCLUSIVE BREASTFEEDING;
6 MOS: 178 DO, 05/30/17 EXCLUSIVE BREASTFEEDING; 9 MOS: 276 DO, 09/05/17 EXCLUSIVE
BREASTFEEDING; 1 YR: 382 DO, 12/20/17 MOSTLY BREASTFEEDING
PATIENT3, TERRY SCOTT 000003 COMMUNITY #1 M 0 11/15/17
AC
PATIENT4, ROBERT 000004 COMMUNITY #1 M 0 02/05/17
AC SCIR: 6 MOS: 187 DO, 08/11/17 EXCLUSIVE BREASTFEEDING
PATIENT11, STEVEN CODY 000011 COMMUNITY #2 M 0 09/04/17
AC SCIR: 2 MOS: 60 DO, 11/03/17 MOSTLY BREASTFEEDING
```

Figure 2-120: Sample Patient List, Breastfeeding Rates

# 2.10.10 Use of High-Risk Medications in the Elderly

#### **Denominators**

Active Clinical patients ages 65 and older with no hospice indicator during the Report Period. Broken down by gender and age groups (65 through 74, 75 through 84, greater than (>) 85).

*User Population patients* ages 65 and older with no hospice indicator during the Report Period. Broken down by gender.

#### Numerators

Patients who received at least one high-risk medication for the elderly during the Report Period.

Patients who received at least two different high-risk medications for the elderly during the Report Period.

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

**Note:** The logic below is a deviation from the logic written by PQA, as PQA requires at least two prescriptions fills for the same high-risk medication during the Report Period, while the logic below only requires one prescription fill.

For nitrofurantoin, a patient must have received a cumulative days supply for any nitrofurantoin product greater than 90 days during the Report Period.

For nonbenzodiazepine hypnotics, a patient must have received a cumulative days supply for any nonbenzodiazepine hypnotic products greater than 90 days during the Report Period.

Subject Defined	CPT Codes	SNOMED Codes
Hospice	99377, 99378, G9473 through G9479	170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

*Medication definitions*: High-risk medications for the elderly defined with medication taxonomies:

- BGP HEDIS ANTICHOLINERGIC MEDS: First-generation antihistamines (Includes combination drugs) (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Diphenhydramine (oral), Doxylamine, Hydroxyzine, Promethazine, Triprolidine); Antiparkinson agents (Benztropine (oral), Trihexyphenidyl)
- BGP HEDIS ANTITHROMBOTIC MEDS: (Ticlopidine, Dipyridamole, oral short-acting)
- BGP HEDIS ANTI-INFECTIVE MEDS: (Nitrofurantoin)
- BGP HEDIS CARDIOVASCULAR MEDS: Alpha blockers, central (Guanfacine, Methyldopa, Reserpine); Cardiovascular, other (Disopyramide, Digoxin, Nifedipine, immediate release)
- BGP HEDIS CENTRAL NERVOUS MEDS: Tertiary TCAs (Includes combination drugs) (Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine); Antipsychotics, first-generation (conventional) (ThioridazineBarbiturates (Amobarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital); Central Nervous System, other (Chloral hydrate, Meprobamate); Nonbenzodiazepine hypnotics (Eszopiclone, Zolpidem, Zaleplon); Vasodilators (Ergoloid mesylates, Isoxsuprine)
- BGP HEDIS ENDOCRINE MEDS: Endocrine (Desiccated thyroid, Estrogens with or without progesterone (oral and topical patch products only), Megestrol); Sulfonylureas, long-duration (Chlorpropamide, Glyburide)
- BGP HEDIS GASTROINTESTINAL MEDS: (Trimethobenzamide)

- BGP HEDIS PAIN MEDS: Other (Meperidine, Pentazocine); Non-COX-selective NSAIDs (Indomethacin, Ketorolac)
- BGP HEDIS SKL MUSCLE RELAX MED (Includes combination drugs) (Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

Note: For each medication, the days' supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 16.1**

1. Added denominator exclusion and logic to exclude patients with a hospice indicator anytime during the Report Period.

## **Patient List Description**

List of patients 65 and older with at least one high-risk medication.

#### **Measure Source**

**HEDIS** 

#### Measure Past Performance and Long-Term Targets

```
DU
                            November 25, 2017
                                                                   Page 324
       *** IHS 2017 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Use of High-Risk Medications in the Elderly
                   REPORT
                               PREV YR
                                           % CHG from BASE
                                                                 % CHG from
                                              PREV YR % PERIOD
                    PERTOD
                                 PERIOD
                                                                    BASE %
Active Clinical
Pts 65+ w/ no
                                                           108
hospice
                      128
                                     120
```

<pre># w/ Exposure to   1+ High-Risk Med # w/ Exposure to   Multiple High-Risk</pre>	21	16.4	33	27.5	-11.1	50	46.3	-29.9	
Meds	7	5.5	13	10.8	-5.4	13	12.0	-6.6	
Male Active Clinical 65+ w/ no hospice	43		44			38			
# w/ Exposure to 1+ High-Risk Med # w/ Exposure to	3	7.0	7	15.9	-8.9	16	42.1	-35.1	
Multiple High-Risk Meds	1	2.3	4	9.1	-6.8	3	7.9	-5.6	
Female Active Clinical 65+ w/ no hospice	85		76			70			
# w/ Exposure to 1+ High-Risk Med # w/ Exposure to	18	21.2	26	34.2	-13.0	34	48.6	-27.4	
Multiple High-Risk Meds	6	7.1	9	11.8	-4.8	10	14.3	-7.2	
User Pop Pts 65+ w/ no hospice	147		139			128			
<pre># w/ Exposure to   1+ High-Risk Med # w/ Exposure to   Multiple High-Risk</pre>	21	14.3	33	23.7	-9.5	50	39.1	-24.8	
Meds	7	4.8	13	9.4	-4.6	13	10.2	-5.4	

Figure 2-121: Sample Report, Use of High-Risk Medications in the Elderly

DU November 25, 2017 Page 326  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Use of High-Risk Medications in the Elderly (con't)  ACTIVE CLINICAL PATIENTS 65+  Age Distribution 65-74 75-84 85+								
CURRENT REPORT PERIOD AC Patients 65+	91	30	6					
<pre># w/ Exposure to 1+   High-Risk Med % w/ Exposure to 1+</pre>	17	1	3					
1 High-Risk Med	18.7	3.3	50.0					

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

# w/ Exposure to Multiple				
High-Risk Meds	7	0	0	
% w/ Exposure to Multiple				
High-Risk Meds	7.7	0.0	0.0	
PREVIOUS YEAR PERIOD				
AC Patients 65+	87	24	7	
ne racrenes os:	0,	2.	,	
# w/ Exposure to 1+				
High-Risk Med	20	9	4	
% w/ Exposure to 1+				
High-Risk Med	23.0	37.5	57.1	
# w/ Exposure to Multiple				
High-Risk Meds	8	4	1	
% w/ Exposure to Multiple	0	4	Τ.	
High-Risk Meds	9.2	16.7	14.3	
might kibh heab	7.2	10.7	11.5	
CHANGE FROM PREV YR %				
# w/ Exposure to 1+				
High-Risk Med	-4.3	-34.2	-7.1	
# w/ Exposure to Multiple				
High-Risk Meds	-1.5	-16.7	-14.3	

Figure 2-122: Sample Report, Use of High-Risk Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Use of High Risk Medications in the Elderly: List of patients 65 and older with at least one high-risk medication. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR .\_\_\_\_ PATIENT1, JONELLE 000001 COMMUNITY #1 F 69 06/08/48 UP,AC 2 drugs: 08/04/17 ESTERIFIED ESTROGENS 0.625MG TAB (ORAL ESTROGEN); 08/04/17 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT2, PAULINE 000002 COMMUNITY #1 F 70 04/12/47 UP,AC 1 drug:11/02/17 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT3, NADINE 000003 COMMUNITY #1 F 82 02/16/35 UP,AC 2 drugs: 09/25/17 DIAZEPAM 5MG TAB (BENZODIAZEPINE); 09/25/17 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT4, JESSE NATHAN 000004 COMMUNITY #1 M 77 10/16/40 1 drug:08/27/17 CYCLOBENZAPRINE HCL 10MG TAB (SKL MUSCLE)

Figure 2-123: Sample Patient List, Use of High-Risk Medications in the Elderly

# 2.10.11 Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

#### **Denominators**

Active Clinical patients ages 65 and older.

User Population patients ages 65 and older.

#### **Numerators**

Patients who received at least two prescription fills for any benzodiazepine sedative hypnotic medications for more than 90 days.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

The patient must have received a cumulative days supply for any benzodiazepine sedative hypnotic products greater than 90 days during the Report Period.

*Medication definitions*: Benzodiazepine sedative hypnotic medications defined with medication taxonomy BGP PQA BENZODIAZ MEDS (Estazolam, Flurazepam, Quazepam, Temazepam, Triazolam).

Note: For each medication, the days' supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2017, Discontinued Date=11/19/2017, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

#### **Measure Source**

**PQA** 

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 324  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Use of High-Risk Me	dications i	n the El	derly					
	REPORT PERIOD				f from BA REV YR % P			
Active Clinical Pts 65+	127		118			109		
# w/ 2+ Benzodiazepine Sedative Hypnotic Meds	1	0.8	0	0.0	+0.8	0	0.0	+0.8
User Pop Pts 65+	147		139			129		
# w/ 2+ Benzodiazepine Sedative Hypnotic Meds	1	0.7	0	0.0	+0.7	0	0.0	+0.7

Figure 2-124: Sample Report, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly: List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1, JONELLE 000001 COMMUNITY #1 F 69 02/19/48
UP, AC
PATIENT2, PAULINE 000002 COMMUNITY #1 F 70 03/14/47
UP, AC 02/02/17 TEMAZEPAM 15MG CAP (60); 06/02/17 TEMAZEPAM PATIENT3, NADINE 000003 COMMUNITY #1 F 82 03/02/35
UP, AC
PATIENT4, JESSE NATHAN 000004 COMMUNITY #1 M 77 04/13/40

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

UP,AC

Figure 2-125: Sample Patient List, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

## 2.10.12 Functional Status Assessment in Elders

#### **Denominator**

Active Clinical patients ages 55 and older. Broken down by gender.

#### **Numerator**

Patients screened for functional status at any time during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Functional status screening definition: Any non-null values in V Elder Care for (1) at least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence and (2) at least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the Report Period.

## **Key Logic Changes from CRS Version 16.1**

None.

#### **Patient List Description**

List of patients greater than or equal to (=>) 55 with functional status codes, if any. The following are the abbreviations used in the Numerator column:

- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER–Transfers
- FEED–Feeding
- CONT-Continence
- FIN–Finances
- COOK–Cooking
- SHOP–Shopping
- HSWK–Housework/Chores

- MEDS–Medications
- TRNS–Transportation

#### **Measure Source**

None

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 328  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Functional Status A	Assessment	in El	ders						
					CHG from PREV YR %				
Active Clinical Pts 55+	318		298			286			
# w/ Functional Status Screening	3	0.9	1	0.3	+0.6	5	1.7	-0.8	
Male Active Clinical 55+	127		120			111			
# w/ Functional Status Screening	1	0.8	0	0.0	+0.8	1	0.9	-0.1	
Female Active Clinical 55+	191		178			175			
# w/ Functional Status Screening	2	1.0	1	0.6	+0.5	4	2.3	-1.2	

Figure 2-126: Sample Report, Functional Status Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Functional Status Assessment in Elders: List of patients 55+ with functional
status codes, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR

PATIENT1,GLENDA JOYCE 000001 COMMUNITY #1 F 57 11/12/60

```
PATIENT2, NADINE
                       000002 COMMUNITY #1 F 61
                                                    09/22/56
PATIENT3, CHARLOTTE MAE 000003 COMMUNITY #1 F 64 10/18/53
                             YES: 02/24/17 BATH, CONT, COOK, DRES, FEED, FIN, HSWK,
MEDS, SHOP, TLT, TRNS, XFER
PATIENT4, KATHERINE ANN 000004 COMMUNITY #1 F 66 10/29/51
                             YES: 07/11/17 BATH, FIN
AC YES: 07/11/17 BATH, FIN PATIENT5,ANNA MARIE 000005 COMMUNITY #1 F 66
                                                    12/01/51
PATIENT6, DIANA
                      000006 COMMUNITY #1 F 67
                                                    08/14/50
PATIENT7, PEGGY ANN
                       000007 COMMUNITY #1 F 70
                                                    05/12/47
                            NO: 05/20/17 FIN
```

Figure 2-127: Sample Patient List, Functional Status Assessment in Elders

#### 2.10.13 Fall Risk Assessment in Elders

#### **Denominators**

Active Clinical patients ages 65 and older. Broken down by gender.

User Population patients ages 65 and older. Broken down by gender.

#### **Numerators**

Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.

**Note**: This numerator does *not* include refusals.

- a. Patients who have been screened for fall risk in the past year
- b. Patients with a documented history of falling in the past year
- c. Patients with a fall-related injury diagnosis in the past year
- d. Patients with abnormality of gait/balance or mobility diagnosis in the past year

Patients with a documented refusal of fall risk screening exam in the past year

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Fall risk screening/fall related diagnosis is defined as any of the codes in the table below.

Subject Defined	ICD and Other Codes	Exam Code	E Codes (Injury)
Fall Risk Exam	<b>CPT</b> : 1100F, 1101F, 3288F	Exam: 37 (Fall Risk)	
History of Falling	POV: ICD-9: V15.88 (Personal History of Fall); ICD-10: Z91.81		
Fall-related Injury			POV (Cause Codes #1-3): ICD-9: E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*; ICD-10: (All codes ending in A or D only) W01.*, W06.*-W08.*, W10.*, W18.*, W19.*
Abnormality of Gait/Balance or Mobility	POV: ICD-9: 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9; ICD-10: G25.7*, G25.89, G25.9, G26, I69.*93, I73.9, R26.*, R27.*		
Refusal		Exam: 37 (Fall Risk)	

## **Key Logic Changes from CRS Version 16.1**

None.

## **Patient List Description**

List of patients 65 years or older with fall risk assessment, if any.

#### **Measure Source**

HP 2010 15–28 Reduce hip fractures among older adults.

## Measure Past Performance and Long-Term Targets

```
DU November 25, 2017 Page 331

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Fall Risk Assessment in Elders (con't)

Active Clinical

Pts 65+ 127 118 109
```

# w/ Fall Risk									
Screen/Dx-No									
Refusals	15	11.8	36	30.5	-18.7	33	30.3	-18.5	
A. # w/ Fall Risk									
Screen w/ % of									
Total Screened	8	53.3	21	58.3	-5.0	19	57.6	-4.2	
B. # w/ History of									
Fall w/ % of Total									
Screened	2	13.3	3	8.3	+5.0	4	12.1	+1.2	
C. # w/ Fall									
Injury w/ % of									
Total Screened	4	26.7	12	33.3	-6.7	11	33.3	-6.7	
D. # w/ Abnormal									
Gait w/ % of Total									
Screened		20.0		16.7			15.2		
# w/ Refusal	1	0.8	0	0.0	+0.8	0	0.0	+0.8	
Male Active									
	42		43			39			
# w/ Fall Risk									
Screen/Dx-No									
Refusals	3	7.1	9	20.9	-13.8	9	23.1	-15.9	
A. # w/ Fall Risk									
Screen w/ % of									
Total Screened	1	33.3	8	88.9	-55.6	6	66.7	-33.3	
B. # w/ History of									
Fall w/ % of Total									
Screened	1	33.3	0	0.0	+33.3	1	11.1	+22.2	
C. # w/ Fall									
Injury w/ % of									
Total Screened	1	33.3	1	11.1	+22.2	2	22.2	+11.1	
D. # w/ Abnormal									
Gait w/ % of Total									
Screened		100.0	0						
# w/ Refusal	1	2.4	0	0.0	+2.4	0	0.0	+2.4	

Figure 2-128: Sample Report, Fall Risk Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Fall Risk Assessment in Elders: List of patients 65 years and older with fall risk assessment, if any. HRN PATIENT NAME COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR 000001 COMMUNITY #1 F 68 06/12/49 PATIENT1, SHERRY UP,AC PATIENT2, LORETTA LYNN 000002 COMMUNITY #1 F 78 04/11/39 UP,AC Refused 03/03/17 Ex 37
PATIENT17,NICOLE 000017 COMMUNITY #2 F 71 09/12/46 Refused 03/03/17 Ex 37 UP,AC Abnormal Gait: 11/24/17 POV 443.9 PATIENT18, VERONICA 000018 COMMUNITY #2 F 72 10/15/45 Screen: 03/03/17 CPT 1100F PATIENT19, STEPHANIE 000019 COMMUNITY #2 F 76 08/17/41

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures September 2016

```
UP,AC Fall Injury: 11/10/17 E-CODE E883.9
```

Figure 2-129: Sample Patient List, Fall Risk Assessment in Elders

#### 2.10.14 Palliative Care

#### **Denominators**

No denominator; count only.

#### **Numerators**

Count only: Number of *Active Clinical patients* with at least one palliative care visit during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

Count only: Number of palliative care visits for *Active Clinical patients* during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Palliative care visit definition: POV ICD-9: V66.7; ICD-10: Z51.5.

## **Patient List Description**

List of patients with a palliative care visit.

#### **Key Logic Changes from CRS Version 16.1**

None.

#### **Measure Source**

None

## Measure Past Performance and Long-Term Targets

```
DU November 25, 2017 Page 334

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016
```

В	aseline Period:	Jan 01, 2010	) to Dec 31,	2010	
Palliative Care					
		PREV YR PERIOD		·-	CHG from BASE
Total # of Patients w/ 1+ Palliative Care Visit	10	0	+10	0	+10
A. Total # of Patients <18 w/ 1 Palliative Care Visit B. Total # of	+	0	+3	0	+3
Patients 18-54 w/ 1+ Palliative Car Visit C. Total # of Patients 55+ w/ 1	e 2	0	+2	0	+2
Palliative Care Visit	5	0	+5	0	+5
Total # of Palliative Care Visits A. Total # of	10	0	+10	0	+10
Palliative Care Visits-Pts <18 B. Total # of	3	0	+3	0	+3
Palliative Care Visits-Pts 18-54 C. Total # of	2	0	+2	0	+2
Palliative Care Visits-Pts 55+	5	0	+5	0	+5

Figure 2-130: Sample Report, Palliative Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Palliative Care: List of patients with a palliative care visit, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR PATIENT1, JOHN 000012 Community #1 M 57 12/12/60 AC 1 visit: 05/01/17
PATIENT2, ROBERT 000013 Community #1 M 59 06/19/58 1 visit: 05/01/17 2 visits: 01/25/17, 05/10/17 PATIENT3, JAMES 000014 Community #2 M 67 01/12/50 0 visits: PATIENT4, TONYA 000015 Community #3 F 78 03/28/39 1 visit: 06/01/16

CRS Clinical Performance Measure Logic Manual for FY 2017 Clinical Measures
September 2016

PATIENT5, RITA ANN	000016 Community #3 F 96 08/17/21	
AC	2 visits: 06/01/17; 06/07/17	
PATIENT6,Clifford	000017 Community #3 M 24 11/14/93	
AC	3 visits: 01/25/17, 05/10/17, 08/01/17	

Figure 2-131: Sample Patient List, Palliative Care

## 2.10.15 Annual Wellness Visit

#### **Denominators**

Active Clinical patients ages 65 and older. Broken down by gender.

#### **Numerators**

Patients with at least one Annual Wellness Exam in the past 15 months.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Annual Wellness Exam: CPT G0438, G0439, G0402.

## **Patient List Description**

List of patients with an annual wellness visit in the past 15 months.

## **Key Logic Changes from CRS Version 16.1**

None.

#### Measure Source

None

## **Measure Past Performance and Long-Term Targets**

```
DU November 25, 2017 Page 337

*** IHS 2017 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2017 to Dec 31, 2017

Previous Year Period: Jan 01, 2016 to Dec 31, 2016

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Annual Wellness Visit

REPORT PREV YR CHG from BASE CHG from
```

	PERIOD		PERIOD		PREV YR PERIOD		В	ASE
Active Clinical Pts 65+	127		118			109		
# w/ Annual Wellness Exam	3	2.4	0	0.0	+2.4	0	0.0	+2.4
Male Active Clinical Pts 65+	42		43			39		
# w/ Annual Wellness Exam	1	2.4	0	0.0	+2.4	0	0.0	+2.4
Female Active Clinical Pts 65+	85		75			70		
# w/ Annual Wellness Exam	2	2.4	0	0.0	+2.4	0	0.0	+2.4

Figure 2-132: Sample Report, Annual Wellness Visit

UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Annual Wellness Visit: List of patients with an annual wellness visit in the past 15 months, if any. PATIENT NAME HRN COMMUNITY SEX AGE DOB DENOMINATOR NUMERATOR Patient1,DENISE 000001 Community #1 F 65 05/12/52 12/31/16 G0402 Patient2, MELISSA GAYLE 000002 Community #1 F 66 07/14/51 Patient3, JESSICA DAWN 000003 Community #1 F 67 11/12/50 02/22/17 G0438 Patient4, RUTH ALICE 000004 Community #1 F 69 01/19/48 Patient5, BRYSON DEWAY 000005 Community #1 F 72 05/02/45 Patient6, BRITTNEY ANN 000006 Community #1 F 73 07/14/44 05/31/17 G0439 Patient7,MARK 000007 Community #1 M 67 11/19/50 AC Patient8, HOWIE 000008 Community #1 M 72 12/08/45 10/01/17 G0402

Figure 2-133: Sample Patient List, Annual Wellness Visit

## 2.10.16 Optometry

#### **Denominators**

Active Clinical patients ages 18 and older with a diagnosis of primary open-angle glaucoma during the Report Period. (GPRA Developmental Denominator (NQF 0086))

#### **Numerators**

Patients with an optic nerve head evaluation during the Report Period. (GPRA Developmental Denominator (NQF 0086))

## **Logic Description**

Age is calculated at the beginning of the Report Period.

*Primary open-angle glaucoma*: Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 365.10-365.12, 365.15; ICD-10: H40.10\* - H40.12\*, H40.15\*; SNOMED data set PXRM OPEN ANGLE GLAUCOMA (Problem List only).

Optic nerve head evaluation: CPT 2027F.

## **Patient List Description**

List of patients >=18 with primary open-angle glaucoma and optic nerve head evaluation, if any.

## **Key Logic Changes from CRS Version 16.1**

- 1. Added logic to primary open-angle glaucoma definition to look at the Problem List.
- 2. Added SNOMED data set PXRM OPEN ANGLE GLAUCOMA to primary openangle glaucoma definition (for Problem List only).

#### Measure Source

NQF 0086

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2017 Page 337
\*\*\* IHS 2017 Selected Measures with Community Specified Report \*\*\*

```
DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2017 to Dec 31, 2017
             Previous Year Period: Jan 01, 2016 to Dec 31, 2016
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Optometry
                    REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %
                                                                   % CHG from
AC Pts 18+ w/
Primary Open-Angle
Glaucoma
                                       13
# w/ Optic Nerve
                         1 20.0
                                                                         +20.0
                                        0 \quad 0.0 \quad +20.0
                                                              0.0
 Head Eval
```

Figure 2-134: Sample Report, Optometry

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Optometry: List of patients 18+ with primary open-angle glaucoma and optic nerve head evaluation, if any. HRN COMMUNITY SEX AGE DOB PATIENT NAME DENOMINATOR NUMERATOR Patient1, DENISE 000001 Community #1 F 20 06/06/97 AC Patient2, MELISSA GAYLE 000002 Community #1 F 76 08/15/41 Patient3, JESSICA DAWN 000003 Community #1 F 47 07/14/70 Patient4, RUTH ALICE 000004 Community #1 M 35 05/08/82 Patient5, BRYSON DEWAY 000005 Community #1 M 38 09/09/79 04/04/17 2027F

Figure 2-135: Sample Patient List, Optometry

## 2.10.17 Goal Setting

#### **Denominators**

User Population patients.

Number of goal topics set during the Report Period.

Number of goal topics met during the Report Period.

#### **Numerators**

Number of patients who set at least one goal during the Report Period.

Number of goals set for ALCOHOL OR OTHER DRUGS.

Number of goals set for DIABETES CURRICULUM.

Number of goals set for MEDICATIONS.

Number of goals set for MONITORING.

Number of goals set for NUTRITION.

Number of goals set for OTHER.

Number of goals set for PHYSICAL ACTIVITY.

Number of goals set for STRESS AND COPING.

Number of goals set for TOBACCO.

Number of goals set for WELLNESS AND SAFETY.

Number of patients who met at least one goal during the Report Period.

Number of goals met for ALCOHOL OR OTHER DRUGS.

Number of goals met for DIABETES CURRICULUM.

Number of goals met for MEDICATIONS.

Number of goals met for MONITORING.

Number of goals met for NUTRITION.

Number of goals met for OTHER.

Number of goals met for PHYSICAL ACTIVITY.

Number of goals met for STRESS AND COPING.

Number of goals met for TOBACCO.

Number of goals met for WELLNESS AND SAFETY.

## **Logic Description**

Patient education codes must be the standard national patient education codes, which are included in the Patient and Family Education Protocols and Codes (PEPC) manual published each year. If codes are found that are not in the table, they will not be reported on (i.e., locally-developed codes).

Numerator Logic:

For Goal Set, the Goal Setting value must be "Goal Set" and the Goal Start Date must be during the Report Period..

For Goal Met, the Goal Status value must be "Goal Met" and the Date/Time Last Modified must be during the Report Period. The patient is not required to have set a goal during the Report Period.

## **Patient List Description**

List of User Population patients with goal setting information during the Report Period.

## **Key Logic Changes from CRS Version 16.1**

None.

#### **Measure Source**

None

## Measure Past Performance and Long-Term Targets

November 25, 2017 Page 338  *** IHS 2017 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2017 to Dec 31, 2017  Previous Year Period: Jan 01, 2016 to Dec 31, 2016  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Goal Setting	DDDODE		ava 5		ava 5		
	REPORT PERIOD	PREV YR PERIOD	CHG from PREV YR		CHG from BASE		
User Pop Pts	2,466	2,561		2,516			
# w/ Goal Set	5	0.2 0	0.0 +0.2	0	0.0 +0.2		

W Cool Book on Cot	9		0			0			
# Goal Topics Set	9		U			0			
# ALCOHOL OR OTHER									
DRUGS Set	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# DIABETES									
CURRICULUM Set		11.1	0	0.0	+11.1	0	0.0	+11.1	
# MEDICATIONS Set	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# MONITORING Set		0.0	0	0.0	+0.0	0	0.0	+0.0	
# NUTRITION Set		22.2	0	0.0	+22.2	0	0.0	+22.2	
# OTHER Set # PHYSICAL	1	11.1	0	0.0	+11.1	0	0.0	+11.1	
ACTIVITY Set # STRESS AND	4	44.4	0	0.0	+44.4	0	0.0	+44.4	
COPING Set	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# TOBACCO Set		11.1	0	0.0	+11.1	0	0.0	+11.1	
# WELLNESS AND	_		ŭ	0.0		Ŭ	0.0		
SAFETY Set	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
User Pop Pts	2 166		0 E61			2,516			
user Pop Pts	2,400		2,501			2,510			
# w/ Goal Met	1	0.0	0	0.0	+0.0	0	0.0	+0.0	
# Goal Topics Met	3		0			0			
# ALCOHOL OR OTHER									
DRUGS Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# DIABETES	ŭ	•••	ŭ	0.0		ŭ	0.0		
CURRICULUM Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# MEDICATIONS Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# MONITORING Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# NUTRITION Met	1	33.3	0	0.0	+33.3	0	0.0	+33.3	
# OTHER Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# PHYSICAL									
ACTIVITY Met	1	33.3	0	0.0	+33.3	0	0.0	+33.3	
# STRESS AND									
COPING Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# TOBACCO Met	1	33.3	0	0.0	+33.3	0	0.0	+33.3	
# WELLNESS AND									
SAFETY Met	0	0.0	0	0.0	+0.0	0	0.0	+0.0	

Figure 2-136: Sample Report, Goal Setting

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Goal Setting: List of User Population patients who received patient education during the Report Period with goal setting information. PATIENT NAME HRN COMMUNITY SEX AGE DOB
DENOMINATOR NUMERATOR PATIENT NAME -----Patient1, Paula 000001 Community #1 F 34 11/14/83 GS: 11/17/17 - PHYSICAL ACTIVITY UP Patient2, PENNY 000002 Community #1 F 43 08/01/74 Patient3, RITA 000003 Community #1 F 64 07/02/53 GS: 04/15/17 - NUTRITION, GM: 06/15/17 - NUTRITION Patient4, HARRY 000004 Community #1 M 50 05/01/67 GM: 10/30/17 - DIABETES CURRICULUM Patient5, ROSS 000005 Community #1 M 55 06/05/62 Patient6, FELIPE 000006 Community #1 M 57 06/01/60 GS: 09/10/17 - TOBACCO Patient7, MARK 000007 Community #1 M 67 05/08/50 Patient8, CATHERINE 000008 Community #2 F 72 04/08/45 GM: 07/30/17 - OTHER

Figure 2-137: Sample Patient List, Goal Setting

## **Contact Information**

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

Phone: (888) 830-7280 (toll free)Web: <a href="http://www.ihs.gov/helpdesk/">http://www.ihs.gov/helpdesk/</a>

Email: support@ihs.gov